var title_f37_15_38128="Ciprofloxacin: Pediatric drug information";
var content_f37_15_38128=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ciprofloxacin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12644919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?6/50/6947?source=see_link\">",
"       Ciprofloxacin (ophthalmic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/48/38658?source=see_link\">",
"       Ciprofloxacin (otic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?43/11/44216?source=see_link\">",
"       Ciprofloxacin (systemic): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13157 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.211.0.116-3CD79DF107-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_15_38128=[""].join("\n");
var outline_f37_15_38128=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?6/50/6947?source=related_link\">",
"      Ciprofloxacin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/48/38658?source=related_link\">",
"      Ciprofloxacin (otic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?43/11/44216?source=related_link\">",
"      Ciprofloxacin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_15_38129="Patient information: Postpartum hemorrhage (The Basics)";
var content_f37_15_38129=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?21/52/22338\">",
"         Patient information: Blood donation (giving blood) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?16/21/16723\">",
"         Patient information: C-section (cesarean delivery) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?3/41/3731\">",
"         Patient information: Hysterectomy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?12/13/12499\">",
"         Patient information: Labor and delivery (childbirth) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?6/16/6405\">",
"         Patient information: Abdominal hysterectomy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?11/45/11988\">",
"         Patient information: C-section (cesarean delivery) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Postpartum hemorrhage (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/postpartum-hemorrhage-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H16297519\">",
"      <span class=\"h1\">",
"       What is postpartum hemorrhage?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Postpartum hemorrhage is a condition in which a woman loses a very large amount of blood after childbirth. This can happen after a woman gives birth through the vagina (called a &ldquo;vaginal birth&rdquo;) or after a doctor does surgery to get the baby out (called a &ldquo;c-section&rdquo; or &ldquo;cesarean delivery&rdquo;).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16297534\">",
"      <span class=\"h1\">",
"       What causes postpartum hemorrhage?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most of the time, postpartum hemorrhage happens because the uterus does not contract (tighten) well after birth.",
"     </p>",
"     <p>",
"      Others causes of postpartum hemorrhage are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Tears of the vagina, cervix or uterus",
"       </li>",
"       <li>",
"        Small pieces of the placenta or membranes that stay stuck to the uterus after the baby is born. The placenta is the organ that forms between the mother and her baby. It brings the baby nutrients and oxygen and carries away waste.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16297549\">",
"      <span class=\"h1\">",
"       What are the symptoms of postpartum hemorrhage?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main symptom is bleeding from the woman&rsquo;s vagina. If the woman loses a lot of blood, she may feel weak and lightheaded.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16297564\">",
"      <span class=\"h1\">",
"       How is postpartum hemorrhage treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If the hemorrhage happens because the uterus has not contracted well, treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Massaging the uterus &ndash; A nurse, doctor, or midwife will use his or her hands to press down on the woman&rsquo;s lower belly and massage the uterus. This helps the uterus contract.",
"       </li>",
"       <li>",
"        Medicines that help the uterus contract",
"       </li>",
"       <li>",
"        Checking to see if there are bits of the placenta and membranes stuck in the uterus. If so, the doctor or midwife will remove them. He or she might use tools to remove the tissue.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If the hemorrhage happens because of injuries or tears, the doctor or midwife will stitch up any tears. If the bleeding is very severe, a woman might need a blood transfusion. For a transfusion, blood donated by someone else is given through an &ldquo;IV&rdquo; (a tube that goes into a vein). If the doctor or midwife can&rsquo;t stop the bleeding, he or she might have to take out the woman&rsquo;s uterus (called a &ldquo;hysterectomy&rdquo;). But that is rarely needed.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16297579\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant again?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most of the time, a postpartum hemorrhage does not happen again in future pregnancies. But make sure your doctor or midwife knows about your past postpartum hemorrhage. Compared with women who have not had a postpartum hemorrhage, you have a higher chance of having the problem again.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H16297594\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/13/12499?source=see_link\">",
"       Patient information: Labor and delivery (childbirth) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/21/16723?source=see_link\">",
"       Patient information: C-section (cesarean delivery) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/52/22338?source=see_link\">",
"       Patient information: Blood donation (giving blood) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/41/3731?source=see_link\">",
"       Patient information: Hysterectomy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/45/11988?source=see_link\">",
"       Patient information: C-section (cesarean delivery) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/16/6405?source=see_link\">",
"       Patient information: Abdominal hysterectomy (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?37/15/38129?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83068 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-FC54B750F8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_15_38129=[""].join("\n");
var outline_f37_15_38129=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16297519\">",
"      What is postpartum hemorrhage?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16297534\">",
"      What causes postpartum hemorrhage?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16297549\">",
"      What are the symptoms of postpartum hemorrhage?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16297564\">",
"      How is postpartum hemorrhage treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16297579\">",
"      What if I want to get pregnant again?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16297594\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/16/6405?source=related_link\">",
"      Patient information: Abdominal hysterectomy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/52/22338?source=related_link\">",
"      Patient information: Blood donation (giving blood) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/45/11988?source=related_link\">",
"      Patient information: C-section (cesarean delivery) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/21/16723?source=related_link\">",
"      Patient information: C-section (cesarean delivery) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/41/3731?source=related_link\">",
"      Patient information: Hysterectomy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/13/12499?source=related_link\">",
"      Patient information: Labor and delivery (childbirth) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_15_38130="Sjogrens syndrome parotid gland";
var content_f37_15_38130=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F85931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F85931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Parotid gland enlargement in Sj&ouml;gren&rsquo;s syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 336px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The parotid gland is enlarged in this patient with Sj&ouml;gren's syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; 2012 American College of Rheumatology. Used with permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_15_38130=[""].join("\n");
var outline_f37_15_38130=null;
var title_f37_15_38131="Artificial tears: Pediatric drug information";
var content_f37_15_38131=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"16\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Artificial tears: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24211?source=see_link\">",
"    see \"Artificial tears: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/31/3572?source=see_link\">",
"    see \"Artificial tears: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F136850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Advanced Eye Relief&trade; Dry Eye Environmental [OTC];",
"     </li>",
"     <li>",
"      Advanced Eye Relief&trade; Dry Eye Rejuvenation  [OTC];",
"     </li>",
"     <li>",
"      Bion&reg; Tears [OTC];",
"     </li>",
"     <li>",
"      HypoTears [OTC];",
"     </li>",
"     <li>",
"      Murine Tears&reg; [OTC];",
"     </li>",
"     <li>",
"      Soothe&reg; Hydration [OTC];",
"     </li>",
"     <li>",
"      Soothe&reg; [OTC];",
"     </li>",
"     <li>",
"      Systane&reg; Ultra [OTC];",
"     </li>",
"     <li>",
"      Systane&reg; [OTC];",
"     </li>",
"     <li>",
"      Tears Again&reg; [OTC];",
"     </li>",
"     <li>",
"      Tears Naturale&reg; Forte [OTC];",
"     </li>",
"     <li>",
"      Tears Naturale&reg; Free [OTC];",
"     </li>",
"     <li>",
"      Tears Naturale&reg; II [OTC];",
"     </li>",
"     <li>",
"      Viva-Drops&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F136851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Teardrops&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F999166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Ophthalmic Agent, Miscellaneous",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F13315405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic:",
"     <b>",
"      Ocular dryness/irritation:",
"     </b>",
"     1 drop into eye(s) as needed to relieve symptoms;",
"     <b>",
"      Note:",
"     </b>",
"     Neonatal data are unavailable; dosage extrapolated from older pediatric patients.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F999174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24211?source=see_link\">",
"      see \"Artificial tears: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Ocular dryness/irritation:",
"     </b>",
"     1-2 drops into eye(s) as needed to relieve symptoms",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Dry eye associated with ocular inflammation (eg, blepharitis, conjunctivitis, keratitis):",
"     </b>",
"     1-2 drops into eye(s) at least twice daily or as needed to relieve symptoms (Sethuraman, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"     <b>",
"      Ocular dryness/irritation:",
"     </b>",
"     1-2 drops into eye(s) as needed to relieve symptoms",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F136845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution, ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Advanced Eye Relief&trade; Dry Eye Environmental: Glycerin 1% (15 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Advanced Eye Relief&trade; Dry Eye Rejuvenation: Glycerin 0.3% and propylene glycol 1% (30 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     HypoTears: Polyvinyl alcohol 1% and polyethylene glycol 400 1% (30 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Murine Tears&reg;: Polyvinyl alcohol 0.5% and povidone 0.6% (15 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Soothe&reg; Hydration: Povidone 1.25% (15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Systane&reg; Ultra: Polyethylene glycol 400 0.4% and propylene glycol 0.3% (5 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Systane&reg;: Polyethylene glycol 400 0.4% and propylene glycol 0.3% (5 mL, 15 mL, 30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tears Again&reg;: Polyvinyl alcohol 1.4% (30 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tears Naturale&reg; II: Dextran 70 0.1% and hydroxypropyl methylcellulose 2910 0.3% (30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tears Naturale&reg; Forte: Dextran 70 1%, glycerin 0.2%, and hydroxypropyl methylcellulose  2910 0.3% (30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution, ophthalmic [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Bion&reg; Tears: Dextran 70 0.1% and hydroxypropyl methylcellulose 2910 0.3% per 0.4 mL (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Soothe&reg;: Glycerin 0.6% and propylene glycol 0.6% per 0.6 mL (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Systane&reg; Ultra: Polyethylene glycol 400 0.4% and propylene glycol 0.3% per 0.4 mL (24s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tears Naturale&reg; Free: Dextran 70 0.1% and hydroxypropyl methylcellulose 2910 0.3% per 0.5 mL (36s, 60s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Viva-Drops&reg;: Polysorbate 80 1% (0.5 mL, 10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F136834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13315406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Wash hands thoroughly before administration; do not touch tip of container to the eye or any surface; replace cap after use. Some products should not be used with contact lenses; consult specific product information.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F13315403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature; see product-specific labeling for any additional storage requirements.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F999167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic lubricant; for relief of dry eyes and eye irritation; protectant against further irritation (OTC: FDA approved in adults; refer to product-specific information regarding FDA approval in pediatric patients); has also been used for symptomatic treatment of dry eye associated with conjunctivitis, blepharitis, and keratitis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F136862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Isopto&reg; Tears may be confused with Isoptin&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F136861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ocular: blurred vision, crusting of eyelids, mild stinging",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13315401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component (consult product-specific information)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F13315402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic solutions may contain benzalkonium chloride which may be absorbed by contact lenses; remove contact lenses before use. Preservative-free formulations are single-use containers; once opened they should be discarded; do not reuse. When used for self-medication (OTC), use should be discontinued and healthcare provider contacted if changes in vision, eye pain, continued redness, or irritation occur, or if the condition worsens or persists for more than 72 hours. Use in neonates or infants should be directed by a prescriber. To avoid contamination, do not touch tip of container to any surface. Replace cap after using. Do not use if solution is cloudy or changes color.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F999169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Individual product formulations may include (as an active ingredient) polyvinyl alcohol, povidone, carboxymethylcellulose, hydroxymethylcellulose, hydroxypropyl methylcellulose, or dextran 70; refer to product labeling for specific ingredients. Additionally, some formulations contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; avoid  products containing propylene glycol in neonates. Some formulations may contain polysorbate 80 (Tween 80&reg;) which may cause allergic reactions in susceptible individuals. In premature neonates, thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported after receiving parenteral products containing polysorbate 80 (Alade, 1986;",
"     <i>",
"      MMWR",
"     </i>",
"     , 1984).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6218082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13315404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Products contain demulcents (ie, cellulose derivatives, dextran 70, gelatin, polyols, polyvinyl alcohol, or povidone); usually a water-soluble polymer, applied topically to the eye to protect and lubricate mucous membrane surfaces and relieve dryness and irritation",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F999179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/31/3572?source=see_link\">",
"      see \"Artificial tears: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Wash hands thoroughly before use; if irritation or condition worsens or persists for longer than 3 days, discontinue use; do not touch tip of container to any surface; close immediately after use",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alade SL, Brown RE, and Paquet A Jr, \"Polysorbate 80 and E-Ferol Toxicity,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1986, 77(4):593-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/15/38131/abstract-text/3960626/pubmed\" id=\"3960626\" target=\"_blank\">",
"        3960626",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"'Inactive' Ingredients in Pharmaceutical Products: Update (Subject Review),\"",
"      <i>",
"       Pediatr",
"      </i>",
"      , 1997, 99(2):268-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/15/38131/abstract-text/9024461/pubmed\" id=\"9024461\" target=\"_blank\">",
"        9024461",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control (CDC), \"Unusual Syndrome With Fatalities Among Premature Infants: Association With a New Intravenous Vitamin E Product,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 1984, 33(14):198-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/15/38131/abstract-text/6423951/pubmed\" id=\"6423951\" target=\"_blank\">",
"        6423951",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sethuraman U and Kamat D, \"The Red Eye: Evaluation and Management,\"",
"      <i>",
"       Clin Pediatr (Phila)",
"      </i>",
"      , 2009, 48(6):588-600.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/15/38131/abstract-text/19357422/pubmed\" id=\"19357422\" target=\"_blank\">",
"        19357422",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17056 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.65.66-BC5B390E05-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_15_38131=[""].join("\n");
var outline_f37_15_38131=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136850\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136851\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999166\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13315405\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999174\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136845\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136834\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13315406\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13315403\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999167\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136862\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136861\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13315401\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13315402\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999169\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298775\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6218082\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13315404\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999179\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/17056\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/17056|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24211?source=related_link\">",
"      Artificial tears: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/31/3572?source=related_link\">",
"      Artificial tears: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_15_38132="Severe perioral dermatitis";
var content_f37_15_38132=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F50527&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F50527&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Severe perioral dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous papules and confluent areas of erythema are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_15_38132=[""].join("\n");
var outline_f37_15_38132=null;
var title_f37_15_38133="T2 T1 MRI panc adeno";
var content_f37_15_38133=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F55392&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F55392&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pancreatic adenocarcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 541px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    T2-weighted (A) and T1-weighted (B) fat saturated magnetic resonance (MR) images of a patient with pancreatic adenocarcinoma. Panels A and B both demonstrate atrophy of the pancreatic tail parenchyma, with dilatation of the main pancreatic duct (A arrow). The pancreatic cancer is best visualized on the T1-weighted image as a hypointense solid tumor (B arrow) in the body of the pancreas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Rocio Perez-Johnston.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_15_38133=[""].join("\n");
var outline_f37_15_38133=null;
var title_f37_15_38134="Mycoplasma pneumonia lung imaging A";
var content_f37_15_38134=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 604px\">",
"   <div class=\"ttl\">",
"    Mycoplasma pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 584px; height: 466px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph (A) shows a bilateral reticulonodular pattern. High-resolution computed tomography (CT) image at the level of the main bronchi (B) demonstrates bilateral ground-glass opacities and centrilobular nodules (arrows). High-resolution CT scan at the level of the basal segmental bronchi (C) shows centrilobular nodules (straight arrows), branching opacities (tree-in-bud pattern) (curved arrow), ground glass opacities, small foci of consolidation, and mild thickening of the interlobular septa (arrowheads). The patient was a 20-year-old man with Mycoplasma pneumoniae pneumonia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Viruses, Mycoplasma, and Chlamydia. In: Imaging of Pulmonary Infections, M&uuml;ller NL, Franquet T, Lee KS (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_15_38134=[""].join("\n");
var outline_f37_15_38134=null;
var title_f37_15_38135="Flexible bronchoscopy: Indications and contraindications";
var content_f37_15_38135=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Flexible bronchoscopy: Indications and contraindications",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/15/38135/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/15/38135/contributors\">",
"     Kevin C Wilson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/15/38135/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/15/38135/contributors\">",
"     Praveen N Mathur, MB, BS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/15/38135/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/15/38135/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/15/38135/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 12, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H17213836\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchoscopy is a procedure to visualize the tracheobronchial tree [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38135/abstract/1\">",
"     1",
"    </a>",
"    ]. There are three types of bronchoscopy: rigid, flexible, and virtual bronchoscopy (",
"    <a class=\"graphic graphic_table graphicRef51458 \" href=\"mobipreview.htm?30/58/31659\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rigid bronchoscopy visualizes the proximal airways. It is almost always performed in the operating room under general anesthesia and is usually performed in situations in which relatively large amounts of tissue are targeted for removal (eg, laser ablation of tracheal or mainstem bronchial tumors), since the working channels are significantly larger than those of flexible bronchoscopes (",
"      <a class=\"graphic graphic_table graphicRef67992 \" href=\"mobipreview.htm?1/12/1227\">",
"       table 2",
"      </a>",
"      ). The rigid bronchoscope consists of an inflexible tube that encloses a telescope, light source, and working channels (",
"      <a class=\"graphic graphic_picture graphicRef53603 \" href=\"mobipreview.htm?28/58/29603\">",
"       picture 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38135/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/33/37394?source=see_link\">",
"       \"Rigid bronchoscopy: Instrumentation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Flexible bronchoscopy is the most common type of bronchoscopy. It visualizes the trachea, proximal airways, and segmental airways out to the third generation of branching and can be used to sample and treat lesions in those airways. Flexible bronchoscopy is generally performed in a procedure room with conscious sedation. The flexible bronchoscope consists of a flexible sheath that contains cables that allow the tip of the bronchoscope to be flexed and extended, fiberoptic fibers for transmitting endobronchial images, a light source, and a working channel (",
"      <a class=\"graphic graphic_figure graphicRef67231 \" href=\"mobipreview.htm?27/7/27762\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38135/abstract/3\">",
"       3",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Several variants of traditional flexible bronchoscopy exist [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38135/abstract/4\">",
"       4",
"      </a>",
"      ]. Endobronchial ultrasound is performed using a flexible bronchoscope that has an ultrasound probe built into its distal end. It provides real-time ultrasound images of tissues adjacent to the airway, facilitating transbronchial needle aspiration of abnormalities such as enlarged lymph nodes. Electromagnetic navigation bronchoscopy is performed using a flexible bronchoscope with an electromagnetic guidance system. This provides an endobronchial map that is used to direct a special biopsy catheter into the distal airways for more accurate sampling of small peripheral abnormalities. Non-magnetic navigation systems are also available. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/32/19976?source=see_link\">",
"       \"Endobronchial ultrasound: Indications, advantages, and complications\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/26/43427?source=see_link\">",
"       \"Endobronchial ultrasound: Technical aspects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Virtual bronchoscopy consists of computer generated pictures of the endobronchial tree, which are constructed from computed tomography (CT) images of the thorax (",
"      <a class=\"graphic graphic_figure graphicRef78262 \" href=\"mobipreview.htm?9/12/9408\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38135/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]. It has the advantage of being noninvasive, being able to define the airways out to the seventh generation of branching, and providing important information about structures outside the airways (eg, lymph nodes). However, it is not yet widely available and mucosal abnormalities are not well seen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Indications and contraindications for flexible bronchoscopy are reviewed here. The equipment, procedure, and complications of flexible bronchoscopy are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/50/43816?source=see_link\">",
"     \"Flexible bronchoscopy: Equipment, procedure, and complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20971776\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flexible bronchoscopy is indicated for diagnostic or therapeutic reasons.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20971783\">",
"    <span class=\"h2\">",
"     Diagnostic indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are numerous diagnostic indications for flexible bronchoscopy, including the following (",
"    <a class=\"graphic graphic_table graphicRef58406 \" href=\"mobipreview.htm?11/56/12172\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef72287 \" href=\"mobipreview.htm?2/18/2347\">",
"     table 4",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Suspected pneumonia &ndash; Specimens for microbiological analysis can be collected by flexible bronchoscopy. This is helpful when pneumonia is suspected on the basis of an infiltrate on a chest radiograph and symptoms or signs of pneumonia (eg, fever, cough), but the patient cannot produce sputum for collection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38135/abstract/7\">",
"       7",
"      </a>",
"      ]. The value of bronchoscopic sampling in patients who can produce sputum for analysis is controversial and uncertain, as discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24040?source=see_link&amp;anchor=H322290#H322290\">",
"       \"Clinical presentation and diagnosis of ventilator-associated pneumonia\", section on 'Respiratory sampling'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Parenchymal nodules or masses &ndash; Flexible bronchoscopy is a reasonable approach for the diagnostic evaluation of large central masses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38135/abstract/8\">",
"       8",
"      </a>",
"      ]. It can assess the degree of extrinsic compression caused by the mass and specimens can be collected for pathological analysis by washing or lavaging the airway supplying the lesion, or by direct sampling of peribronchial lesions with brushings or transbronchial needle aspiration. Flexible bronchoscopy is much less useful for smaller peripheral nodules. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/31/44537?source=see_link&amp;anchor=H15#H15\">",
"       \"Diagnostic evaluation and management of the solitary pulmonary nodule\", section on 'Bronchoscopy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mediastinal lymphadenopathy or masses &ndash; Flexible bronchoscopy with transbronchial needle aspiration is used to sample enlarged mediastinal lymph nodes or mediastinal masses, potentially eliminating the need for mediastinoscopy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/35/3642?source=see_link&amp;anchor=H11#H11\">",
"       \"Transbronchial needle aspiration\", section on 'Mediastinal lymphadenopathy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hemoptysis &ndash; Flexible bronchoscopy may identify the cause of bleeding, which is important for determining appropriate therapy and prognosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38135/abstract/9\">",
"       9",
"      </a>",
"      ]. Even if the source of bleeding cannot be identified, flexible bronchoscopy may localize the area of bleeding, which will guide endobronchial balloon tamponade, angiographic embolization, or surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38135/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/24/14727?source=see_link\">",
"       \"Etiology and evaluation of hemoptysis in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30454?source=see_link\">",
"       \"Massive hemoptysis: Initial management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Suspected airway obstruction &ndash; Airway obstruction may be expected on the basis of history (eg, aspiration), an abnormal physical exam finding (eg, focal wheezing), an abnormal pulmonary function test result (eg, flattening of the inspiratory or expiratory limbs of the flow-volume loop), or an abnormal radiographic finding (eg, focal hyperlucency on a chest radiograph). Flexible bronchoscopy may be helpful in confirming airway obstruction and identifying the cause. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37351?source=see_link&amp;anchor=H2#H2\">",
"       \"Diagnosis and management of central airway obstruction\", section on 'Diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/36/35399?source=see_link&amp;anchor=H4#H4\">",
"       \"Airway foreign bodies in adults\", section on 'Diagnostic flexible bronchoscopy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Persistent atelectasis &ndash; Flexible bronchoscopy is warranted in patients who have persistent atelectasis that is either of unknown cause or suspected of being due to airway obstruction. The purpose of bronchoscopy is to identify and remove any obstructing lesion (eg, mucus plug, foreign body). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/36/35399?source=see_link&amp;anchor=H4#H4\">",
"       \"Airway foreign bodies in adults\", section on 'Diagnostic flexible bronchoscopy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Persistent infiltrate &ndash; Slow or incomplete resolution of presumed pneumonia despite treatment is common. Flexible bronchoscopy can obtain specimens as part of the evaluation for an alternative etiology. The evidence suggests that among the persistent infiltrates that are eventually definitively diagnosed, most can be diagnosed by bronchoscopy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38135/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/24/23945?source=see_link&amp;anchor=H28#H28\">",
"       \"Nonresolving pneumonia\", section on 'Bronchoscopy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Suspected lung transplantation rejection &ndash; When a patient who has had a lung transplantation presents with a clinical syndrome suggestive of rejection or infection, most clinicians perform flexible bronchoscopy with bronchoalveolar lavage",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      transbronchial biopsies in an attempt to distinguish rejection and infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38135/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/57/3994?source=see_link\">",
"       \"Evaluation and treatment of acute lung transplant rejection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Suspected tracheobronchomalacia &ndash; Bronchoscopic visualization of dynamic airway collapse is the gold standard for diagnosing tracheomalacia and tracheobronchomalacia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38135/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/42/18088?source=see_link&amp;anchor=H11#H11\">",
"       \"Tracheomalacia and tracheobronchomalacia in adults\", section on 'Bronchoscopy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Smoke inhalation &ndash; Flexible bronchoscopy is frequently performed in fire victims to diagnose smoke inhalation. Evidence of smoke inhalation includes carbonaceous debris, mucosal pallor, mucosal ulceration,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mucosal erythema [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38135/abstract/15\">",
"       15",
"      </a>",
"      ]. Patients with smoke inhalation require close monitoring of their upper airway because obstruction due to edema is common. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/53/17242?source=see_link&amp;anchor=H7#H7\">",
"       \"Emergency care of moderate and severe thermal burns in adults\", section on 'Diagnostic tests and monitoring'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chest trauma &ndash; Blunt or penetrating trauma to the chest or neck can cause a laceration of the airway, which is generally suspected when a patient develops pneumomediastinum and pneumothorax following trauma. Airway lacerations that follow blunt chest trauma generally involve the membranous portion of the distal trachea or proximal mainstem bronchi. Such injuries can be visualized and their severity determined by flexible bronchoscopy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38135/abstract/16\">",
"       16",
"      </a>",
"      ]. Small injuries may be managed conservatively (ie, placing the end of the endotracheal tube distal to the laceration, minimization of airway pressures), but severe injuries require surgical repair.",
"     </li>",
"     <li>",
"      Cough &ndash; Flexible bronchoscopy is usually one of the last diagnostic modalities employed in the evaluation of patients with subacute or chronic cough, but it may occasionally identify a foreign body, airways disease, or a tumor as the cause of the cough [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38135/abstract/17-19\">",
"       17-19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/18/5418?source=see_link&amp;anchor=H16#H16\">",
"       \"Evaluation of subacute and chronic cough in adults\", section on 'Diagnostic approach'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Suspected tracheoesophageal fistula &ndash; Tracheoesophageal fistulas can be congenital, due to malignancy (eg, esophageal or lung cancer), or a complication of prolonged intubation. The initial diagnostic evaluation of a suspected tracheoesophageal fistula generally involves an upper gastrointestinal series with thickened water soluble contrast material. However, if this study is negative and suspicion remains high, flexible bronchoscopy can be performed to look for the fistula. Administration of a contrast agent (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/7/1143?source=see_link\">",
"       methylene blue",
"      </a>",
"      ) into the esophagus during bronchoscopy may help identify the tracheoesophageal fistula [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38135/abstract/20\">",
"       20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/27/29114?source=see_link&amp;anchor=H16#H16\">",
"       \"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula\", section on 'Tracheoesophageal fistula and esophageal atresia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Suspected bronchopleural fistula &ndash; When a post-lobectomy or post-pneumonectomy patient develops a bronchopleural fistula, flexible bronchoscopy may be used to evaluate the integrity of the surgical stump [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38135/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. In contrast, bronchoscopy is not helpful in identifying the location of a bronchopleural fistula following lung biopsy, thoracentesis, or attempted central venous catheter insertion because the bronchoscope cannot visualize the peripheral airways or lung.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20971826\">",
"    <span class=\"h2\">",
"     Therapeutic indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are also numerous therapeutic indications for flexible bronchoscopy, including the following (",
"    <a class=\"graphic graphic_table graphicRef58406 \" href=\"mobipreview.htm?11/56/12172\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef72287 \" href=\"mobipreview.htm?2/18/2347\">",
"     table 4",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mucus accumulation &mdash; Mucus accumulation in the airways may be severe enough to interfere with ventilation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      oxygenation, or to precipitate recurrent atelectasis. Flexible bronchoscopy to suction mucus through the working channel (ie, pulmonary toilet) may be helpful in this situation.",
"     </li>",
"     <li>",
"      Foreign bodies &mdash; Foreign objects can be removed from the tracheobronchial tree using a large variety of retrieval devices on the distal end of catheters passed through the working channel of a flexible bronchoscope (eg, grasping forceps and baskets) (",
"      <a class=\"graphic graphic_picture graphicRef59552 \" href=\"mobipreview.htm?19/44/20161\">",
"       picture 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38135/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/36/35399?source=see_link&amp;anchor=H11#H11\">",
"       \"Airway foreign bodies in adults\", section on 'Flexible bronchoscopy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Endotracheal tube management &ndash; Flexible bronchoscopy may be used to guide the insertion of an endotracheal tube or to confirm the position of an endotracheal tube [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38135/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Laser therapy &mdash; Lasers can be used during flexible bronchoscopy to ablate endobronchial lesions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38135/abstract/25\">",
"       25",
"      </a>",
"      ]. The most common is the neodymium-yttrium-aluminum-garnet (Nd:YAG) laser, which directly burns and desiccates abnormal tissues occluding large airways. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38645?source=see_link\">",
"       \"Bronchoscopic laser resection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Photodynamic therapy &ndash; Photodynamic therapy is a variation of laser therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38135/abstract/25\">",
"       25",
"      </a>",
"      ]. First, a fluorescent dye (usually a hematoporphyrin derivative) is administered into the airway, which accumulates within neoplastic tissue. Then, during flexible bronchoscopy, light of a certain wavelength is used to activate the fluorescent dye, leading to the death of the neoplastic tissue. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/55/37749?source=see_link\">",
"       \"Photodynamic therapy of lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Electrocoagulation &mdash; During electrocoagulation, a catheter containing an electrically heated tip is passed through the working channel of a flexible bronchoscope and used to burn away targeted tissue within the airways [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38135/abstract/25\">",
"       25",
"      </a>",
"      ]. Some of the catheters are designed with metal snares heated by electrical current that can snare and burn through tissue for removal. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11447?source=see_link\">",
"       \"Endobronchial electrocautery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cryotherapy &mdash; During cryotherapy, a catheter containing a metallic tip that is cooled by liquid nitrogen is passed through the working channel of a flexible bronchoscope and placed onto the targeted tissue [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38135/abstract/25\">",
"       25",
"      </a>",
"      ]. This causes a low temperature thermal injury that kills the tissue. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10453?source=see_link\">",
"       \"Bronchoscopic cryosurgery: Principles and technique\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Balloon dilatation &mdash; Catheters analogous to those used for endovascular angioplasty can be passed through the working channel of a flexible bronchoscope, placed adjacent to abnormal airway narrowing, and inflated to a controlled pressure to expand the airway [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38135/abstract/25\">",
"       25",
"      </a>",
"      ]. This is generally followed by endobronchial stent placement to maintain the enlarged airway lumen. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27126?source=see_link\">",
"       \"Flexible bronchoscopy balloon dilation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Brachytherapy catheters &mdash; Brachytherapy involves passing a catheter with a radioactive pellet through the working channel of a flexible bronchoscope and placing the radioactive pellet next to the targeted malignant tissue [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38135/abstract/25\">",
"       25",
"      </a>",
"      ]. The radioactive pellets emit short range radiotherapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32038?source=see_link\">",
"       \"Endobronchial brachytherapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tracheobronchial stents &mdash; Expandable stents are wrapped around catheters that can be passed through the working channel of a flexible bronchoscope into the airways obstructed by tumor or stricture [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38135/abstract/25\">",
"       25",
"      </a>",
"      ]. The stents are most commonly placed in conjunction with ablative therapies or bronchoplasty. The operator positions the stent-catheter complex at the desired site, after which the cord wrapping the stent is unwound, allowing the stent to expand and slide off the catheter. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/0/34823?source=see_link\">",
"       \"Airway stents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bronchial thermoplasty &ndash; Bronchial thermoplasty uses a special catheter with a heated coiled at the distal end. The catheter is passed through the working channel of a flexible bronchoscope and the coil is placed in direct contact with the airway wall. The coil is slowly moved along the airway with the intent of using heat to weaken smooth muscle. This procedure is directed towards severe asthmatics with the goal of limiting bronchospasm by permanently weakening the smooth muscles of the airway [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38135/abstract/26\">",
"       26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/36/33354?source=see_link&amp;anchor=H30#H30\">",
"       \"Alternative and experimental agents for the treatment of asthma\", section on 'Bronchial thermoplasty'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3441165\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most contraindications to flexible bronchoscopy are related to the potential for bronchoscopy to cause tachycardia, bronchospasm, or hypoxemia. Contraindications include current or recent myocardial ischemia; poorly controlled heart failure; significant hypotension, hypertension, bradycardia, or tachycardia; exacerbation of asthma or chronic obstructive pulmonary disease; severe hypoxemia; and life-threatening cardiac arrhythmias. Additional contraindications exist when brushing, biopsy, or needle aspiration is planned, which are related to bleeding risk. They include recent anti-platelet agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ), anticoagulant therapy, thrombocytopenia, coagulopathy, elevated blood urea nitrogen (BUN), or elevated serum creatinine.",
"   </p>",
"   <p>",
"    The following describes our approach for handling these contraindications. We recognize that other reasonable approaches also exist:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We postpone non-emergent bronchoscopy in patients who are currently having or have had any of the following events within the past six weeks: myocardial ischemia (ie, unstable angina, myocardial infarction), decompensated heart failure, an exacerbation of asthma or chronic obstructive pulmonary disease, or life-threatening cardiac arrhythmias [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38135/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      We avoid non-emergent bronchoscopy in patients with severe hypoxemia, which we define as a resting arterial oxygen tension (PaO2) &lt;60 mmHg or an oxyhemoglobin saturation (SpO2) &lt;90 percent while receiving a fraction of inspired oxygen [FiO2] &ge;50 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38135/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      We avoid non-emergent brushing, biopsy, or needle aspiration in patients who have taken an antiplatelet agent within the past five days or subcutaneous low molecular weight",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      in the past 12 hours, or who have a platelet count of 50,000",
"      <span class=\"nowrap\">",
"       platelets/mm3",
"      </span>",
"      or lower, an international normalized ratio (INR) of 1.3 or greater, or an elevated partial thromboplastin time (PTT) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38135/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. For patients who receive platelets or fresh frozen plasma to correct the abnormality, we repeat the relevant laboratory study to confirm that the abnormality has been corrected, before proceeding with the procedure.",
"     </li>",
"     <li>",
"      Among patients whose BUN &gt;30 or whose serum creatinine is &gt;2",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      we generally administer",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      (DDAVP) approximately 30 minutes before the procedure if brushing, biopsy, or needle aspiration is anticipated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38135/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These thresholds are based upon clinical experience, since the reduction of bronchoscopy-related complications has been scarcely studied. However, we have found that these criteria significantly reduce the frequency of bronchoscopy complications, which was largely attributable to a reduction in the incidence of minor bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38135/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recommendation to hold antiplatelet agents prior to bronchoscopy is supported by a prospective cohort study of 604 patients who underwent flexible bronchoscopy with transbronchial biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38135/abstract/30\">",
"     30",
"    </a>",
"    ]. The study found that the risk of bleeding was significantly higher among patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    alone (89 percent) and clopidogrel plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (100 percent), compared to control patients (3.4 percent). However, the possibility that the bleeding risk associated with antiplatelet medications is agent-specific cannot be excluded, since another study found no increased risk of bleeding among patients taking aspirin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38135/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other contraindications include an inability to cooperate with the procedure, an unstable cervical spine, an immobile cervical spine, and limited motion of the temporomandibular joint.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/43/22195?source=see_link\">",
"       \"Patient information: Coughing up blood (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3441440\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Flexible bronchoscopy is a procedure that visualizes the lumen and mucosa of the trachea, proximal airways, and segmental airways to the third generation of branching. It can be used to diagnose or treat abnormalities within or adjacent to these airways. (See",
"      <a class=\"local\" href=\"#H17213836\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are numerous indications for flexible bronchoscopy, which can be categorized as diagnostic or therapeutic indications. Common diagnostic uses include sampling in patients with suspected pneumonia who cannot produce sputum for collection and microbiological analysis, inspection for the site and source of hemoptysis, and sampling nodules, masses, or lymph nodes that are within or adjacent to the airways. Common therapeutic uses include the removal of excess mucus or foreign bodies, the treatment of endobronchial abnormalities, and the deployment of endobronchial stents. (See",
"      <a class=\"local\" href=\"#H20971783\">",
"       'Diagnostic indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20971826\">",
"       'Therapeutic indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most contraindications to flexible bronchoscopy are related to the potential of bronchoscopy to cause tachycardia or bronchospasm. They include current or recent myocardial ischemia, poorly controlled heart failure, asthma exacerbation, chronic obstructive pulmonary disease exacerbation, severe hypoxemia, and life-threatening cardiac arrhythmias. Additional contraindications exist when brushing or biopsy is planned, which are related to bleeding risk. They include recent anti-platelet agents, anticoagulant therapy, thrombocytopenia, coagulopathy, elevated blood urea nitrogen, and elevated serum creatinine. (See",
"      <a class=\"local\" href=\"#H3441165\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Bronchoscopy - a medical dictionary, bibliography, and annotated research guide to internet references, ICON Health Publications, 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38135/abstract/2\">",
"      Bolliger CT, Mathur PN, Beamis JF, et al. ERS/ATS statement on interventional pulmonology. European Respiratory Society/American Thoracic Society. Eur Respir J 2002; 19:356.",
"     </a>",
"    </li>",
"    <li>",
"     Textbook of bronchoscopy, Feinsilver, SJ, Fein, AM (Eds), William &amp; Wilkens, Baltimore 1995.",
"    </li>",
"    <li>",
"     Thoracic endoscopy: advances in interventional pulmonology, Simoff, MJ, Sterman, DH, Ernst, A (Eds), Oxford:Blackwell/Futura, Malden, MA 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38135/abstract/5\">",
"      Vining DJ, Liu K, Choplin RH, Haponik EF. Virtual bronchoscopy. Relationships of virtual reality endobronchial simulations to actual bronchoscopic findings. Chest 1996; 109:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38135/abstract/6\">",
"      Boiselle PM, Ernst A. Recent advances in central airway imaging. Chest 2002; 121:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38135/abstract/7\">",
"      van der Eerden MM, Vlaspolder F, de Graaff CS, et al. Value of intensive diagnostic microbiological investigation in low- and high-risk patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2005; 24:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38135/abstract/8\">",
"      Tan BB, Flaherty KR, Kazerooni EA, et al. The solitary pulmonary nodule. Chest 2003; 123:89S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38135/abstract/9\">",
"      Gong H Jr, Salvatierra C. Clinical efficacy of early and delayed fiberoptic bronchoscopy in patients with hemoptysis. Am Rev Respir Dis 1981; 124:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38135/abstract/10\">",
"      Karmy-Jones R, Cuschieri J, Valli&egrave;res E. Role of bronchoscopy in massive hemoptysis. Chest Surg Clin N Am 2001; 11:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38135/abstract/11\">",
"      Feinsilver SH, Fein AM, Niederman MS, et al. Utility of fiberoptic bronchoscopy in nonresolving pneumonia. Chest 1990; 98:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38135/abstract/12\">",
"      Faro A, Visner G. The use of multiple transbronchial biopsies as the standard approach to evaluate lung allograft rejection. Pediatr Transplant 2004; 8:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38135/abstract/13\">",
"      Nuutinen J. Acquired tracheobronchomalacia. A clinical study with bronchological correlations. Ann Clin Res 1977; 9:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38135/abstract/14\">",
"      Liberman M. Bronchoscopic evaluation of the trachea and dilation of the trachea. Semin Thorac Cardiovasc Surg 2009; 21:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38135/abstract/15\">",
"      American Burn Association. Inhalation injury: diagnosis. J Am Coll Surg 2003; 196:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38135/abstract/16\">",
"      Chu CP, Chen PP. Tracheobronchial injury secondary to blunt chest trauma: diagnosis and management. Anaesth Intensive Care 2002; 30:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38135/abstract/17\">",
"      Kvale PA, Selecky PA, Prakash UB, American College of Chest Physicians. Palliative care in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132:368S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38135/abstract/18\">",
"      Rank MA, Kelkar P, Oppenheimer JJ. Taming chronic cough. Ann Allergy Asthma Immunol 2007; 98:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38135/abstract/19\">",
"      Brown KK. Chronic cough due to nonbronchiectatic suppurative airway disease (bronchiolitis): ACCP evidence-based clinical practice guidelines. Chest 2006; 129:132S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38135/abstract/20\">",
"      Karnak I, Senocak ME, Hi&ccedil;s&ouml;nmez A, B&uuml;y&uuml;kpamuk&ccedil;u N. The diagnosis and treatment of H-type tracheoesophageal fistula. J Pediatr Surg 1997; 32:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38135/abstract/21\">",
"      McManigle JE, Fletcher GL, Tenholder MF. Bronchoscopy in the management of bronchopleural fistula. Chest 1990; 97:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38135/abstract/22\">",
"      York EL, Lewall DB, Hirji M, et al. Endoscopic diagnosis and treatment of postoperative bronchopleural fistula. Chest 1990; 97:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38135/abstract/23\">",
"      Limper AH, Prakash UB. Tracheobronchial foreign bodies in adults. Ann Intern Med 1990; 112:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38135/abstract/24\">",
"      Dellinger RP. Fiberoptic bronchoscopy in adult airway management. Crit Care Med 1990; 18:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38135/abstract/25\">",
"      Wahidi MM, Herth FJ, Ernst A. State of the art: interventional pulmonology. Chest 2007; 131:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38135/abstract/26\">",
"      Cox G, Miller JD, McWilliams A, et al. Bronchial thermoplasty for asthma. Am J Respir Crit Care Med 2006; 173:965.",
"     </a>",
"    </li>",
"    <li>",
"     file://main.uab.edu/pulmonary/Templates/Inner.aspx?pid=92617 (Accessed on August 08, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38135/abstract/28\">",
"      Wahidi MM, Rocha AT, Hollingsworth JW, et al. Contraindications and safety of transbronchial lung biopsy via flexible bronchoscopy. A survey of pulmonologists and review of the literature. Respiration 2005; 72:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38135/abstract/29\">",
"      Dransfield MT, Garver RI, Weill D. Standardized guidelines for surveillance bronchoscopy reduce complications in lung transplant recipients. J Heart Lung Transplant 2004; 23:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38135/abstract/30\">",
"      Ernst A, Eberhardt R, Wahidi M, et al. Effect of routine clopidogrel use on bleeding complications after transbronchial biopsy in humans. Chest 2006; 129:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38135/abstract/31\">",
"      Herth FJ, Becker HD, Ernst A. Aspirin does not increase bleeding complications after transbronchial biopsy. Chest 2002; 122:1461.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4400 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-60.18.131.125-4DC6258CCE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_15_38135=[""].join("\n");
var outline_f37_15_38135=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3441440\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17213836\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20971776\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20971783\">",
"      Diagnostic indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20971826\">",
"      Therapeutic indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3441165\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3441440\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4400\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4400|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/7/27762\" title=\"figure 1\">",
"      Flexible bronchoscope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/12/9408\" title=\"figure 2\">",
"      Virtual bronch central",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4400|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?28/58/29603\" title=\"picture 1\">",
"      Rigid bronchoscope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/44/20161\" title=\"picture 2\">",
"      Flexible bronchoscopes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4400|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/58/31659\" title=\"table 1\">",
"      Types of bronchoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/12/1227\" title=\"table 2\">",
"      Indications rigid bronchoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/56/12172\" title=\"table 3\">",
"      Indications for bronchoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/18/2347\" title=\"table 4\">",
"      Bronchoscopy in ICU",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/36/35399?source=related_link\">",
"      Airway foreign bodies in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/0/34823?source=related_link\">",
"      Airway stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/36/33354?source=related_link\">",
"      Alternative and experimental agents for the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10453?source=related_link\">",
"      Bronchoscopic cryosurgery: Principles and technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38645?source=related_link\">",
"      Bronchoscopic laser resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24040?source=related_link\">",
"      Clinical presentation and diagnosis of ventilator-associated pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/27/29114?source=related_link\">",
"      Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37351?source=related_link\">",
"      Diagnosis and management of central airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/31/44537?source=related_link\">",
"      Diagnostic evaluation and management of the solitary pulmonary nodule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/53/17242?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32038?source=related_link\">",
"      Endobronchial brachytherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/11/11447?source=related_link\">",
"      Endobronchial electrocautery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/32/19976?source=related_link\">",
"      Endobronchial ultrasound: Indications, advantages, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/26/43427?source=related_link\">",
"      Endobronchial ultrasound: Technical aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/24/14727?source=related_link\">",
"      Etiology and evaluation of hemoptysis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/57/3994?source=related_link\">",
"      Evaluation and treatment of acute lung transplant rejection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/18/5418?source=related_link\">",
"      Evaluation of subacute and chronic cough in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27126?source=related_link\">",
"      Flexible bronchoscopy balloon dilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/50/43816?source=related_link\">",
"      Flexible bronchoscopy: Equipment, procedure, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30454?source=related_link\">",
"      Massive hemoptysis: Initial management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/24/23945?source=related_link\">",
"      Nonresolving pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/43/22195?source=related_link\">",
"      Patient information: Coughing up blood (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/55/37749?source=related_link\">",
"      Photodynamic therapy of lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/33/37394?source=related_link\">",
"      Rigid bronchoscopy: Instrumentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/42/18088?source=related_link\">",
"      Tracheomalacia and tracheobronchomalacia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/35/3642?source=related_link\">",
"      Transbronchial needle aspiration",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_15_38136="Pathogenesis and treatment of infertility in women with endometriosis";
var content_f37_15_38136=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis and treatment of infertility in women with endometriosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/15/38136/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/15/38136/contributors\">",
"     Mark D Hornstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/15/38136/contributors\">",
"     William E Gibbons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/15/38136/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/15/38136/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/15/38136/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/15/38136/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/15/38136/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovulatory disorders, tubal obstruction, and semen abnormalities are relatively easy to diagnose and account for the cause of infertility in approximately 75 percent of couples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/1\">",
"     1",
"    </a>",
"    ]. When couples with these abnormalities are excluded, infertility in the other 25 percent of couples is usually due to endometriosis, which may be present in 40 percent of the female partners of these couples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/2\">",
"     2",
"    </a>",
"    ]. The remaining cases are classified as unexplained infertility (",
"    <a class=\"graphic graphic_table graphicRef80115 \" href=\"mobipreview.htm?40/44/41675\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/18/3367?source=see_link\">",
"     \"Causes of female infertility\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/61/40921?source=see_link\">",
"     \"Evaluation of female infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although endometriosis impairs fertility, it does not usually completely prevent conception. A combination of surgery, ovulation induction plus intrauterine insemination, and in vitro fertilization can be used to help these women conceive.",
"   </p>",
"   <p>",
"    This topic will provide an approach to treatment of infertility in women with endometriosis. Other aspects of endometriosis are reviewed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19210?source=see_link\">",
"       \"Pathogenesis, clinical features, and diagnosis of endometriosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14810?source=see_link\">",
"       \"Overview of the treatment of endometriosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/46/5863?source=see_link\">",
"       \"Diagnosis and management of ovarian endometriomas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25254?source=see_link\">",
"       \"Thoracic endometriosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS OF INFERTILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanisms of infertility associated with endometriosis are controversial and likely depend, in part, on the stage of disease. Endometriosis is surgically staged using the American Society of Reproductive Medicine (ASRM) staging system (",
"    <a class=\"graphic graphic_figure graphicRef66366 \" href=\"mobipreview.htm?17/34/17954\">",
"     figure 1",
"    </a>",
"    ). The spectrum of disease ranges from minimal presence of ectopic tissue (eg, 1 to 5 mm implants on the pelvic peritoneum) to severe anatomic distortion (deep ovarian endometriomas, major pelvic adhesions with obliteration of normal pelvic organ relationships).",
"   </p>",
"   <p>",
"    Although stage I or II endometriosis may be the only abnormal finding identified during an infertility evaluation, there is no high quality evidence proving that early stage disease is the cause of infertility in these patients. It is hypothesized that",
"    <span class=\"nowrap\">",
"     minimal/mild",
"    </span>",
"    endometriosis is associated with overproduction of prostaglandins, metalloproteinases, cytokines, and chemokines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/3\">",
"     3",
"    </a>",
"    ], and that the resulting inflammatory process impairs ovarian, peritoneal, tubal, and endometrial function, leading to defective folliculogenesis, fertilization,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    implantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Support for this theory comes from studies showing that women with endometriosis have increased numbers of macrophages and cytokines in their peritoneal fluid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/5-7\">",
"     5-7",
"    </a>",
"    ] and that their peritoneal fluid inhibits sperm function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/8\">",
"     8",
"    </a>",
"    ] and ciliary function in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/9\">",
"     9",
"    </a>",
"    ], which could impair fertilization. In addition, a m&uuml;llerian tract \"field defect\" may be present so that even eutopic endometrium may not function normally, which could impair implantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/10\">",
"     10",
"    </a>",
"    ]. Progesterone resistance may also be involved and related to a reduction in the concentration of progesterone receptors and progesterone coactivators (eg, Hic-5) in the endometrium of women with endometriosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is better evidence that",
"    <span class=\"nowrap\">",
"     moderate/severe",
"    </span>",
"    endometriosis causes infertility. In a study of monkeys with experimentally induced endometriosis, the pregnancy rate was about 40 percent in normal controls, but only 12 percent in animals with advanced endometriosis and 0 percent if ovarian adhesions were present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/12\">",
"     12",
"    </a>",
"    ]. Minimal endometriosis did not diminish the pregnancy rate.",
"   </p>",
"   <p>",
"    The major pelvic adhesions present in advanced endometriosis may contribute to reduced fertility by impairing oocyte release, blocking sperm entry into the peritoneal cavity, or inhibiting tubal pickup. The functional mechanisms discussed above for",
"    <span class=\"nowrap\">",
"     mild/moderate",
"    </span>",
"    disease probably also contribute to impaired fertility in women with advanced stage disease.",
"   </p>",
"   <p>",
"    Reduced pregnancy rates for women with advanced endometriosis (compared to women with early stage endometriosis or tubal factor infertility) may also be due to premature depletion of the ovarian follicle pool [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/13\">",
"     13",
"    </a>",
"    ], abnormal folliculogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/14\">",
"     14",
"    </a>",
"    ], or reduced fertilization potential of oocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/15\">",
"     15",
"    </a>",
"    ]. A history of previous bilateral ovarian surgery may also play a role; women with a previous oophorectomy and a contralateral ovarian cystectomy appear to have poor responses to ovarian stimulation and a low pregnancy rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     APPROACH TO TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initially, it is important to identify and treat all reversible causes of infertility in the couple. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/56/17287?source=see_link\">",
"     \"Overview of infertility\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/5/14425?source=see_link\">",
"     \"Overview of treatment of female infertility\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3610?source=see_link\">",
"     \"Treatment of male infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fertility specialists differ on whether laparoscopy is an important component of a thorough infertility evaluation. In many fertility centers, laparoscopy is not performed prior to initiating therapy for infertility because it requires general anesthesia, carries a small risk of serious complications, and is a resource intensive step. The indications for, and benefits of, diagnostic laparoscopy during infertility evaluation are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/61/40921?source=see_link&amp;anchor=H17#H17\">",
"     \"Evaluation of female infertility\", section on 'Role of laparoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the absence of a definitive laparoscopic diagnosis of endometriosis, we initially treat infertility patients with suspected endometriosis in the same way as those with unexplained infertility: they receive three to four cycles of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate and intrauterine insemination (IUI). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/57/25496?source=see_link\">",
"     \"Unexplained infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If pregnancy does not occur after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    and IUI, a decision needs to be made whether to (1) proceed to laparoscopy to try to make a definitive diagnosis of endometriosis and initiate operative treatment, or (2) proceed to gonadotropin injections plus IUI, or (3) proceed to in vitro fertilization (IVF). Factors that impact upon this decision are the age of the female partner, whether other infertility factors (eg, male factor) were noted during the infertility evaluation, and practical issues, such as the presence and extent of fertility coverage. A flowchart of the general approach to treatment of infertility in women with endometriosis is provided in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef62685 \" href=\"mobipreview.htm?15/0/15374\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Since the pathophysiology of endometriosis is controversial, the therapy, particularly in stages associated with minimal adhesion formation, is primarily empiric. For women under 35 years of age, a reasonable approach is laparoscopy with resection of endometriosis, if present, followed by an extended period (up to six months) of attempted conception before resorting to ovulation induction (trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    then gonadotropin injections) plus IUI. Alternatively, clinicians may proceed directly to clomiphene and IUI. In older women, however, clinicians may skip laparoscopy and move directly to gonadotropin induction plus IUI or, if laparoscopy is performed and endometriosis can be resected, decrease the length of the post-surgical period before attempting ovulation induction (trial of clomiphene then gonadotropin injections) plus IUI. The more rapid pace to intervention in older women is to ensure that if IVF is necessary, the treatment will be started before the ovarian follicle pool wanes and the success of IVF decreases. In women with high stage disease, moving directly to IVF is an option.",
"   </p>",
"   <p>",
"    In the setting of multiple infertility factors (eg, significant male factor component, decreased ovarian reserve), we would probably go straight to IVF because the presence of multiple factors has a large negative effect on conservative therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Medical therapy is ineffective",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized clinical trials consistently report that hormone therapy with agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    or GnRH agonists for suppression of endometriosis does NOT improve fertility or pregnancy rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/16-21\">",
"     16-21",
"    </a>",
"    ]. The lack of improvement applies to women treated with medical therapy alone, as well as those treated with combined medical and surgical therapy versus surgery alone. On the other hand, hormonal suppression is an effective therapy of endometriosis related pain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14810?source=see_link\">",
"     \"Overview of the treatment of endometriosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SURGICAL RESECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations to patients after laparoscopy are based on the operative findings and results of surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Mild/minimal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with lower stage endometriosis at diagnostic laparoscopy, randomized and controlled trials have shown that ablation or excision of endometriosis implants improves fertility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/16,22,23\">",
"     16,22,23",
"    </a>",
"    ], and is cost-effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/24\">",
"     24",
"    </a>",
"    ]. Postoperatively, for women under age 35, it is reasonable to offer six months of timed intercourse before moving on to ovulation induction plus IUI (see below).",
"   </p>",
"   <p>",
"    For women over age 35, ovulation induction plus IUI can be initiated after a shorter period of timed intercourse or immediately after surgery. In our experience, infertility patients with endometriosis are anxious to continue treatment and most elect to proceed with ovulation induction plus IUI sooner rather than later.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Moderate/severe disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women with moderate to severe endometriosis, surgery involves resection of ovarian endometriomas and superficial and deep peritoneal implants, as well as resection of pelvic adhesions to restore pelvic anatomy and function. The efficacy of surgical excision of advanced endometriosis to improve fertility has not been proven in randomized trials, but data from observational studies support this approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/17,25\">",
"     17,25",
"    </a>",
"    ]. Even if IVF is ultimately indicated, excision of deep infiltrating endometriosis at laparoscopy may improve IVF pregnancy rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If surgical resection of advanced disease is successful, ovulation induction plus IUI can be initiated immediately after surgery or after three to six months of attempting to conceive. As discussed above, in our experience infertility patients with endometriosis are anxious to continue treatment and most elect to proceed with ovulation induction plus IUI right after surgery.",
"   </p>",
"   <p>",
"    However, if at the end of the surgical procedure the fallopian tubes are not patent, severe tubal adhesions are still present, or if the burden of disease was severe, then proceeding to IVF is probably a better approach than a trial of postsurgical ovulation induction, particularly in older reproductive age women or if there is a co-existing male factor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Repeated surgical resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major benefit of surgical therapy is achieved shortly after the first attempt because severe, periovarian adhesions will generally recur over time and limit tubal pick-up of the ovum. If initial surgery does not result in pregnancy, subsequent surgical procedures are not likely to be effective for increasing fecundability. A systematic review of studies evaluating reproductive performance after repeat surgery of recurrent endometriosis found that only about 25 percent of patients achieved conception after the second surgery and this rate was about one-half that after initial surgery and lower than the rate of conception after IVF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Physicians should carefully weigh the limited benefits of second and third operative procedures to enhance fertility against the potential risks of major surgery and the likelihood of success with IVF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical techniques for treatment of endometriosis to enhance fertility are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/18/9513?source=see_link\">",
"     \"Reproductive surgery for female infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     OVULATION INDUCTION PLUS IUI",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women under age 35,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate plus IUI is a reasonable and cost effective approach. For women over age 35, it is not clear whether gonadotropin injection plus IUI offers an advantage over clomiphene plus IUI, but many clinicians prefer gonadotropins in this age group since more follicles are likely to develop (see below).",
"   </p>",
"   <p>",
"    The intent of combined therapy is to enhance follicular development, ovulation, and luteal progesterone levels (to offset the associated progesterone resistance) while placing a large number of motile sperm high in the reproductive tract to facilitate fertilization. Evidence from randomized trials shows that ovulation induction and IUI should be used together [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/28\">",
"     28",
"    </a>",
"    ], and that this combined therapy improves fecundability in women with early stage endometriosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9626?source=see_link\">",
"     \"Ovulation induction with clomiphene citrate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/48/25351?source=see_link\">",
"     \"Procedure for intrauterine insemination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Clomiphene plus IUI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the clinical trials evaluating the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    plus IUI have focused on women with early stage endometriosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/30\">",
"     30",
"    </a>",
"    ]. Nevertheless, many authorities believe the benefits of these treatments, which have been clearly demonstrated in clinical trials in women with infertility and early stage endometriosis, probably also extend to women with advanced disease if their fallopian tubes are patent and if adhesions have been surgically resected. The per cycle pregnancy rate appears to drop significantly after three or four cycles of clomiphene plus IUI. Therefore, after three or four postoperative cycles of these treatments, the clinician should move on to gonadotropin injections plus IUI. Patients with severe and remitting pain, suggestive of persistent or recurrent disease, should go directly to IVF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Gonadotropin plus IUI",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many patients, the next step after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    failure is to try a course of gonadotropin injections plus IUI. The rationale for this therapy is the same as discussed above: enhance follicular development, ovulation, and fertilization. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/10/13482?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of ovulation induction\", section on 'Gonadotropin therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/48/25351?source=see_link\">",
"     \"Procedure for intrauterine insemination\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple randomized trials in women with mild endometriosis have demonstrated the efficacy of a gonadotropin plus IUI compared with no treatment or either treatment alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/31-36\">",
"     31-36",
"    </a>",
"    ]. As discussed above, many authorities believe the benefit of this treatment also extends to women with advanced disease if their fallopian tubes are patent and if adhesions have been surgically resected.",
"   </p>",
"   <p>",
"    The efficacy of gonadotropin injections plus IUI for treatment of endometriosis-related infertility was best illustrated in a large clinical trial sponsored by the National Institutes of Health [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/35\">",
"     35",
"    </a>",
"    ]. Over 900 infertile couples (most of whom carried the diagnosis of early stage endometriosis or unexplained infertility) were randomly assigned to one of four treatment groups:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intracervical insemination of sperm (ICI)",
"     </li>",
"     <li>",
"      Intrauterine insemination of sperm (IUI)",
"     </li>",
"     <li>",
"      FSH injections plus ICI",
"     </li>",
"     <li>",
"      FSH injections plus IUI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The purpose of the ICI group was to serve as control treatment group, equivalent to natural intercourse.",
"   </p>",
"   <p>",
"    Fecundability after FSH plus IUI was significantly higher than with ICI or IUI alone. Fecundability for the four treatment groups was: ICI alone (0.02), IUI alone (0.05), FSH plus ICI (0.04), FSH plus IUI (0.09). The main disadvantage of this approach is the increase in the rate of multiple gestation. Among the ongoing pregnancies in the groups receiving FSH injections, 3 percent were quadruplets, 5 percent were triplets, and 20 percent were twins. For this reason, some authorities prefer skipping this step and moving directly from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    plus IUI treatment to IVF, where the number of embryos transferred into the uterus is under the control of the clinician.",
"   </p>",
"   <p>",
"    The per cycle pregnancy rate drops significantly after three or four cycles of gonadotropin injections plus IUI. Therefore, after three cycles of these treatments, the clinician should talk to the couple about the advantages of proceeding to treatment with IVF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An alternative approach to the treatment of mild endometriosis is to move directly from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    and IUI to IVF. In a large prospective trial, 503 patients under age 40 with unexplained infertility and low stage endometriosis following clomiphene and IUI treatment were randomly assigned to receive three cycles of",
"    <span class=\"nowrap\">",
"     FSH/IUI",
"    </span>",
"    followed by up to six cycles of IVF (conventional care) or an accelerated treatment consisting of IVF only [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/38\">",
"     38",
"    </a>",
"    ]. Compared to conventional care, patients accelerated to IVF had an increased rate of pregnancy (hazard ratio 1.25, 95% CI 1.00-1.56), a shortened median time to pregnancy (8 versus 11 months), and lower charges per delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     IN VITRO FERTILIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;IVF is the most resource-intensive step of infertility therapy, but also the treatment associated with the highest per cycle pregnancy rate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37770?source=see_link\">",
"     \"In vitro fertilization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no prospective, large scale, randomized trials demonstrating the efficacy of IVF in the treatment of infertility caused by endometriosis. Observational series have reported that IVF procedures in women with endometriosis routinely result in a treatment cycle pregnancy rate of approximately 0.30, which is higher than the 0.03 baseline fecundability of women with mild endometriosis and infertility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. However, a meta-analysis of observational studies found that women with endometriosis-related infertility undergoing IVF were less likely to achieve pregnancy than women with tubal factor infertility (OR 0.56, 95% CI 0.44-0.70) and pregnancy rates after IVF were lower in women with severe endometriosis than in those with mild endometriosis (OR 0.60, 95% CI 0.42-0.87) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The results of this analysis remain controversial, as subsequent reports have not found that IVF is less successful in women with endometriosis than in other women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. For example, national data from the Society for Assisted Reproductive Technologies (SART) demonstrated that the IVF success rate in patients with endometriosis approximated that of patients with other diagnoses (overall live birth rate IVF 27 percent, for women with endometriosis 32 percent, for women with unexplained infertility 29 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The stage of disease appears to be an important factor, marked reduction of oocyte pick-up in severe disease provides few options for therapy. In advanced stage endometriosis, fewer oocytes are retrieved for IVF, thus fewer pregnancies are achieved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Endometrioma",
"    </span>",
"    &nbsp;&mdash;&nbsp;One clinical conundrum is how to approach a woman with an ovarian endometrioma (ovarian endometriosis cyst) who is planning to undergo IVF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/48\">",
"     48",
"    </a>",
"    ]. A major concern is that resection of endometriomas results in the loss of small follicles adjacent to the cyst wall, resulting in a reduced oocyte pool and reduced ovulation frequency in the ovary from which the endometrioma has been excised, which itself is associated with infertility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/49-51\">",
"     49-51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Few prospective or randomized trials have been performed to evaluate the benefit of removing endometriomas prior to IVF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Meta-analyses of randomized and controlled studies of surgery versus no treatment of endometriomas prior to IVF found no significant difference between groups in ovarian response to controlled ovarian stimulation or in clinical pregnancy rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    Although there is no consensus on the optimum approach, most fertility specialists would not necessarily excise these lesions prior to initiating IVF since a benefit has not been clearly demonstrated and ovarian surgery may diminish ovarian function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/52,54,56\">",
"     52,54,56",
"    </a>",
"    ]. It is probably best to resect endometriomas prior to IVF only for gynecological indications, such as pelvic pain or suspicion of ovarian malignancy, or if the size or location of the endometrioma would limit oocyte retrieval during IVF. Drainage and ablation, rather than excision, is not effective. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/46/5863?source=see_link\">",
"     \"Diagnosis and management of ovarian endometriomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cost effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;An analysis of the cost effectiveness of various infertility treatments found that for infertile women with advanced endometriosis, rapid progression through the steps to IVF was the most cost effective treatment algorithm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/57\">",
"     57",
"    </a>",
"    ]. However, in low stage disease, progression from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    and IUI directly to IVF, rather than utilization of gonadotropins and IUI prior to the IVF, resulted in a net group savings of approximately $9800 per live birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/38\">",
"     38",
"    </a>",
"    ]. Based upon data from 1993, the cost of IVF per live birth was in the range of 22,000 to 43,000 dollars, depending upon the clinical characteristics of the infertile couples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/58\">",
"     58",
"    </a>",
"    ]. These costs are within the range of current costs for adopting a child. Furthermore, IVF success rates have increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38136/abstract/59\">",
"     59",
"    </a>",
"    ] and costs per live birth have decreased since 1993.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/8/5251?source=see_link\">",
"       \"Patient information: Endometriosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/63/26611?source=see_link\">",
"       \"Patient information: Endometriosis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The step-wise approach to the treatment of infertility associated with endometriosis balances the risk and cost of the intervention with the efficacy of the treatment. These steps may include: identifying and treating reversible causes of infertility, surgical resection of endometriosis,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/22/23909?source=see_link\">",
"       clomiphene",
"      </a>",
"      plus intrauterine insemination, gonadotropin plus intrauterine insemination, and in vitro fertilization. (See each step above).",
"     </li>",
"     <li>",
"      Four factors that impact upon decision making are the age of the female partner, whether other infertility factors (eg, male factor) were noted during the infertility evaluation, the stage of endometriosis",
"      <span class=\"nowrap\">",
"       (minimal/mild",
"      </span>",
"      versus",
"      <span class=\"nowrap\">",
"       moderate/severe),",
"      </span>",
"      and practical issues, such as the presence and extent of fertility coverage, and the preference of the patient. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Approach to treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with",
"      <span class=\"nowrap\">",
"       minimal/mild",
"      </span>",
"      endometriosis at diagnostic laparoscopy, we recommend ablation or excision of endometriosis implants (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Postoperatively, women under age 35 may attempt timed intercourse for up to six months. If they fail to conceive, we suggest ovulation induction plus intrauterine insemination (IUI) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For women over age 35, ovulation induction plus IUI may be initiated after three to six months of timed intercourse or immediately after surgery, given the decreased fecundity in older women. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Mild/minimal disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For young women with",
"      <span class=\"nowrap\">",
"       moderate/severe",
"      </span>",
"      endometriosis at laparoscopy, we suggest resection of endometriosis and adhesions (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If surgical resection of advanced disease is successful, we suggest ovulation induction plus IUI (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This can be initiated immediately after surgery or after three to six months of attempting to conceive. (See",
"      <span class=\"nowrap\">",
"       Moderate/severe",
"      </span>",
"      disease\" above).",
"     </li>",
"     <li>",
"      We suggest not attempting repeat surgical resection of endometriosis for infertility (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Repeated surgical procedures do not enhance fertility. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Repeated surgical resection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For ovulation induction in women under age 35, we suggest three or four cycles of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/22/23909?source=see_link\">",
"       clomiphene",
"      </a>",
"      citrate as first line therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ) and gonadotropin injections or IVF as second line therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For women over age 35, we suggest gonadotropin injections for first line therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Ovulation induction is paired with IUI. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Ovulation induction plus IUI'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest in vitro fertilization for women who fail to conceive with the above measures (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In vitro fertilization is also appropriate if at the end of the surgical procedure the fallopian tubes are not patent, severe tubal adhesions are still present, or if the burden of disease was severe. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'In vitro fertilization'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Moderate/severe disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We resect endometriomas prior to in vitro fertilization only for gynecological indications, such as pelvic pain or suspicion of ovarian malignancy or if the endometrioma would interfere with egg retrieval in an IVF cycle. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Endometrioma'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/1\">",
"      Smith S, Pfeifer SM, Collins JA. Diagnosis and management of female infertility. JAMA 2003; 290:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/2\">",
"      Tanahatoe SJ, Hompes PG, Lambalk CB. Investigation of the infertile couple: should diagnostic laparoscopy be performed in the infertility work up programme in patients undergoing intrauterine insemination? Hum Reprod 2003; 18:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/3\">",
"      Bulun SE. Endometriosis. N Engl J Med 2009; 360:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/4\">",
"      Gupta S, Goldberg JM, Aziz N, et al. Pathogenic mechanisms in endometriosis-associated infertility. Fertil Steril 2008; 90:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/5\">",
"      Haney AF, Muscato JJ, Weinberg JB. Peritoneal fluid cell populations in infertility patients. Fertil Steril 1981; 35:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/6\">",
"      Halme J, Becker S, Haskill S. Altered maturation and function of peritoneal macrophages: possible role in pathogenesis of endometriosis. Am J Obstet Gynecol 1987; 156:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/7\">",
"      Fakih H, Baggett B, Holtz G, et al. Interleukin-1: a possible role in the infertility associated with endometriosis. Fertil Steril 1987; 47:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/8\">",
"      Oral E, Arici A, Olive DL, Huszar G. Peritoneal fluid from women with moderate or severe endometriosis inhibits sperm motility: the role of seminal fluid components. Fertil Steril 1996; 66:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/9\">",
"      Lyons RA, Djahanbakhch O, Saridogan E, et al. Peritoneal fluid, endometriosis, and ciliary beat frequency in the human fallopian tube. Lancet 2002; 360:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/10\">",
"      Lessey BA, Castelbaum AJ, Sawin SW, et al. Aberrant integrin expression in the endometrium of women with endometriosis. J Clin Endocrinol Metab 1994; 79:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/11\">",
"      Aghajanova L, Velarde MC, Giudice LC. The progesterone receptor coactivator Hic-5 is involved in the pathophysiology of endometriosis. Endocrinology 2009; 150:3863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/12\">",
"      Schenken RS, Asch RH, Williams RF, Hodgen GD. Etiology of infertility in monkeys with endometriosis: luteinized unruptured follicles, luteal phase defects, pelvic adhesions, and spontaneous abortions. Fertil Steril 1984; 41:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/13\">",
"      Hornstein MD, Barbieri RL, McShane PM. Effects of previous ovarian surgery on the follicular response to ovulation induction in an in vitro fertilization program. J Reprod Med 1989; 34:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/14\">",
"      Toya M, Saito H, Ohta N, et al. Moderate and severe endometriosis is associated with alterations in the cell cycle of granulosa cells in patients undergoing in vitro fertilization and embryo transfer. Fertil Steril 2000; 73:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/15\">",
"      Pal L, Shifren JL, Isaacson KB, et al. Impact of varying stages of endometriosis on the outcome of in vitro fertilization-embryo transfer. J Assist Reprod Genet 1998; 15:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/16\">",
"      Kennedy S, Bergqvist A, Chapron C, et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod 2005; 20:2698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/17\">",
"      Adamson GD, Pasta DJ. Surgical treatment of endometriosis-associated infertility: meta-analysis compared with survival analysis. Am J Obstet Gynecol 1994; 171:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/18\">",
"      Seibel MM, Berger MJ, Weinstein FG, Taymor ML. The effectivenss of danazol on subsequent fertility in minimal endometriosis. Fertil Steril 1982; 38:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/19\">",
"      Loverro G, Carriero C, Rossi AC, et al. A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III-IV endometriosis. Eur J Obstet Gynecol Reprod Biol 2008; 136:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/20\">",
"      Harrison RF, Barry-Kinsella C. Efficacy of medroxyprogesterone treatment in infertile women with endometriosis: a prospective, randomized, placebo-controlled study. Fertil Steril 2000; 74:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/21\">",
"      Parazzini F, Fedele L, Busacca M, et al. Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial. Am J Obstet Gynecol 1994; 171:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/22\">",
"      Jacobson TZ, Barlow DH, Koninckx PR, et al. Laparoscopic surgery for subfertility associated with endometriosis. Cochrane Database Syst Rev 2002; :CD001398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/23\">",
"      Marcoux S, Maheux R, B&eacute;rub&eacute; S. Laparoscopic surgery in infertile women with minimal or mild endometriosis. Canadian Collaborative Group on Endometriosis. N Engl J Med 1997; 337:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/24\">",
"      Moayeri SE, Lee HC, Lathi RB, et al. Laparoscopy in women with unexplained infertility: a cost-effectiveness analysis. Fertil Steril 2009; 92:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/25\">",
"      Olive DL, Lee KL. Analysis of sequential treatment protocols for endometriosis-associated infertility. Am J Obstet Gynecol 1986; 154:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/26\">",
"      Bianchi PH, Pereira RM, Zanatta A, et al. Extensive excision of deep infiltrative endometriosis before in vitro fertilization significantly improves pregnancy rates. J Minim Invasive Gynecol 2009; 16:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/27\">",
"      Vercellini P, Somigliana E, Vigan&ograve; P, et al. The effect of second-line surgery on reproductive performance of women with recurrent endometriosis: a systematic review. Acta Obstet Gynecol Scand 2009; 88:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/28\">",
"      Arici A, Byrd W, Bradshaw K, et al. Evaluation of clomiphene citrate and human chorionic gonadotropin treatment: a prospective, randomized, crossover study during intrauterine insemination cycles. Fertil Steril 1994; 61:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/29\">",
"      Deaton JL, Gibson M, Blackmer KM, et al. A randomized, controlled trial of clomiphene citrate and intrauterine insemination in couples with unexplained infertility or surgically corrected endometriosis. Fertil Steril 1990; 54:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/30\">",
"      Dickey RP, Taylor SN, Lu PY, et al. Effect of diagnosis, age, sperm quality, and number of preovulatory follicles on the outcome of multiple cycles of clomiphene citrate-intrauterine insemination. Fertil Steril 2002; 78:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/31\">",
"      Fedele L, Bianchi S, Marchini M, et al. Superovulation with human menopausal gonadotropins in the treatment of infertility associated with minimal or mild endometriosis: a controlled randomized study. Fertil Steril 1992; 58:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/32\">",
"      Tummon IS, Asher LJ, Martin JS, Tulandi T. Randomized controlled trial of superovulation and insemination for infertility associated with minimal or mild endometriosis. Fertil Steril 1997; 68:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/33\">",
"      Nulsen JC, Walsh S, Dumez S, Metzger DA. A randomized and longitudinal study of human menopausal gonadotropin with intrauterine insemination in the treatment of infertility. Obstet Gynecol 1993; 82:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/34\">",
"      Chaffkin LM, Nulsen JC, Luciano AA, Metzger DA. A comparative analysis of the cycle fecundity rates associated with combined human menopausal gonadotropin (hMG) and intrauterine insemination (IUI) versus either hMG or IUI alone. Fertil Steril 1991; 55:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/35\">",
"      Guzick DS, Carson SA, Coutifaris C, et al. Efficacy of superovulation and intrauterine insemination in the treatment of infertility. National Cooperative Reproductive Medicine Network. N Engl J Med 1999; 340:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/36\">",
"      Sallam HN, Garcia-Velasco JA, Dias S, Arici A. Long-term pituitary down-regulation before in vitro fertilization (IVF) for women with endometriosis. Cochrane Database Syst Rev 2006; :CD004635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/37\">",
"      Isaksson R, Tiitinen A. Superovulation combined with insemination or timed intercourse in the treatment of couples with unexplained infertility and minimal endometriosis. Acta Obstet Gynecol Scand 1997; 76:550.",
"     </a>",
"    </li>",
"    <li>",
"     Reindollar, RH, Regan, MM, Neumann, PJ, Levine, BS, et al. A randomized clinical trial to evaluate optimal treatment for unexplained infertility in the fast track and standard treatment (FASTT) trial. Fertil Steril 2009; :. [Epub ahead of print].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/39\">",
"      Olivennes F, Feldberg D, Liu HC, et al. Endometriosis: a stage by stage analysis--the role of in vitro fertilization. Fertil Steril 1995; 64:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/40\">",
"      Oehninger S, Acosta AA, Kreiner D, et al. In vitro fertilization and embryo transfer (IVF/ET): an established and successful therapy for endometriosis. J In Vitro Fert Embryo Transf 1988; 5:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/41\">",
"      Chillik CF, Acosta AA, Garcia JE, et al. The role of in vitro fertilization in infertile patients with endometriosis. Fertil Steril 1985; 44:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/42\">",
"      Barnhart K, Dunsmoor-Su R, Coutifaris C. Effect of endometriosis on in vitro fertilization. Fertil Steril 2002; 77:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/43\">",
"      Brosens I. Endometriosis and the outcome of in vitro fertilization. Fertil Steril 2004; 81:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/44\">",
"      Gibbons WE. Management of endometriosis in fertility patients. Fertil Steril 2004; 81:1204.",
"     </a>",
"    </li>",
"    <li>",
"     www.sart.org/find_frm.html.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/46\">",
"      Molloy D, Martin M, Speirs A, et al. Performance of patients with a \"frozen pelvis\" in an in vitro fertilization program. Fertil Steril 1987; 47:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/47\">",
"      Yanushpolsky EH, Best CL, Jackson KV, et al. Effects of endometriomas on ooccyte quality, embryo quality, and pregnancy rates in in vitro fertilization cycles: a prospective, case-controlled study. J Assist Reprod Genet 1998; 15:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/48\">",
"      Somigliana E, Vercellini P, Vigan&oacute; P, et al. Should endometriomas be treated before IVF-ICSI cycles? Hum Reprod Update 2006; 12:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/49\">",
"      Horikawa T, Nakagawa K, Ohgi S, et al. The frequency of ovulation from the affected ovary decreases following laparoscopic cystectomy in infertile women with unilateral endometrioma during a natural cycle. J Assist Reprod Genet 2008; 25:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/50\">",
"      Exacoustos C, Zupi E, Amadio A, et al. Laparoscopic removal of endometriomas: sonographic evaluation of residual functioning ovarian tissue. Am J Obstet Gynecol 2004; 191:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/51\">",
"      Ragni G, Somigliana E, Benedetti F, et al. Damage to ovarian reserve associated with laparoscopic excision of endometriomas: a quantitative rather than a qualitative injury. Am J Obstet Gynecol 2005; 193:1908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/52\">",
"      Demirol A, Guven S, Baykal C, Gurgan T. Effect of endometrioma cystectomy on IVF outcome: a prospective randomized study. Reprod Biomed Online 2006; 12:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/53\">",
"      Pabuccu R, Onalan G, Goktolga U, et al. Aspiration of ovarian endometriomas before intracytoplasmic sperm injection. Fertil Steril 2004; 82:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/54\">",
"      Tsoumpou I, Kyrgiou M, Gelbaya TA, Nardo LG. The effect of surgical treatment for endometrioma on in vitro fertilization outcomes: a systematic review and meta-analysis. Fertil Steril 2009; 92:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/55\">",
"      Benschop L, Farquhar C, van der Poel N, Heineman MJ. Interventions for women with endometrioma prior to assisted reproductive technology. Cochrane Database Syst Rev 2010; :CD008571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/56\">",
"      Gupta S, Agarwal A, Agarwal R, Loret de Mola JR. Impact of ovarian endometrioma on assisted reproduction outcomes. Reprod Biomed Online 2006; 13:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/57\">",
"      Philips Z, Barraza-Llorens M, Posnett J. Evaluation of the relative cost-effectiveness of treatments for infertility in the UK. Hum Reprod 2000; 15:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/58\">",
"      Trad FS, Hornstein MD, Barbieri RL. In vitro fertilization: a cost-effective alternative for infertile couples? J Assist Reprod Genet 1995; 12:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38136/abstract/59\">",
"      Cramer DW, Liberman RF, Powers D, et al. Recent trends in assisted reproductive techniques and associated outcomes. Obstet Gynecol 2000; 95:61.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7408 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-199.231.185.123-BC6E475435-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_15_38136=[""].join("\n");
var outline_f37_15_38136=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS OF INFERTILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      APPROACH TO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Medical therapy is ineffective",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SURGICAL RESECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Mild/minimal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Moderate/severe disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Repeated surgical resection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      OVULATION INDUCTION PLUS IUI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Clomiphene plus IUI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Gonadotropin plus IUI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      IN VITRO FERTILIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Endometrioma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cost effectiveness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/7408\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/7408|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?15/0/15374\" title=\"algorithm 1\">",
"      Rx infertility endometrios",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/7408|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/34/17954\" title=\"figure 1\">",
"      Classification of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/7408|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/44/41675\" title=\"table 1\">",
"      Diseases related to infertility",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/18/3367?source=related_link\">",
"      Causes of female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/46/5863?source=related_link\">",
"      Diagnosis and management of ovarian endometriomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/61/40921?source=related_link\">",
"      Evaluation of female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/56/37770?source=related_link\">",
"      In vitro fertilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/56/17287?source=related_link\">",
"      Overview of infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/10/13482?source=related_link\">",
"      Overview of ovulation induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14810?source=related_link\">",
"      Overview of the treatment of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/5/14425?source=related_link\">",
"      Overview of treatment of female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9626?source=related_link\">",
"      Ovulation induction with clomiphene citrate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19210?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/63/26611?source=related_link\">",
"      Patient information: Endometriosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/8/5251?source=related_link\">",
"      Patient information: Endometriosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/48/25351?source=related_link\">",
"      Procedure for intrauterine insemination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/18/9513?source=related_link\">",
"      Reproductive surgery for female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25254?source=related_link\">",
"      Thoracic endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3610?source=related_link\">",
"      Treatment of male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/57/25496?source=related_link\">",
"      Unexplained infertility",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_15_38137="Overview of surgical procedures for resectable primary rectal cancer";
var content_f37_15_38137=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of surgical procedures for resectable primary rectal cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/15/38137/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/15/38137/contributors\">",
"     Ronald Bleday, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/15/38137/contributors\">",
"     David Shibata, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/15/38137/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/15/38137/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/15/38137/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/15/38137/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/15/38137/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1848046\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is the cornerstone of curative therapy for patients with resectable rectal adenocarcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/1\">",
"     1",
"    </a>",
"    ]. The operative procedure selected depends upon stage, size, and location. Superficial",
"    <span class=\"nowrap\">",
"     (T0/T1)",
"    </span>",
"    and small (&lt;3 cm) cancers may be effectively managed with limited surgery, such as local excision. However, most patients have more deeply invasive tumors that require a sphincter-sparing procedure or abdominoperineal resection (APR). Locally advanced tumors that are adherent or fixed to adjoining structures (eg, sacrum, pelvic sidewalls, prostate, or bladder) require a more extensive resection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87594804\">",
"    <span class=\"h1\">",
"     LOCAL EXCISION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients whose rectal cancers have nonaggressive features can be treated by local excision, including the transanal, transsphincteric, and posterior parasacral approaches. Local excision permits removal of both the tumor and adjoining rectal tissue in one specimen without tumor fragmentation, and allows assessment of inked margins, histologic differentiation, vascular involvement, and depth of invasion.",
"   </p>",
"   <p>",
"    The selection criteria for performing a local excision alone (eg, T1 lesion, less than 3 cm in diameter) are reviewed separately (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"mobipreview.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/16/34057?source=see_link&amp;anchor=H87589066#H87589066\">",
"     \"Surgical oncologic principles for resection of primary rectal adenocarcinoma\", section on 'Local excision'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Select patients (eg, elderly with comorbid illnesses, refusal of major resection) with rectal cancers deeper than T1 can be treated with a local excision if used in conjunction with radiation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemotherapy, administered preoperatively or postoperatively. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/51/4922?source=see_link&amp;anchor=H6323794#H6323794\">",
"     \"Adjuvant therapy for resected rectal cancer\", section on 'Adjuvant chemoradiotherapy for T2-3 rectal cancer after local excision'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients undergoing a local excision must be closely followed indefinitely, as almost one-third of local recurrences occur more than five years after resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Patients whose preoperative staging was either a T3 or T4 who have downstaged to a T2 cancer can be closely followed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. All patients with a T2, T3, or T4 cancer who have positive margins should undergo reoperation, generally between one to eight weeks. For patients who have also received neoadjuvant radiation therapy, we delay further procedures until the site has completely healed.",
"   </p>",
"   <p>",
"    Recurrences are likely to present with an advanced and unfavorable histology and are associated with low survival rates following salvage surgery. For example, a retrospective review of 175 patients with rectal cancer treated initially by a local excision found that patients with low-risk T1 cancers completely resected had a local recurrence rate of 6 percent",
"    <span class=\"nowrap\">",
"     (6/93",
"    </span>",
"    patients), and the median time to local recurrence was 20 months (range 4 to 36 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/6\">",
"     6",
"    </a>",
"    ]. The 10-year disease-free survival and overall survival were 92 percent and 98 percent, respectively. Additional pertinent findings from this study include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients undergoing an immediate reoperation because of unfavorable histologic findings (eg, inadequate margins, &ge;T2 cancers) had a lower local recurrence rate compared with patients treated without immediate reoperation in anticipation of salvage surgery (8",
"      <span class=\"nowrap\">",
"       [3/39",
"      </span>",
"      patients] versus 37",
"      <span class=\"nowrap\">",
"       [16/43",
"      </span>",
"      patients] percent).",
"     </li>",
"     <li>",
"      Patients treated by immediate reoperation were less likely to develop metastatic disease (10 versus 23 percent).",
"     </li>",
"     <li>",
"      Ten-year disease-free survival was significantly better for patients treated with an immediate reoperation (86 versus 54 percent).",
"     </li>",
"     <li>",
"      Ten-year overall survival was significantly better for patients treated with an immediate reoperation (89 versus 72 percent).",
"     </li>",
"     <li>",
"      Recurrences were less likely to be an unfavorable histology",
"      <span class=\"nowrap\">",
"       (AJCC/UICC&ndash;III/IV)",
"      </span>",
"      for patients initially treated successfully with a local excision or immediate reoperation compared with patients undergoing salvage surgery for a recurrence (3 versus 14 versus 28 percent) (",
"      <a class=\"graphic graphic_table graphicRef72913 \" href=\"mobipreview.htm?23/26/23982\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with positive resection margins or tumors deeper than T1 on the final histologic review and who refuse immediate reoperation, an alternative is chemoradiation therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87595929\">",
"    <span class=\"h2\">",
"     Transanal excision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transanal excision (TAE) is the most commonly used local resection procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The goal of the procedure is a complete, full-thickness excision of the rectal cancer with a minimum lateral margin of 1 cm, a histologically negative deep margin, and a primary closure. If the margins of excision are positive for cancer, an additional resection is necessary, such as a wider TAE or a major intra-abdominal operation (ie, sphincter-sparing or APR with total mesorectal excision). TAE can be used alone",
"    <span class=\"nowrap\">",
"     (T0/T1",
"    </span>",
"    cancers) or in combination with chemoradiation therapy (T2 rectal cancers).",
"   </p>",
"   <p>",
"    The benefits of TAE include minimal, if any, compromise of anorectal, bladder, and sexual function, and fewer postoperative complications. A retrospective review of 479 patients with T1 rectal cancer found significantly fewer general postoperative complications for patients treated by the conventional TAE or transanal endoscopic microsurgery (n = 120) compared with a major resection (8 versus 25 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/10\">",
"     10",
"    </a>",
"    ]. TAE may be ideal for patients with comorbid illnesses or frailty that preclude a major resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/8,11-13\">",
"     8,11-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The disadvantage of TAE alone is the high recurrence rate, ranging from 0 to 31 percent, and potential compromise for cure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/2,3,8,9,11,13-15\">",
"     2,3,8,9,11,13-15",
"    </a>",
"    ]. In a prospective study of 291 patients with T1M0 rectal cancer within 15 cm from the anal verge, patients treated with a TAE without neoadjuvant therapy were more likely to have macroscopic tumor remnants compared with patients undergoing a major resection",
"    <span class=\"nowrap\">",
"     (6/35",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     0/226",
"    </span>",
"    patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/8\">",
"     8",
"    </a>",
"    ]. Patients treated with a TAE had a significantly higher five-year local recurrence rate (12 versus 6 percent) and lower five-year survival rate (70 versus 80 percent) and five-year disease-free rate (64 versus 77 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1273103\">",
"    <span class=\"h2\">",
"     Transanal endoscopic microsurgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transanal endoscopic microsurgery (TEM) is a minimally invasive technique that facilitates local excision of rectal cancers between 4 to 18 cm from the anal verge, higher than can be accessible with the conventional TAE approach because of the greater exposure and precision of the excision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/16-28\">",
"     16-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Local recurrence rates for T1 rectal cancers treated by TEM alone are comparable to more extensive operative procedures (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"mobipreview.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ). A retrospective review of 74 patients with rectal cancer treated by TEM alone found a lower five-year local recurrence rate for patients with T1 tumors (n = 52) compared with T2 tumors (4.1 versus 19.5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/18\">",
"     18",
"    </a>",
"    ]. In comparison, the local recurrence rates for patients with T1 (n = 17) and T2 rectal cancers (n = 83) following a major intra-abdominal resection were 0 percent and 9.4 percent, respectively.",
"   </p>",
"   <p>",
"    An alternative to TEM alone is the administration of preoperative radiation therapy to improve disease-free survival. In a retrospective review of 137 patients with T0-T3 rectal cancer, patients with",
"    <span class=\"nowrap\">",
"     T0/T1",
"    </span>",
"    cancers had a greater disease-free survival rate at 46 months compared with patients with T2 or T3 lesions (100 versus 81 versus 59 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/23\">",
"     23",
"    </a>",
"    ]. The overall morbidity rate was 10 percent.",
"   </p>",
"   <p>",
"    There are no prospective trials comparing TAE with TEM for excision of rectal cancer. However, in a retrospective review of 259 patients with rectal adenomas, fragmentation of the specimen was more common with TAE (n = 43) compared with TEM (23.8 versus 1.4 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/29\">",
"     29",
"    </a>",
"    ]. TAE was also associated with a higher recurrence rate of the adenoma (28.7 versus 6.1 percent).",
"   </p>",
"   <p>",
"    Treatment-related morbidity compares favorably to anterior resection, although TEM is associated with short-term reduction in anorectal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/17,30-32\">",
"     17,30-32",
"    </a>",
"    ]. Although uncommon, inadvertent entry into the peritoneal cavity during the procedure may require conversion to an open procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/33\">",
"     33",
"    </a>",
"    ]. Given this risk, the utility of full-thickness tumor excision using TEM is most applicable to lesions below the peritoneal reflection. However, due to the configuration of the equipment, TEM is generally not useful for distal lesions.",
"   </p>",
"   <p>",
"    The limitations of the procedure include equipment expense and technical expertise (",
"    <a class=\"graphic graphic_figure graphicRef58698 \" href=\"mobipreview.htm?37/4/37953\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87595937\">",
"    <span class=\"h2\">",
"     Transsphincteric (York-Mason) procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transsphincteric (York-Mason) procedure is performed to resect rectal cancers located in the middle portion of the rectum beyond the reach of a transanal excision by dividing the levator ani and puborectalis muscles, and external anal sphincter, and performing a segmental resection with primary closure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/34\">",
"     34",
"    </a>",
"    ]. The York-Mason procedure has largely been replaced with the transanal endoscopic microscope approach for these cancers. However, this procedure is also an option for treating local recurrences confined to the presacral space following an APR.",
"   </p>",
"   <p>",
"    The transsphincteric and transsacral approaches are more extensive than a TAE or TEM and have a greater degree of associated morbidity, mainly because of disruption of normal musculofascial planes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/35\">",
"     35",
"    </a>",
"    ]. In a retrospective of 19 patients with benign or malignant rectal lesions undergoing a transsphincteric or transsacral approach, 8 nonfatal complications occurred, including fecal fistulas, wound complications, rectal stricture, and sacrococcygeal hernia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/34\">",
"     34",
"    </a>",
"    ]. Fecal incontinence was temporary when it occurred, and one patient required a permanent colostomy. Six patients had a primary or recurrent malignancy, and no local recurrences were reported, but three patients died of cardiovascular disease or complications of systemic therapy for metastatic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87595953\">",
"    <span class=\"h2\">",
"     Transsacral (Kraske) procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transsacral (Kraske) procedure can be performed to resect rectal cancers in the posterior and middle portion of the rectum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/36\">",
"     36",
"    </a>",
"    ]. The rectum is circumferentially mobilized and the cancer is excised by a partial or segmental resection of the rectum with a primary closure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/34\">",
"     34",
"    </a>",
"    ]. The technique is still used in special circumstances where a TEM cannot be used. It can also be used for treating fistula that develop from a low anterior resection anastomoses and for the local recurrence post APR. This procedure is also an option for treating local recurrences confined to the presacral space following an APR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87594840\">",
"    <span class=\"h2\">",
"     Other local techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less extensive procedures can be used for highly select patients, such as those with untreatable metastatic disease or comorbidities that preclude any other surgical options. These options include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fulguration &ndash; Fulguration (electrocoagulation) is performed by inserting an electrode into the wall of the rectal cancer and destroying the cancer and a circumferential rim of normal tissue to control for local recurrence. While it had been advocated as a curative procedure with a 58 percent five-year survival, it is now generally reserved for palliative purposes. Fulguration may be optimal for patients with bulky bleeding rectal cancers who are too ill to undergo more extensive procedures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]. The disadvantages of this procedure include postoperative fever, the lack of a surgical specimen for staging, the requirement for repeated procedures, and the need to convert to more radical procedures in a large number of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Endocavitary radiation by contact",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      interstitial brachytherapy &ndash; Endocavitary radiation entails the placement of a high dose rate radioactive source (eg, Iridium-192) directly into the rectum through a special proctoscope. A surgical specimen is not available for staging purposes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/39\">",
"       39",
"      </a>",
"      ]. A retrospective review of 102 patients identified a local control rate of 83 percent for T1 cancers and 38 percent for T2 cancers for patients treated by contact therapy or interstitial brachytherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/40\">",
"       40",
"      </a>",
"      ]. In addition to a high failure rate, there is also a high rate of persistent (unresponsive) disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1845484\">",
"    <span class=\"h1\">",
"     SPHINCTER-SPARING PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with invasive rectal cancers that are not candidates for a local excision can be resected using a sphincter-sparing procedure, (eg, low anterior resection, coloanal resection) provided the distal margin of resection is histologically negative for malignancy. The criteria for sphincter-sparing procedures are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/16/34057?source=see_link&amp;anchor=H87589426#H87589426\">",
"     \"Surgical oncologic principles for resection of primary rectal adenocarcinoma\", section on 'Sphincter-sparing resection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Morbidity and mortality and management of complications of colorectal surgery are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/57/1946?source=see_link\">",
"     \"Management of intra-abdominal, pelvic, and genitourinary complications of colorectal surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/5/4186?source=see_link\">",
"     \"Management of anastomotic complications of colorectal surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Local recurrence rates for patients treated with a sphincter-sparing procedure range from 6 to 31 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/42-47\">",
"     42-47",
"    </a>",
"    ], and are similar to patients treated with an abdominal perineal resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/42,44-46,48\">",
"     42,44-46,48",
"    </a>",
"    ]. Local recurrence rates can be lowered by obtaining histologically negative margins of resection, performing a total mesorectal excision, and, for select patients, the administration of neoadjuvant or adjuvant chemoradiation therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/16/34057?source=see_link&amp;anchor=H87589530#H87589530\">",
"     \"Surgical oncologic principles for resection of primary rectal adenocarcinoma\", section on 'Principles of resection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/22/42346?source=see_link\">",
"     \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/51/4922?source=see_link\">",
"     \"Adjuvant therapy for resected rectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1845491\">",
"    <span class=\"h2\">",
"     Low anterior resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A low anterior resection (LAR), also referred to as an anterior resection (AR), is used to surgically treat invasive cancers located in the upper to middle third of the rectum. A very low anterior resection can be used for cancers in the distal rectum, provided the distal margin is histologically clear of malignant cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/16/34057?source=see_link&amp;anchor=H87590738#H87590738\">",
"     \"Surgical oncologic principles for resection of primary rectal adenocarcinoma\", section on 'Distal margin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The resection includes removal of the sigmoid colon and rectum to a level where the distal margin is free of cancer, with a primary anastomosis between the descending colon and rectum or anal sphincter (",
"    <a class=\"graphic graphic_figure graphicRef80416 \" href=\"mobipreview.htm?17/24/17807\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef84656 \" href=\"mobipreview.htm?26/35/27185\">",
"     figure 3",
"    </a>",
"    ). A diverting ostomy is performed to protect the anastomosis if it is low, under tension, or a positive air leak is detected on proctoscopic testing. We have a low threshold for using a temporary diverting ostomy in patients who have had preoperative chemoradiation and in those patients on immunosuppressive therapy, such as steroids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/50\">",
"     50",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2792368\">",
"    <span class=\"h2\">",
"     Very low and ultra low anterior resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sphincter-sparing procedures for cancers in the distal rectum (very low and ultra low anterior resections) are reserved for patients who have a distal rectal cancer that does not invade the anal sphincter",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    is not amenable to a conventional LAR. The anastomosis between the colon and anal sphincter can be performed as a straight side-to-end reservoir, a colonic J-pouch reservoir, or a transverse coloplasty, depending on the surgeon&rsquo;s preference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1845505\">",
"     'Coloanal anastomosis with colonic J-pouch reservoir'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Typically, we use a side-to-end reservoir since it has the fewest staple lines. We use the J pouch in patients with a redundant colon and wide pelvis to accommodate the extra width of the pouch. We create a pouch no greater than 6 to 8 cm long to avoid evacuation difficulties. (See",
"    <a class=\"local\" href=\"#H1845505\">",
"     'Coloanal anastomosis with colonic J-pouch reservoir'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The resection includes completely mobilizing the splenic flexure to achieve sufficient length of the vascular pedicle of the descending colon to perform a coloanal anastomosis (",
"    <a class=\"graphic graphic_figure graphicRef73756 \" href=\"mobipreview.htm?40/32/41479\">",
"     figure 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef81960 \" href=\"mobipreview.htm?3/3/3127\">",
"     figure 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef81638 \" href=\"mobipreview.htm?38/22/39265\">",
"     figure 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef56301 \" href=\"mobipreview.htm?37/16/38145\">",
"     figure 7",
"    </a>",
"    ). The rectum is transected at the level of the pelvic floor musculature, and a primary anastomosis is performed between the colon proximal to or at the level of the anal sphincter. The coloanal anastomosis preserves the anal sphincter mechanism with the distal margin at the minimally acceptable level adequate for cancer clearance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/16/34057?source=see_link&amp;anchor=H87590738#H87590738\">",
"     \"Surgical oncologic principles for resection of primary rectal adenocarcinoma\", section on 'Distal margin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Functional results are favorable following a coloanal anastomosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. In a retrospective review of 81 patients undergoing a straight side-to-end coloanal anastomosis for rectal cancer, fecal continence was complete in 51 percent, with major leakage in 21 percent and minor leakage in 5 percent, while incontinence to flatus was present in 21 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/51\">",
"     51",
"    </a>",
"    ]. Overall function was excellent in 28 percent, good in 28 percent, fair in 32 percent, and poor in 12 percent of patients. Long-term postoperative function measured by a quality of life instrument (EORTC QLQ-C30) found that patients with a coloanal anastomosis (straight or J-pouch reservoir) and treated with preoperative (n = 27) or postoperative radiation therapy (n = 36) had worse functional outcomes compared with patients who received no radiation therapy (n = 58) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/52\">",
"     52",
"    </a>",
"    ]. An analysis was not performed to assess function based on type of reservoir.",
"   </p>",
"   <p>",
"    The Anterior Perineal Plane for Ultra Low Anterior Resection of the rectum (APPEAR) is a prospective NIH pilot study (NCT00534131) recruiting patients with malignant and benign low rectal disease who will undergo a complete resection of the diseased rectum and an anastomosis under direct vision between the bowel (ie, colon or small bowel in the case of inflammatory bowel disease) and the anal sphincter mechanism. Patients eligible for this trial include those for whom a conventional sphincter sparing procedure (LAR) is contraindicated because of perceived lack of oncologic clearance of the distal margin or because it is technically impossible. For further information on this trial, please see the NIH Clinical Trial website:",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00534131\">",
"     file://clinicaltrials.gov/ct2/show/NCT00534131.",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1845505\">",
"    <span class=\"h3\">",
"     Coloanal anastomosis with colonic J-pouch reservoir",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative to the straight coloanal anastomosis is the colonic J-pouch, which provides a larger neorectal reservoir compared with the straight reservoir [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/42\">",
"     42",
"    </a>",
"    ]. A side-to-side anastomosis is performed at the distal 8 cm of the colon to create a pouch with an undistended volume capacity between 60 and 105 mL, an optimal reservoir capacity that facilitates evacuation without incontinence or defecation complications (",
"    <a class=\"graphic graphic_figure graphicRef82078 \" href=\"mobipreview.htm?13/35/13873\">",
"     figure 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/53-57\">",
"     53-57",
"    </a>",
"    ]. Larger reservoirs result in difficulties evacuating the colon; smaller reservoirs are associated with incontinence and frequent bowel movements. A defunctioning ileostomy does not prevent an anastomotic leak [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/58\">",
"     58",
"    </a>",
"    ], but is advisable for patients at a higher risk of an anastomotic leak (eg, obese, preoperative radiation therapy, an anastomosis below 5 cm, steroid usage). Approximately 5 to 25 percent of patients with rectal cancer are not candidates for a colonic J-pouch for technical reasons (eg, inability to sufficiently mobilize the colon for a low anastomosis, bulky anal sphincter, narrow pelvis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mortality and long-term bowel function (eg, frequency of bowel movements, urgency, and incontinence) of patients undergoing a colonic J-pouch are comparable with the straight coloanal reservoir approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/60-63\">",
"     60-63",
"    </a>",
"    ]. Patients undergoing a colonic J-pouch have better bowel function immediately after the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/59\">",
"     59",
"    </a>",
"    ], but bowel function adapts to the straight reservoir and there is no significant functional difference at two years. Morbidity rates (eg, anastomotic leaks, bleeding, fistulas) are low, with many studies showing comparable or fewer complications for patients undergoing a J-pouch reservoir [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/60-63\">",
"     60-63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1845512\">",
"    <span class=\"h3\">",
"     Transverse coloplasty reservoir",
"    </span>",
"    &nbsp;&mdash;&nbsp;A neorectal reservoir can be created by a transverse coloplasty (TC). TC is acceptable for patients undergoing a sphincter-sparing procedure, but who are not ideal candidates for a J-pouch or a straight coloanal anastomosis because of a narrow pelvis or other technical limitations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/59,64-69\">",
"     59,64-69",
"    </a>",
"    ]. The TC is created by performing an 8 to 10 cm longitudinal colotomy between the colonic tenia, beginning approximately 4 to 6 cm proximal to the distal end of the mobilized descending colon, and reapproximating the incision transversely (",
"    <a class=\"graphic graphic_figure graphicRef61426 \" href=\"mobipreview.htm?33/9/33939\">",
"     figure 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/59\">",
"     59",
"    </a>",
"    ]. The distal end of the colon is anastomosed to the anal sphincter.",
"   </p>",
"   <p>",
"    Functional results are mixed following a TC. In a randomized trial of 279 patients undergoing reconstruction following a low sphincter-sparing resection, patients undergoing a TC had similar bowel function at two years compared with those undergoing a straight coloanal anastomosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/70\">",
"     70",
"    </a>",
"    ]. Patients treated with a colonic J-pouch had fewer bowel movements and less incontinence in comparison with TC patients. Other randomized trials have identified complication rates, functional outcomes, and quality of life of patients undergoing TC reconstruction comparable to the colonic J-pouch approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/66,67,69\">",
"     66,67,69",
"    </a>",
"    ]. Hence, the J-pouch is the reservoir of choice for the authors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87595450\">",
"    <span class=\"h1\">",
"     ABDOMINAL PERINEAL RESECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An abdominal perineal resection (APR) includes the resection of the sigmoid colon, rectum, and anus, and the construction of a permanent colostomy. This procedure is the gold standard for surgical therapy of low-lying rectal cancers, and it remains the standard against which sphincter sparing procedures (SSP) and local excision procedures are compared. Criteria for an APR (eg, inability to achieve a negative distal margin by a sphincter-sparing procedure) are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/16/34057?source=see_link&amp;anchor=H87589433#H87589433\">",
"     \"Surgical oncologic principles for resection of primary rectal adenocarcinoma\", section on 'Abdominal perineal resection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Variable results have been reported for local recurrence rates for patients treated with an APR compared with a SSP. For example, a retrospective review of 655 consecutive patients undergoing an APR or SSP with curative intent, found the five-year cumulative local recurrence rate for patients resected by an APR (n = 246) was not statistically higher compared with patients resected by a SSP (5.5 versus 3.6 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/71\">",
"     71",
"    </a>",
"    ]. An APR was performed for all patients with low rectal cancers if a 1 cm histologically negative distal margin could not be achieved by a SSP. Five-year cause-specific survival and all-stage disease-free survival did not differ significantly between an APR and SSP (91.3 versus 91.6 percent and 90.2 versus 90.0 percent, respectively). However, the National Surgical Adjuvant Breast and Bowel Project (protocol R-01) found that patients treated with a sphincter-sparing procedure had a higher local recurrence rate compared with patients undergoing an APR (13 versus 5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/72\">",
"     72",
"    </a>",
"    ]. There was no significant difference in disease-free survival and overall survival.",
"   </p>",
"   <p>",
"    Long-term quality of life (QOL) after APR is similar to that after SSP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/73-78\">",
"     73-78",
"    </a>",
"    ], with the exception of depression related to changes in body image following an APR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/79\">",
"     79",
"    </a>",
"    ]. Poor postoperative sphincter function after a SSP may result in poor QOL. Progressively lower surgical anastomoses are associated with a corresponding progressive decline in anorectal function (eg, increased stool frequency, more incontinence and perianal irritation, decreased stool and flatus discrimination, more incomplete evacuations, and decreased rectal compliance) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. In one prospective study, longitudinal QOL was compared between 50 patients who had SSP and 23 who had an APR for rectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/76\">",
"     76",
"    </a>",
"    ]. Despite the permanent colostomy after APR, QOL was significantly worse in patients who had a SSP with an anastomosis within 5 cm of the anal verge. Thus, patients with disease involvement of the anal sphincter musculature or rectovaginal septum, poor continence preoperatively, or diarrheal disorders, where a low anastomosis would lead to fecal incontinence, are best treated with APR. Radiation treatments after an APR did not adversely affect QOL when compared with APR alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103735992\">",
"    <span class=\"h1\">",
"     MULTIVISCERAL RESECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A multivisceral resection specifically includes the resection of the cancer and adjacent organs invaded by the cancer. A total pelvic exenteration (TPE) is the surgical en bloc removal of the pelvic organs, including the rectum, bladder, and internal reproductive organs (ie,",
"    <span class=\"nowrap\">",
"     prostate/seminal",
"    </span>",
"    vesicles or uterus, ovaries",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vagina) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/83\">",
"     83",
"    </a>",
"    ]. Continence-sparing surgery may be possible provided histologically negative margins can be achieved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/16/34057?source=see_link&amp;anchor=H87589530#H87589530\">",
"     \"Surgical oncologic principles for resection of primary rectal adenocarcinoma\", section on 'Principles of resection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A modified exenteration can be either anterior, posterior, supralevator, or composite, depending on the organs or structures involved:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anterior exenterations leave the rectum in place while the bladder and internal reproductive organs are removed.",
"     </li>",
"     <li>",
"      A posterior pelvic exenteration (PPE) involves removal of the rectum, anus, uterus, ovaries, and posterior vaginal wall.",
"     </li>",
"     <li>",
"      A supralevator exenteration is one in which a sphincter-saving procedure can be performed. It could be a PPE where a primary colorectal anastomosis is performed, or an en bloc removal of the bladder, or uterus and ovaries and posterior vaginal wall, and rectum where a primary colorectal anastomosis is performed.",
"     </li>",
"     <li>",
"      Composite resections are exenterative procedures whereby the en bloc resection includes resection of bony structures such as the sacrum and coccyx.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    TPE is reserved as the surgical approach for patients with locally advanced primary cancer involving adjacent organs (T4) (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"mobipreview.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ) or bony structures, or as a salvage procedure for recurrent cancer, when a less radical procedure is not technically possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/86-89\">",
"     86-89",
"    </a>",
"    ]. TPE is used in conjunction with a multimodality approach for most patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/22/42346?source=see_link\">",
"     \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/51/4922?source=see_link\">",
"     \"Adjuvant therapy for resected rectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Retrospective studies show that TPE and multivisceral resections can be performed with low mortality (range 0 to 8 percent) but high morbidity (range 26 to 61 percent) and high reoperation rates (20 to 30 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/85,90-98\">",
"     85,90-98",
"    </a>",
"    ]. Patients undergoing a TPE for locally advanced primary rectal cancer have a better five-year control rate compared with patients with recurrent rectal cancer (89 versus 38 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/92\">",
"     92",
"    </a>",
"    ]. The overall five-year survival rate is also better for patients with primary rectal cancer (range, 43 to 66 versus 1 to 8 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/83,85,92,93\">",
"     83,85,92,93",
"    </a>",
"    ]. In a retrospective review of 1741 patients with T4 nonmetastatic locally advanced rectal cancer, patients treated with a multivisceral resection had a better overall five-year survival compared with patients undergoing a standard colorectal resection (35.1 versus 27.7 percent, hazard ratio = 0.81, 95% CI 0.70-0.94), with no increase in mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38137/abstract/99\">",
"     99",
"    </a>",
"    ]. Receipt of adjuvant or neoadjuvant radiation was also associated with a better overall survival, and a multivisceral resection was associated with a survival benefit regardless of the nodal status or type of radiation therapy (preoperative or postoperative) administered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1845575\">",
"    <span class=\"h1\">",
"     PALLIATIVE RECTAL SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who present with locally unresectable primary, recurrent, or metastatic disease, the goal of surgery is relief of obstruction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    control of hemorrhage rather than cure. Palliation can be achieved through local procedures (eg, fulguration, local excision), proximal diversion, or stent placement. Management is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/37/11866?source=see_link\">",
"     \"Treatment of locally advanced unresectable or recurrent rectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/34/5673?source=see_link\">",
"     \"Enteral stents for the management of malignant colorectal obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1848054\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is the cornerstone of curative therapy for patients with rectal cancer.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with superficial, well-differentiated T1 rectal cancers (limited to submucosa), no evidence of metastatic disease to regional nodes, and a high level of compliance, we recommend a local excision via the transanal endoscopic microsurgical (TEM) approach for lesions greater than 3 cm above the dentate line and the transanal excision for lower lesions, since the TEM device typically does not work in the anal canal (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H87594804\">",
"       'Local excision'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/16/34057?source=see_link&amp;anchor=H87589066#H87589066\">",
"       \"Surgical oncologic principles for resection of primary rectal adenocarcinoma\", section on 'Local excision'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with positive resection margins or tumors deeper than T1 on the final histologic review and limited comorbid illness, we recommend a reoperation once healing has occurred rather than awaiting salvage surgery for a recurrence (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H87594804\">",
"       'Local excision'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a resectable rectal cancer that does not meet the criteria for a local excision, we recommend a sphincter-sparing procedure (eg, low anterior resection) if a histologically negative distal margin can be achieved (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1845484\">",
"       'Sphincter-sparing procedures'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/16/34057?source=see_link&amp;anchor=H87589426#H87589426\">",
"       \"Surgical oncologic principles for resection of primary rectal adenocarcinoma\", section on 'Sphincter-sparing resection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients undergoing a coloanal anastomosis, we use a temporary ostomy. (See",
"      <a class=\"local\" href=\"#H2792368\">",
"       'Very low and ultra low anterior resection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients undergoing a coloanal anastomosis, we use a J-pouch to restore bowel continuity when technically feasible (eg, wide pelvis). Otherwise, we perform a side-to-end reservoir in patients with a narrow pelvis. (See",
"      <a class=\"local\" href=\"#H2792368\">",
"       'Very low and ultra low anterior resection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with rectal cancer where the distal margin is positive or has a high likelihood of being positive (eg, very low lying rectal cancers), we recommend an abdominal perineal resection (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H87595450\">",
"       'Abdominal perineal resection'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/16/34057?source=see_link&amp;anchor=H87589433#H87589433\">",
"       \"Surgical oncologic principles for resection of primary rectal adenocarcinoma\", section on 'Abdominal perineal resection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with locally advanced rectal cancer invading adjacent organs, we recommend a multivisceral resection to completely resect all gross cancer (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Bowel",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bladder continuity can be re-established in margins of resection that are histologically clear of malignancy. (See",
"      <a class=\"local\" href=\"#H103735992\">",
"       'Multivisceral resection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/1\">",
"      McCourt M, Armitage J, Monson JR. Rectal cancer. Surgeon 2009; 7:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/2\">",
"      Balch GC, De Meo A, Guillem JG. Modern management of rectal cancer: a 2006 update. World J Gastroenterol 2006; 12:3186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/3\">",
"      Paty PB, Nash GM, Baron P, et al. Long-term results of local excision for rectal cancer. Ann Surg 2002; 236:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/4\">",
"      Wentworth S, Russell GB, Tuner II, et al. Long-term results of local excision with and without chemoradiation for adenocarcinoma of the rectum. Clin Colorectal Cancer 2005; 4:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/5\">",
"      Greenberg JA, Shibata D, Herndon JE 2nd, et al. Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984. Dis Colon Rectum 2008; 51:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/6\">",
"      Borschitz T, Gockel I, Kiesslich R, Junginger T. Oncological outcome after local excision of rectal carcinomas. Ann Surg Oncol 2008; 15:3101.",
"     </a>",
"    </li>",
"    <li>",
"     Rectal cancer. NCCN Clinical Practice Guidelines in Oncology. version 3.2012. www.nccn.org/professionals/physician_gls/pdf/rectal.pdf (Accessed on April 09, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/8\">",
"      Endreseth BH, Myrvold HE, Romundstad P, et al. Transanal excision vs. major surgery for T1 rectal cancer. Dis Colon Rectum 2005; 48:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/9\">",
"      Garcia-Aguilar J, Mellgren A, Sirivongs P, et al. Local excision of rectal cancer without adjuvant therapy: a word of caution. Ann Surg 2000; 231:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/10\">",
"      Ptok H, Marusch F, Meyer F, et al. Oncological outcome of local vs radical resection of low-risk pT1 rectal cancer. Arch Surg 2007; 142:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/11\">",
"      Gonzalez QH, Heslin MJ, Shore G, et al. Results of long-term follow-up for transanal excision for rectal cancer. Am Surg 2003; 69:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/12\">",
"      Nascimbeni R, Nivatvongs S, Larson DR, Burgart LJ. Long-term survival after local excision for T1 carcinoma of the rectum. Dis Colon Rectum 2004; 47:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/13\">",
"      Nano M, Ferronato M, Solej M, D'Amico S. T1 adenocarcinoma of the rectum: transanal excision or radical surgery? Tumori 2006; 92:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/14\">",
"      Steele GD Jr, Herndon JE, Bleday R, et al. Sphincter-sparing treatment for distal rectal adenocarcinoma. Ann Surg Oncol 1999; 6:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/15\">",
"      Madbouly KM, Remzi FH, Erkek BA, et al. Recurrence after transanal excision of T1 rectal cancer: should we be concerned? Dis Colon Rectum 2005; 48:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/16\">",
"      Neary P, Makin GB, White TJ, et al. Transanal endoscopic microsurgery: a viable operative alternative in selected patients with rectal lesions. Ann Surg Oncol 2003; 10:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/17\">",
"      Wang HS, Lin JK, Yang SH, et al. Prospective study of the functional results of transanal endoscopic microsurgery. Hepatogastroenterology 2003; 50:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/18\">",
"      Lee W, Lee D, Choi S, Chun H. Transanal endoscopic microsurgery and radical surgery for T1 and T2 rectal cancer. Surg Endosc 2003; 17:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/19\">",
"      Langer C, Liersch T, S&uuml;ss M, et al. Surgical cure for early rectal carcinoma and large adenoma: transanal endoscopic microsurgery (using ultrasound or electrosurgery) compared to conventional local and radical resection. Int J Colorectal Dis 2003; 18:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/20\">",
"      Araki Y, Isomoto H, Shirouzu K. Video-assisted gasless transanal endoscopic microsurgery: a review of 217 cases of rectal tumors over the past 10 years. Dig Surg 2003; 20:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/21\">",
"      Demartines N, von Fl&uuml;e MO, Harder FH. Transanal endoscopic microsurgical excision of rectal tumors: indications and results. World J Surg 2001; 25:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/22\">",
"      Winde G, Nottberg H, Keller R, et al. Surgical cure for early rectal carcinomas (T1). Transanal endoscopic microsurgery vs. anterior resection. Dis Colon Rectum 1996; 39:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/23\">",
"      Guerrieri M, Feliciotti F, Baldarelli M, et al. Sphincter-saving surgery in patients with rectal cancer treated by radiotherapy and transanal endoscopic microsurgery: 10 years' experience. Dig Liver Dis 2003; 35:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/24\">",
"      Stipa F, Lucandri G, Ferri M, et al. Local excision of rectal cancer with transanal endoscopic microsurgery (TEM). Anticancer Res 2004; 24:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/25\">",
"      Christoforidis D, Cho HM, Dixon MR, et al. Transanal endoscopic microsurgery versus conventional transanal excision for patients with early rectal cancer. Ann Surg 2009; 249:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/26\">",
"      Tsai BM, Finne CO, Nordenstam JF, et al. Transanal endoscopic microsurgery resection of rectal tumors: outcomes and recommendations. Dis Colon Rectum 2010; 53:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/27\">",
"      Lezoche E, Guerrieri M, Paganini AM, et al. Long-term results in patients with T2-3 N0 distal rectal cancer undergoing radiotherapy before transanal endoscopic microsurgery. Br J Surg 2005; 92:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/28\">",
"      Palma P, Freudenberg S, Samel S, Post S. Transanal endoscopic microsurgery: indications and results after 100 cases. Colorectal Dis 2004; 6:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/29\">",
"      de Graaf EJ, Burger JW, van Ijsseldijk AL, et al. Transanal endoscopic microsurgery is superior to transanal excision of rectal adenomas. Colorectal Dis 2011; 13:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/30\">",
"      Kennedy ML, Lubowski DZ, King DW. Transanal endoscopic microsurgery excision: is anorectal function compromised? Dis Colon Rectum 2002; 45:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/31\">",
"      Herman RM, Richter P, Walega P, Popiela T. Anorectal sphincter function and rectal barostat study in patients following transanal endoscopic microsurgery. Int J Colorectal Dis 2001; 16:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/32\">",
"      Kreis ME, Jehle EC, Haug V, et al. Functional results after transanal endoscopic microsurgery. Dis Colon Rectum 1996; 39:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/33\">",
"      Gavagan JA, Whiteford MH, Swanstrom LL. Full-thickness intraperitoneal excision by transanal endoscopic microsurgery does not increase short-term complications. Am J Surg 2004; 187:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/34\">",
"      Westbrook KC, Lang NP, Broadwater JR, Thompson BW. Posterior surgical approaches to the rectum. Ann Surg 1982; 195:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/35\">",
"      Gimbel MI, Paty PB. A current perspective on local excision of rectal cancer. Clin Colorectal Cancer 2004; 4:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/36\">",
"      Onaitis M, Ludwig K, Perez-Tamayo A, et al. The Kraske procedure: a critical analysis of a surgical approach for mid-rectal lesions. J Surg Oncol 2006; 94:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/37\">",
"      Eisenstat TE, Oliver GC. Electrocoagulation for adenocarcinoma of the low rectum. World J Surg 1992; 16:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/38\">",
"      Salvati EP, Rubin RJ, Eisenstat TE, et al. Electrocoagulation of selected carcinoma of the rectum. Surg Gynecol Obstet 1988; 166:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/39\">",
"      Papillon J, Berard P. Endocavitary irradiation in the conservative treatment of adenocarcinoma of the low rectum. World J Surg 1992; 16:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/40\">",
"      Coatmeur O, Truc G, Barillot I, et al. Treatment of T1-T2 rectal tumors by contact therapy and interstitial brachytherapy. Radiother Oncol 2004; 70:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/41\">",
"      Christoforidis D, McNally MP, Jarosek SL, et al. Endocavitary contact radiation therapy for ultrasonographically staged T1 N0 and T2 N0 rectal cancer. Br J Surg 2009; 96:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/42\">",
"      Zaheer S, Pemberton JH, Farouk R, et al. Surgical treatment of adenocarcinoma of the rectum. Ann Surg 1998; 227:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/43\">",
"      Berger A, Tiret E, Cunningham C, et al. Rectal excision and colonic pouch-anal anastomosis for rectal cancer: oncologic results at five years. Dis Colon Rectum 1999; 42:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/44\">",
"      Rullier E, Laurent C, Carles J, et al. Local recurrence of low rectal cancer after abdominoperineal and anterior resection. Br J Surg 1997; 84:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/45\">",
"      Gamagami RA, Liagre A, Chiotasso P, et al. Coloanal anastomosis for distal third rectal cancer: prospective study of oncologic results. Dis Colon Rectum 1999; 42:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/46\">",
"      Lavery IC, Lopez-Kostner F, Fazio VW, et al. Chances of cure are not compromised with sphincter-saving procedures for cancer of the lower third of the rectum. Surgery 1997; 122:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/47\">",
"      Martin ST, Heneghan HM, Winter DC. Systematic review of outcomes after intersphincteric resection for low rectal cancer. Br J Surg 2012; 99:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/48\">",
"      Arbman G, Nilsson E, Hallb&ouml;&ouml;k O, Sj&ouml;dahl R. Local recurrence following total mesorectal excision for rectal cancer. Br J Surg 1996; 83:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/49\">",
"      Jessup JM, Stewart AK, Menck HR. The National Cancer Data Base report on patterns of care for adenocarcinoma of the rectum, 1985-95. Cancer 1998; 83:2408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/50\">",
"      H&uuml;ser N, Michalski CW, Erkan M, et al. Systematic review and meta-analysis of the role of defunctioning stoma in low rectal cancer surgery. Ann Surg 2008; 248:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/51\">",
"      Paty PB, Enker WE, Cohen AM, et al. Long-term functional results of coloanal anastomosis for rectal cancer. Am J Surg 1994; 167:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/52\">",
"      Hassan I, Larson DW, Cima RR, et al. Long-term functional and quality of life outcomes after coloanal anastomosis for distal rectal cancer. Dis Colon Rectum 2006; 49:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/53\">",
"      Lazorthes F, Fages P, Chiotasso P, et al. Resection of the rectum with construction of a colonic reservoir and colo-anal anastomosis for carcinoma of the rectum. Br J Surg 1986; 73:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/54\">",
"      Parc R, Tiret E, Frileux P, et al. Resection and colo-anal anastomosis with colonic reservoir for rectal carcinoma. Br J Surg 1986; 73:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/55\">",
"      Banerjee AK, Parc R. Prediction of optimum dimensions of colonic pouch reservoir. Dis Colon Rectum 1996; 39:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/56\">",
"      de la Fuente SG, Mantyh CR. Reconstruction techniques after proctectomy: what's the best? Clin Colon Rectal Surg 2007; 20:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/57\">",
"      Lazorthes F, Gamagami R, Chiotasso P, et al. Prospective, randomized study comparing clinical results between small and large colonic J-pouch following coloanal anastomosis. Dis Colon Rectum 1997; 40:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/58\">",
"      Wong NY, Eu KW. A defunctioning ileostomy does not prevent clinical anastomotic leak after a low anterior resection: a prospective, comparative study. Dis Colon Rectum 2005; 48:2076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/59\">",
"      Brown CJ, Fenech DS, McLeod RS. Reconstructive techniques after rectal resection for rectal cancer. Cochrane Database Syst Rev 2008; :CD006040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/60\">",
"      Joo JS, Latulippe JF, Alabaz O, et al. Long-term functional evaluation of straight coloanal anastomosis and colonic J-pouch: is the functional superiority of colonic J-pouch sustained? Dis Colon Rectum 1998; 41:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/61\">",
"      Machado M, Nygren J, Goldman S, Ljungqvist O. Similar outcome after colonic pouch and side-to-end anastomosis in low anterior resection for rectal cancer: a prospective randomized trial. Ann Surg 2003; 238:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/62\">",
"      Ho YH, Seow-Choen F, Tan M. Colonic J-pouch function at six months versus straight coloanal anastomosis at two years: randomized controlled trial. World J Surg 2001; 25:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/63\">",
"      Hallb&ouml;&ouml;k O, P&aring;hlman L, Krog M, et al. Randomized comparison of straight and colonic J pouch anastomosis after low anterior resection. Ann Surg 1996; 224:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/64\">",
"      Mantyh CR, Hull TL, Fazio VW. Coloplasty in low colorectal anastomosis: manometric and functional comparison with straight and colonic J-pouch anastomosis. Dis Colon Rectum 2001; 44:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/65\">",
"      K&ouml;ninger JS, Butters M, Redecke JD, Z'graggen K. Transverse coloplasty pouch after total mesorectal excision: functional assessment of evacuation. Dis Colon Rectum 2004; 47:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/66\">",
"      F&uuml;rst A, Suttner S, Agha A, et al. Colonic J-pouch vs. coloplasty following resection of distal rectal cancer: early results of a prospective, randomized, pilot study. Dis Colon Rectum 2003; 46:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/67\">",
"      Pimentel JM, Duarte A, Greg&oacute;rio C, et al. Transverse coloplasty pouch and colonic J-pouch for rectal cancer--a comparative study. Colorectal Dis 2003; 5:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/68\">",
"      Harris GJ, Lavery IJ, Fazio VW. Reasons for failure to construct the colonic J-pouch. What can be done to improve the size of the neorectal reservoir should it occur? Dis Colon Rectum 2002; 45:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/69\">",
"      Ho YH, Brown S, Heah SM, et al. Comparison of J-pouch and coloplasty pouch for low rectal cancers: a randomized, controlled trial investigating functional results and comparative anastomotic leak rates. Ann Surg 2002; 236:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/70\">",
"      Fazio VW, Zutshi M, Remzi FH, et al. A randomized multicenter trial to compare long-term functional outcome, quality of life, and complications of surgical procedures for low rectal cancers. Ann Surg 2007; 246:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/71\">",
"      Mathis KL, Larson DW, Dozois EJ, et al. Outcomes following surgery without radiotherapy for rectal cancer. Br J Surg 2012; 99:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/72\">",
"      Wolmark N, Fisher B. An analysis of survival and treatment failure following abdominoperineal and sphincter-saving resection in Dukes' B and C rectal carcinoma. A report of the NSABP clinical trials. National Surgical Adjuvant Breast and Bowel Project. Ann Surg 1986; 204:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/73\">",
"      Bruheim K, Svartberg J, Carlsen E, et al. Radiotherapy for rectal cancer is associated with reduced serum testosterone and increased FSH and LH. Int J Radiat Oncol Biol Phys 2008; 70:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/74\">",
"      Pachler J, Wille-J&oslash;rgensen P. Quality of life after rectal resection for cancer, with or without permanent colostomy. Cochrane Database Syst Rev 2005; :CD004323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/75\">",
"      Allal AS, Bieri S, Pelloni A, et al. Sphincter-sparing surgery after preoperative radiotherapy for low rectal cancers: feasibility, oncologic results and quality of life outcomes. Br J Cancer 2000; 82:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/76\">",
"      Grumann MM, Noack EM, Hoffmann IA, Schlag PM. Comparison of quality of life in patients undergoing abdominoperineal extirpation or anterior resection for rectal cancer. Ann Surg 2001; 233:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/77\">",
"      Camilleri-Brennan J, Steele RJ. Objective assessment of morbidity and quality of life after surgery for low rectal cancer. Colorectal Dis 2002; 4:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/78\">",
"      Cornish JA, Tilney HS, Heriot AG, et al. A meta-analysis of quality of life for abdominoperineal excision of rectum versus anterior resection for rectal cancer. Ann Surg Oncol 2007; 14:2056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/79\">",
"      Williams NS, Johnston D. The quality of life after rectal excision for low rectal cancer. Br J Surg 1983; 70:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/80\">",
"      Matzel KE, Stadelmaier U, Muehldorfer S, Hohenberger W. Continence after colorectal reconstruction following resection: impact of level of anastomosis. Int J Colorectal Dis 1997; 12:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/81\">",
"      Abbas MA. Sphincter preservation for distal rectal cancer: how low is too low? Am J Clin Oncol 2008; 31:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/82\">",
"      Kasparek MS, Hassan I, Cima RR, et al. Long-term quality of life and sexual and urinary function after abdominoperineal resection for distal rectal cancer. Dis Colon Rectum 2012; 55:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/83\">",
"      Pawlik TM, Skibber JM, Rodriguez-Bigas MA. Pelvic exenteration for advanced pelvic malignancies. Ann Surg Oncol 2006; 13:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/84\">",
"      Balbay MD, Slaton JW, Trane N, et al. Rationale for bladder-sparing surgery in patients with locally advanced colorectal carcinoma. Cancer 1999; 86:2212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/85\">",
"      Law WL, Chu KW, Choi HK. Total pelvic exenteration for locally advanced rectal cancer. J Am Coll Surg 2000; 190:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/86\">",
"      Nelson H, Petrelli N, Carlin A, et al. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 2001; 93:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/87\">",
"      McGory ML, Shekelle PG, Ko CY. Development of quality indicators for patients undergoing colorectal cancer surgery. J Natl Cancer Inst 2006; 98:1623.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/89\">",
"      Tjandra JJ, Kilkenny JW, Buie WD, et al. Practice parameters for the management of rectal cancer (revised). Dis Colon Rectum 2005; 48:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/90\">",
"      Nakafusa Y, Tanaka T, Tanaka M, et al. Comparison of multivisceral resection and standard operation for locally advanced colorectal cancer: analysis of prognostic factors for short-term and long-term outcome. Dis Colon Rectum 2004; 47:2055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/91\">",
"      Vermaas M, Ferenschild FT, Verhoef C, et al. Total pelvic exenteration for primary locally advanced and locally recurrent rectal cancer. Eur J Surg Oncol 2007; 33:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/92\">",
"      Ferenschild FT, Vermaas M, Verhoef C, et al. Total pelvic exenteration for primary and recurrent malignancies. World J Surg 2009; 33:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/93\">",
"      Lehnert T, Methner M, Pollok A, et al. Multivisceral resection for locally advanced primary colon and rectal cancer: an analysis of prognostic factors in 201 patients. Ann Surg 2002; 235:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/94\">",
"      Sagar PM, Gonsalves S, Heath RM, et al. Composite abdominosacral resection for recurrent rectal cancer. Br J Surg 2009; 96:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/95\">",
"      Palmer G, Martling A, Lagergren P, et al. Quality of life after potentially curative treatment for locally advanced rectal cancer. Ann Surg Oncol 2008; 15:3109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/96\">",
"      Kakuda JT, Lamont JP, Chu DZ, Paz IB. The role of pelvic exenteration in the management of recurrent rectal cancer. Am J Surg 2003; 186:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/97\">",
"      Akasu T, Yamaguchi T, Fujimoto Y, et al. Abdominal sacral resection for posterior pelvic recurrence of rectal carcinoma: analyses of prognostic factors and recurrence patterns. Ann Surg Oncol 2007; 14:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/98\">",
"      Gannon CJ, Zager JS, Chang GJ, et al. Pelvic exenteration affords safe and durable treatment for locally advanced rectal carcinoma. Ann Surg Oncol 2007; 14:1870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38137/abstract/99\">",
"      Govindarajan A, Coburn NG, Kiss A, et al. Population-based assessment of the surgical management of locally advanced colorectal cancer. J Natl Cancer Inst 2006; 98:1474.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15311 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-202.43.93.2-49404BB9CF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_15_38137=[""].join("\n");
var outline_f37_15_38137=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1848054\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1848046\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87594804\">",
"      LOCAL EXCISION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87595929\">",
"      Transanal excision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1273103\">",
"      Transanal endoscopic microsurgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87595937\">",
"      Transsphincteric (York-Mason) procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87595953\">",
"      Transsacral (Kraske) procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87594840\">",
"      Other local techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1845484\">",
"      SPHINCTER-SPARING PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1845491\">",
"      Low anterior resection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2792368\">",
"      Very low and ultra low anterior resection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1845505\">",
"      - Coloanal anastomosis with colonic J-pouch reservoir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1845512\">",
"      - Transverse coloplasty reservoir",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87595450\">",
"      ABDOMINAL PERINEAL RESECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H103735992\">",
"      MULTIVISCERAL RESECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1845575\">",
"      PALLIATIVE RECTAL SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1848054\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15311\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15311|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/4/37953\" title=\"figure 1\">",
"      Transanal endoscopic microsurgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/24/17807\" title=\"figure 2\">",
"      Mobilization of the upper rectum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/35/27185\" title=\"figure 3\">",
"      Proctocolectomy for cancer and division of lateral ligaments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/32/41479\" title=\"figure 4\">",
"      Blood supply to the colon and rectum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/3/3127\" title=\"figure 5\">",
"      Venous drainage of the colon and rectum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/22/39265\" title=\"figure 6\">",
"      Mobilization of the splenic flexure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/16/38145\" title=\"figure 7\">",
"      Dissection of the left mesocolon from Gerota fascia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/35/13873\" title=\"figure 8\">",
"      Colonic J pouch rect reservoir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/9/33939\" title=\"figure 9\">",
"      Coloplasty neorectal reservoir",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15311|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/26/23982\" title=\"table 1\">",
"      2010 TNM staging colorectal CA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/51/4922?source=related_link\">",
"      Adjuvant therapy for resected rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/34/5673?source=related_link\">",
"      Enteral stents for the management of malignant colorectal obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/5/4186?source=related_link\">",
"      Management of anastomotic complications of colorectal surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/57/1946?source=related_link\">",
"      Management of intra-abdominal, pelvic, and genitourinary complications of colorectal surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/22/42346?source=related_link\">",
"      Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/16/34057?source=related_link\">",
"      Surgical oncologic principles for resection of primary rectal adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/37/11866?source=related_link\">",
"      Treatment of locally advanced unresectable or recurrent rectal cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_15_38138="Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer";
var content_f37_15_38138=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/15/38138/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/15/38138/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/15/38138/contributors\">",
"     David P Steensma, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/15/38138/contributors\">",
"     Charles L Loprinzi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/15/38138/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/15/38138/contributors\">",
"     Reed E Drews, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/15/38138/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/15/38138/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/15/38138/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/15/38138/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia is a common complication in patients with malignancy. Anemia can impair the patient's functional status, diminish physiologic reserve, and cause fatigue that can be disabling. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11242?source=see_link\">",
"     \"Cancer-related fatigue: Prevalence, screening and clinical assessment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27098?source=see_link\">",
"     \"Cancer-related fatigue: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/22/23914?source=see_link&amp;anchor=H2#H2\">",
"     \"Hematologic consequences of malignancy: Anemia and bleeding\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to causing symptoms, the presence of anemia has been linked to an adverse prognosis in several malignancies. This has been attributed in part to a poorer response to anticancer treatment, since ionizing radiation and some forms of chemotherapy are dependent upon adequate tissue oxygen levels for cytotoxicity. These observations have been used to provide an additional rationale for aggressively treating anemia in patients receiving cancer therapy.",
"   </p>",
"   <p>",
"    Multiple factors can cause or contribute to anemia in patients with malignancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/22/23914?source=see_link\">",
"     \"Hematologic consequences of malignancy: Anemia and bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As can occur with other chronic inflammatory conditions, some cancer patients have an anemia that is a consequence of the disease and unrelated to treatment. This type of anemia is typically mild (ie, hemoglobin [HGB] level &gt;10",
"      <span class=\"nowrap\">",
"       g/dL),",
"      </span>",
"      and the symptoms may be difficult to distinguish from those caused by the underlying malignancy. Occasionally, anemia may be more severe, impairing functional status, diminishing physiologic reserve, and reducing QOL. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/13/9434?source=see_link\">",
"       \"Anemia of chronic disease (anemia of chronic inflammation)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anemia is often exacerbated by myelosuppressive cancer treatment, particularly in patients who are undergoing intensive chemotherapy or combined modality treatment with both chemotherapy and radiation therapy (RT) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/1-5\">",
"       1-5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In addition to direct effects of the malignancy or its treatment, other causes of anemia may coexist in these patients (eg, blood loss, hemolysis, deficiencies of iron, folate, or vitamin B12). These causes should be actively sought, and when present, treated appropriately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29418?source=see_link&amp;anchor=H50#H50\">",
"       \"Approach to the adult patient with anemia\", section on 'Multiple causes of anemia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The definitive therapy for cancer-related anemia is eradication of the underlying malignancy. However, in many cases, this is not possible and short-term red blood cell (RBC) support may be needed.",
"   </p>",
"   <p>",
"    Erythropoiesis-stimulating agents (ESAs) were initially used to treat anemia in patients with chronic renal failure, including those on hemodialysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/45/33496?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/31/5626?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subsequent trials indicated that ESAs were also effective in patients with cancer and cancer treatment-related anemia, but their use has become controversial because of data linking ESA use to an excess of thromboembolic events, inferior survival and worse cancer outcomes.",
"   </p>",
"   <p>",
"    This topic review will focus primarily on the efficacy and risks associated with the erythropoiesis stimulating agents (ESAs)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/48/2825?source=see_link\">",
"     epoetin alfa",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/49/33560?source=see_link\">",
"     darbepoetin alfa",
"    </a>",
"    in anemic patients with non-hematologic malignancies. The issues surrounding the use of ESAs for patients with hematologic malignancies such as myelodysplastic syndrome (MDS) are more complex and discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/13/23769?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of the complications of multiple myeloma\", section on 'Anemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/12/35017?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of the complications of chronic lymphocytic leukemia\", section on 'Chemotherapy induced anemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/3/36922?source=see_link\">",
"     \"Prognosis and treatment of primary myelofibrosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/54/25450?source=see_link&amp;anchor=H7195992#H7195992\">",
"     \"Management of the complications of the myelodysplastic syndromes\", section on 'Erythropoiesis stimulating agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF TREATMENT OPTIONS FOR ANEMIA IN CANCER PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive therapy for cancer-related anemia is eradication of the underlying malignancy. However, in many cases, this is not possible. Successful treatment of the malignancy with combinations of surgery, chemotherapy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy (RT) may, in the long term, improve the HGB level. However, short-term red blood cell (RBC) support may be needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348976573\">",
"    <span class=\"h2\">",
"     Transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Red blood cell (RBC) transfusions are almost universally successful in raising HGB levels. Transfusions can often ameliorate the patient's symptoms rapidly and improve health-related QOL. Exceptions include patients unable to be transfused because of the presence of multiple alloantibodies and those who refuse transfusions based on religious beliefs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/46/10986?source=see_link\">",
"     \"The approach to the patient who refuses blood transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of RBC transfusions to treat anemia is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/37/21081?source=see_link\">",
"     \"Use of red blood cells for transfusion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/52/5961?source=see_link\">",
"     \"Indications for red cell transfusion in the adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     ESAs: epoetin and darbepoetin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials have established that epoetin and darbepoetin are effective in raising HGB levels and decreasing transfusion requirements in a substantial number of patients with chemotherapy-induced anemia. Both ESAs appear to be equivalent with regard to efficacy and safety [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'ESAs: efficacy, side effects, and clinical use'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    However, use of these agents in patients with cancer has become controversial because of data linking ESA use to an excess of thromboembolic events, inferior survival (particularly when used in patients whose anemia is unrelated to chemotherapy) and worse cancer outcomes. While there is general agreement that ESAs are not indicated in anemic cancer patients who are not receiving chemotherapy (with the exception of lower-risk myelodysplastic syndromes and those patients with coexistent renal failure), whether ESAs should be avoided in patients who are receiving myelosuppressive chemotherapy with the intent of cure remains controversial. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Effect on disease control and survival'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H264001313\">",
"     'Thromboembolic risk'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/45/33496?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/31/5626?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     ESAs versus transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with symptomatic anemia induced by chemotherapy HGB levels can be raised with either ESAs or RBC transfusions. In addition to the issues raised above, many other factors influence the choice of one or the other of these approaches, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical responses to transfusion occur almost immediately, while meaningful responses to ESAs may take weeks to months. Patients with advanced malignancy may have a relatively short life expectancy, and prompt relief of symptoms is important. In these circumstances, transfusion may be particularly appropriate in severely symptomatic patients.",
"     </li>",
"     <li>",
"      Transfusion is now associated with a lower risk of infection (eg, human immunodeficiency virus, hepatitis C) because of improvements in donor screening, compared to the risk when the ESAs were originally developed (",
"      <a class=\"graphic graphic_table graphicRef69661 \" href=\"mobipreview.htm?30/59/31676\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/41/40601?source=see_link\">",
"       \"Laboratory testing of donated blood\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Each unit of transfused RBCs contains 200 to 250 mg of iron. Since the body has no physiologic mechanism to induce iron loss, a patient requiring 25 units of packed RBC will have accumulated five to six grams of excess body iron and may show signs of iron overload. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38856?source=see_link&amp;anchor=H11#H11\">",
"       \"Iron overload syndromes other than hereditary hemochromatosis\", section on 'Transfusional iron overload'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      ESAs have particular advantages for patients who are averse to RBC transfusions or who do not have ready access to an appropriate facility for transfusion. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/46/10986?source=see_link&amp;anchor=H20#H20\">",
"       \"The approach to the patient who refuses blood transfusion\", section on 'Alternative courses of action'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The relative costs of ESAs versus transfusions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/8\">",
"       8",
"      </a>",
"      ], along with insurance coverage and blood availability issues [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/9\">",
"       9",
"      </a>",
"      ], may become important factors in determining which approach will be used.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relative risks and benefits of ESAs versus RBC transfusion in patients undergoing cancer chemotherapy are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef78476 \" href=\"mobipreview.htm?31/32/32267\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Androgens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Androgen use (eg, testosterone,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/34/41508?source=see_link\">",
"     fluoxymesterone",
"    </a>",
"    ) for the treatment of anemia has declined markedly since ESAs became available; androgens are now rarely used to treat cancer-related anemia. Side effects which have limited the application of androgens include acne, virilization in women, priapism in men, peliosis hepatis, liver enzyme abnormalities, an elevated risk of hepatocellular carcinoma, and stimulation of the growth of prostate cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/8/9353?source=see_link&amp;anchor=H9#H9\">",
"     \"Non-iron pharmacologic adjuvants to erythropoiesis stimulating agent therapy in dialysis patients\", section on 'Androgens'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ESAS: EFFICACY, SIDE EFFECTS, AND CLINICAL USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized clinical trials have consistently demonstrated that use of ESAs raises HGB levels and reduces the frequency of red blood cell transfusions in anemic cancer patients who are receiving chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/10\">",
"     10",
"    </a>",
"    ]. With few exceptions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/11,12\">",
"     11,12",
"    </a>",
"    ], most of these trials have not shown that ESAs prolong survival, or improve quality of life (QOL) or patient-reported outcomes (PRO), including fatigue. Furthermore, these trials have also raised questions about serious side effects, including an increased incidence of thromboembolic events and the possibility of adverse cancer outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Meta-analyses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple meta-analyses have addressed issues of benefit and adverse effects from ESAs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/10,14-16\">",
"     10,14-16",
"    </a>",
"    ]. The most recent Cochrane review of 91 trials with 20,102 participants came to the following conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ESAs significantly reduced the use of RBC transfusions (relative risk [RR] 0.65, 95% CI 0.62 to 0.68). Patients treated with an ESA received one unit less of red blood cells on average than the control group.",
"     </li>",
"     <li>",
"      The risk of venous thromboembolism (VTE) was increased in patients receiving ESAs (RR 1.52, 95% CI 1.34 to 1.74). The risk was significantly elevated regardless of the hemoglobin level at baseline (&lt;10, 10 to 12, or &gt;12",
"      <span class=\"nowrap\">",
"       g/dL);",
"      </span>",
"      the impact of target hemoglobin level was not addressed. Additional information on thromboembolic risk and the relationship between target hemoglobin and VTE risk is addressed in detail below. (See",
"      <a class=\"local\" href=\"#H264001313\">",
"       'Thromboembolic risk'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H17\">",
"       'Threshold and target hemoglobin levels'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      There was suggestive evidence that ESAs improve quality of life (QOL) (mean change in the 13-item Functional Assessment of Cancer Therapy (FACT)-Fatigue scale was 2.08 points [95% CI 1.43-2.72]) on a scale of 0 to 52 points. This improvement was less than the 3.0 increase considered to be the minimum for a patient to feel a difference in",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      experience of fatigue-related symptoms.",
"     </li>",
"     <li>",
"      There was strong evidence that ESAs increase mortality during active therapy (hazard ratio [HR] 1.17, 95% CI 1.06-1.29), and modest evidence that they increase overall mortality (HR 1.05, 95% CI 1.00-1.11). However, when the analysis was restricted to trials of patients receiving chemotherapy, there was only a trend toward higher on-study (odds ratio [OR] 1.10, 95% CI 0.98-1.24) and overall mortality (OR 1.04 95% CI 0.98-1.11), neither of which was statistically significant. In trials of no antineoplastic therapy, use of ESAs significantly increased both on-study mortality (OR 1.34, 95% CI 1.07-1.66) and overall mortality (OR 1.23, 95% CI 1.04-1.45). Additional information on the effect of ESAs on survival is provided below. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Effect on disease control and survival'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      When analyzed according to baseline hemoglobin levels, there was a significant increase in overall mortality (OR 1.17, 95% CI 1.06-1.29) and on-study mortality (OR 1.37, 95% CI 1.12-1.68) among patients with baseline levels &gt;12",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      but not at lower levels. The impact of target hemoglobin levels was not addressed.",
"      <br/>",
"      <br/>",
"      These findings are in keeping with published guidelines from the American Society of Clinical Oncology and American Society of Hematology, which state that patients who are",
"      <strong>",
"       not",
"      </strong>",
"      receiving chemotherapy should not receive ESAs, and that use of an ESA is recommended as a treatment option for patients with chemotherapy-associated anemia and a HGB level that has decreased below 10",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H21\">",
"       'ASH/ASCO guidelines'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H18\">",
"       'Use in patients not receiving chemotherapy'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H17\">",
"       'Threshold and target hemoglobin levels'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Use of ESAs significantly increased the risk of hypertension (RR 1.30, 95% CI 1.08-1.56) and",
"      <span class=\"nowrap\">",
"       thrombocytopenia/hemorrhage",
"      </span>",
"      (RR 1.21, 95% CI 1.04-1.42).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H264001313\">",
"    <span class=\"h2\">",
"     Thromboembolic risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, randomized trials and systematic reviews demonstrate a significantly increased risk of thromboembolism in patients receiving ESAs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Meta-analyses'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The absolute risk was addressed in two meta-analyses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/14,17\">",
"     14,17",
"    </a>",
"    ]; the pooled event rates of thromboembolic events were 7 (range 1 to 30 percent) versus 4 (range 0 to 23) percent for epoetin versus controls, respectively in the two studies, whereas the rates were 5 versus 3 percent in one published darbepoetin trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific risk factors for thromboembolism have not been defined in these trials, and clinicians must use caution and clinical judgment when considering the use of one of these agents. Established general risk factors for thromboembolism include a history of thromboses, surgery, and prolonged periods of immobilization or limited activity. Some disease and treatment regimens have also been associated with a higher risk of thromboembolic events (eg, multiple myeloma treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    or corticosteroids). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/36/6730?source=see_link\">",
"     \"Drug-induced thrombosis and vascular disease in patients with malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Effect on disease control and survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of anemia has been linked to shortened survival in a variety of solid tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/18-22\">",
"     18-22",
"    </a>",
"    ], an effect attributed, in part, to a poorer response to anticancer treatments dependent upon oxygen delivery for their cytotoxicity (eg, ionizing radiation and some forms of chemotherapy). It was hypothesized that normalizing HGB levels through the use of ESAs might reduce the degree of tumor hypoxia, thus improving the response to chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    RT and prolonging disease-free and overall survival. This hypothesis was generally supported by observational studies, which suggested that raising HGB levels to &gt;12 or &gt;14.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    improved survival in non-small cell lung cancer and head and neck cancer, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/62/28649?source=see_link\">",
"     \"Methods to overcome radiation resistance in head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, several trials using this approach in various solid tumors treated with radiotherapy or chemotherapy have raised concerns about possible increased mortality with ESAs, summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef83619 \" href=\"mobipreview.htm?25/62/26606\">",
"     table 3",
"    </a>",
"    ). Importantly, target HGB levels were supraphysiologic in all of these trials. The risks of shortened survival and inferior tumor control have neither been excluded nor confirmed when ESAs are dosed to a target HGB value &lt;12",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H691539292\">",
"    <span class=\"h3\">",
"     Potential mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reason for this detrimental survival impact of ESAs is not clear. Several different meta-analyses of controlled trials that reported disease progression outcomes have failed to show that disease progression or tumor response rates are significantly different in patients who do versus those who do not receive ESAs (",
"    <a class=\"graphic graphic_table graphicRef83621 \" href=\"mobipreview.htm?7/31/7677\">",
"     table 4",
"    </a>",
"    ). However, safety data from some individual controlled trials suggest that ESA use might affect disease progression",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mortality in certain cancer patient populations (head and neck cancer receiving radiotherapy only) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. However, in all of these trials, the goal was to maintain HGB at levels at, or above, 12 to 14",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in women and 15 to 16",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in men, both before and during curative radiotherapy, levels which are substantially higher than those recommended by professional society guidelines or approved by the United States FDA. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Threshold and target hemoglobin levels'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    One potential mechanism by which ESA therapy might result in negative outcomes is through promotion of thromboembolic events. However, in the trials described above, the incidence of thromboembolic and other adverse events was only minimally elevated and insufficient to explain the observed differences in survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. In addition, the events would not explain the reduction in survival related to enhanced tumor progression in some of the studies. (See",
"    <a class=\"local\" href=\"#H264001313\">",
"     'Thromboembolic risk'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Another proposed potential mechanism to explain more rapid disease progression and shortened survival following treatment with ESAs is the presence of erythropoietin receptors (EPO-Rs) on the surface of tumor cells, which may promote angiogenesis, tumor growth, tumor cell survival,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    resistance to treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/31-36\">",
"     31-36",
"    </a>",
"    ]. However, laboratory and clinical results raise questions about the significance of these observations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is a lack of compelling evidence for functional EPO-R expression in tumor cells, and for pharmacologically relevant ESA-mediated EPO-R signaling in tumor cell lines and tissues [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/38-40\">",
"       38-40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Several studies suggest that all of the commercially available antibodies used to define the presence of EPO-R prior to 2010 also stain non-specific peptides such as heat shock proteins [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/41,42\">",
"       41,42",
"      </a>",
"      ]. This lack of specificity for the antibodies used to detect EPO-R has implications for interpretation of much of the published literature evaluating EPO-R expression on tumor cells. A newer antibody, A82, introduced in 2010, may be more specific for EPO-R [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Finally, there is some evidence that indirect, non-EPO-R-mediated effects of ESAs may contribute to mechanisms of tumor regulation (including endothelial cell and platelet activation and resulting neovasculogenesis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/44-49\">",
"     44-49",
"    </a>",
"    ]. However, the role that neovascularization plays in tumor progression during ESA therapy remains to be determined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Use in patients treated with curative intent: recommendations of EMA, FDA, ASCO/ASH, and NCCN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preliminary results from many of the trials described above led the European Medicines Agency to recommend in June 2008 that blood transfusions are preferred over ESAs in cancer patients who have chemotherapy-related anemia and a \"reasonably long life expectancy\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Review of the same data also led the US Food and Drug Administration (FDA) to mandate a label change for ESAs, stating that their use was not indicated in patients receiving myelosuppressive chemotherapy when the anticipated outcome was cure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/52\">",
"     52",
"    </a>",
"    ]. However, they did not restrict this recommendation to patients being treated for breast, head and neck, or cervical cancer. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'United States FDA'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Furthermore, to ensure that patients receiving ESAs in the setting of cancer are informed about the risks before they begin treatment, regardless of the intent of therapy, the US FDA has mandated a risk evaluation and mitigation strategy (REMS) risk management program, termed APPRISE (Assisting Provides and Cancer Patients with Risk Information for the Safe Use of ESAs) for use of ESAs in patients with cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'APPRISE: the US FDA Risk Evaluation and Mitigation Strategy program'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Despite these mandates, whether use of ESAs should be avoided in patients receiving myelosuppressive chemotherapy with the intent of cure remains controversial, particularly in view of the 2012 pooled analysis that failed to find a significant adverse impact of ESAs on-study or overall mortality in patients with chemotherapy induced anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/10\">",
"     10",
"    </a>",
"    ], and the fact that no study or meta-analysis has evaluated outcomes of ESA therapy by subgroups defined by chemotherapy intent. Furthermore, determination of the goal of treatment requires clinical judgment of an individual patient&rsquo;s circumstances. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Summary: patient selection for ESAs'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H8\">",
"     'Meta-analyses'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    While the 2012",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    guidelines for cancer and chemotherapy-related anemia state that ESAs are not indicated in patients for whom the cancer treatment goal is cure, updated guidelines for the use of ESAs from the American Society of",
"    <span class=\"nowrap\">",
"     Hematology/American",
"    </span>",
"    Society of Clinical Oncology",
"    <span class=\"nowrap\">",
"     (ASH/ASCO)",
"    </span>",
"    do not differentiate between patients receiving potentially curative cancer therapy and those undergoing palliative cancer treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H348975780\">",
"     'Recommendations from expert groups'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Threshold and target hemoglobin levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;An excessively high hemoglobin level, either prior to treatment with an ESA or as an ESA treatment target, may have contributed to adverse outcomes in the above clinical trials, either by increasing the incidence of thromboembolic events or by accelerating tumor growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/29,54-57\">",
"     29,54-57",
"    </a>",
"    ]. In many of these trials, HGB target levels were in the range of 13 to 15",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"   </p>",
"   <p>",
"    When",
"    ESAs are used in patients with end-stage renal disease (ESRD), higher target HGB levels increase the incidence of thrombotic and vascular events. Studies evaluating target HGB levels in patients with ESRD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/18/41257?source=see_link&amp;anchor=H2#H2\">",
"     \"Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents\", section on 'Target levels'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The data in anemic cancer patients are less extensive, and the relationship between baseline and target HGB levels and the incidence of thrombotic and vascular events is incompletely described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most recent Cochrane meta-analysis of 60 controlled trials of ESAs documented a significantly elevated risk of thrombotic events regardless of the baseline hemoglobin levels (&lt;10",
"      <span class=\"nowrap\">",
"       g/dl:",
"      </span>",
"      RR 1.41, 95% CI 1.06-1.99; 10 to 12",
"      <span class=\"nowrap\">",
"       g/dL:",
"      </span>",
"      RR 1.64, 95% CI 1.33-2.03; &gt;12",
"      <span class=\"nowrap\">",
"       g/dL:",
"      </span>",
"      RR 1.44, 95% CI 1.15-1.80) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An association between target HGB and VTE was suggested in an open label study of epoetin-alfa conducted in patients receiving adjuvant chemotherapy for breast cancer, 77 of 1785 patients evaluable for safety were diagnosed with a clinically relevant thromboembolic event, 55 of whom had baseline HGB levels &gt;12",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a meta-analysis of 12 randomized trials totaling 2297 cancer patients in which epoetin beta was compared to placebo (all but three involving chemotherapy), the overall risk for a thromboembolic event was significantly increased (HR 1.62; 95% CI 1.13 to 2.31) in patients receiving epoetin compared to placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/59,60\">",
"       59,60",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In the analysis based on maximum-achieved HGB level during treatment, there was no evidence for an increased risk of thromboembolic events or mortality when maximum HGB levels were &gt;13",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      as compared to lower levels in the entire cohort of 12 trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/59\">",
"       59",
"      </a>",
"      ]. Again, when the analysis was restricted to the four trials with long-term follow-up, there was a statistically significant, higher mortality rate in patients with a maximum HGB in the 10 to 13",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      range compared to patients with a maximum HGB &lt;10",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      but the mortality rate was not elevated in those patients with a maximal HGB of &gt;13",
"      <span class=\"nowrap\">",
"       g/dL.",
"       <br/>",
"       <br/>",
"       The",
"      </span>",
"      results of this analysis need to be interpreted with caution because of methodologic limitations and potential confounders. As an example, for the subgroup of patients with a maximum achieved HGB &ge;13",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      the comparison was between those patients who were treated to beyond 13",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      with epoetin, and those who either achieved HGB &ge;13",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      without treatment or who were enrolled with baseline HGB &ge;13",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      On the assumption that an increase in HGB independent of epoetin treatment is a good prognostic factor, these analyses would be biased in favor of the control group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In its 2010 updated guidelines for use of ESAs in adult patients with cancer, the",
"    <span class=\"nowrap\">",
"     ASCO/ASH",
"    </span>",
"    expert panel concluded that the use of ESAs to decrease transfusions is recommended for patients with chemotherapy induced anemia and a hemoglobin concentration that has decreased to &lt;10",
"    <span class=\"nowrap\">",
"     g/dL;",
"    </span>",
"    the optimal level at which to initiate ESA therapy in patients with anemia and a HGB level between 10 and 12",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    cannot be determined from the available data [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Furthermore, given that an optimal target HGB could not be definitively determined from the available literature, the panel recommended that HGB should be increased to the lowest concentration needed to avoid transfusion, a level that may vary by patient and condition. (See",
"    <a class=\"local\" href=\"#H348975780\">",
"     'Recommendations from expert groups'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Use in patients not receiving chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Off-label use of ESAs in cancer patients not receiving chemotherapy was frequent in the past [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/61\">",
"     61",
"    </a>",
"    ]. However, results from large clinical trials and meta-analyses support the view that ESAs are not beneficial in this setting and are potentially harmful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/10,57,62,63\">",
"     10,57,62,63",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Meta-analyses'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Based upon these results, ESAs are",
"    <strong>",
"     NOT",
"    </strong>",
"    recommended for the treatment of anemia that is unrelated to chemotherapy in patients with malignancy. Use of ESAs in patients with lower-risk myelodysplastic syndromes to avoid transfusion is an exception to this recommendation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'United States FDA'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H21\">",
"     'ASH/ASCO guidelines'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/54/25450?source=see_link&amp;anchor=H7195992#H7195992\">",
"     \"Management of the complications of the myelodysplastic syndromes\", section on 'Erythropoiesis stimulating agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Variability in and predictors of response to ESAs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all patients with chemotherapy-induced anemia benefit from use of an ESA. Up to 15 to 20 percent still require RBC transfusions, and only 50 to 70 percent have a HGB increment of &ge;1",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    after 8 to 12 weeks of ESA therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are a number of other settings in which ESAs may not be effective, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A common cause of reduced responsiveness to ESAs is an impaired supply of iron to developing erythroid cells. Sufficient stores of bioavailable iron are required to achieve and maintain target HGB levels with ESAs. The concomitant use of parenteral iron may augment erythropoiesis by ensuring adequate delivery of iron to red cell precursors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/65,66\">",
"       65,66",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Iron monitoring and supplementation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      With extensive malignant involvement of the bone marrow, there may be an insufficient number of erythropoietic elements to respond to the ESAs.",
"     </li>",
"     <li>",
"      Although most patients with anemia due to cancer have a serum erythropoietin level that is inappropriately low for the degree of anemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/67\">",
"       67",
"      </a>",
"      ], some cancer patients synthesize large amounts of endogenous erythropoietin in response to anemia (ie, &gt;500",
"      <span class=\"nowrap\">",
"       U/L).",
"      </span>",
"      These patients are unlikely to respond to pharmacological doses of an ESA, although there are no data addressing this issue in patients receiving chemotherapy for solid tumors. Furthermore, a 2003 meta-analysis highlighted the lack of sensitivity or specificity of erythropoietin levels in selecting anemic cancer patients for ESA treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/68\">",
"       68",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Minimum requirements'",
"      </a>",
"      below.) Patients with lower-risk myelodysplastic syndromes (MDS) may be an exception, as serum erythropoietin levels &gt;500",
"      <span class=\"nowrap\">",
"       U/L",
"      </span>",
"      strongly predict lack of ESA response in the MDS setting [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with anemia of chronic disease, the bone marrow may respond poorly to ESAs because of the presence of erythropoiesis-inhibiting cytokines (eg, TNF-alpha, IL-6) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/70\">",
"       70",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/13/9434?source=see_link&amp;anchor=H2#H2\">",
"       \"Anemia of chronic disease (anemia of chronic inflammation)\", section on 'Pathogenesis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cases of pure red cell aplasia due to anti-erythropoietin antibodies have been reported in patients treated with ESAs; ninety percent are in patients treated with Eprex, an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/48/2825?source=see_link\">",
"       epoetin alfa",
"      </a>",
"      product used outside of the US. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/4/8265?source=see_link\">",
"       \"Pure red cell aplasia due to anti-erythropoietin antibodies\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     ASCO/ASH",
"    </span>",
"    expert panel on use of ESAs in adult patients with cancer concluded that starting doses and dose modifications of ESAs after response or nonresponse should follow the US FDA-approved labeling guidelines (",
"    <a class=\"graphic graphic_table graphicRef59470 \" href=\"mobipreview.htm?42/42/43692\">",
"     table 5",
"    </a>",
"    ), and that ESAs should be discontinued after eight weeks in nonresponders (ie, a &lt;1 to 2",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    increase in HGB, or no diminution of transfusion requirements) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Threshold and target hemoglobin levels'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H24\">",
"     'United States FDA'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR ESA THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348975780\">",
"    <span class=\"h2\">",
"     Recommendations from expert groups",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     ASH/ASCO guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical practice guidelines for use of ESAs from the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO) were updated in 2010 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]: (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Use in patients not receiving chemotherapy'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/54/25450?source=see_link&amp;anchor=H7195992#H7195992\">",
"     \"Management of the complications of the myelodysplastic syndromes\", section on 'Erythropoiesis stimulating agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ESAs should",
"      <strong>",
"       NOT",
"      </strong>",
"      be used for patients with cancer and anemia not associated with chemotherapy. Use of ESAs in patients with lower-risk myelodysplastic syndromes to avoid transfusion is an exception to this recommendation.",
"     </li>",
"     <li>",
"      Before any decision regarding use of ESAs is made, appropriate history, physical examination, and diagnostic tests are indicated to identify alternative causes of anemia aside from chemotherapy or the underlying malignancy (",
"      <a class=\"graphic graphic_table graphicRef60121 \" href=\"mobipreview.htm?17/17/17691\">",
"       table 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Clinicians should carefully weigh the risks of thromboembolism in patients who are being considered for ESAs, particularly those with a heightened risk for thromboembolic events (eg, prior history of thromboses, surgery, prolonged periods of immobilization or limited activity, multiple myeloma treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      or a corticosteroid).",
"     </li>",
"     <li>",
"      Use of an ESA is recommended as a treatment option for patients with chemotherapy-associated anemia and a HGB level that has decreased below 10",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      The optimal level at which to initiate ESA therapy in patients with anemia and HGB between 10 and 12",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      cannot be definitively determined from the available literature. Whether or not to initiate treatment with an ESA in such patients must be determined by clinical judgment, consideration of the risks and benefits of ESAs, and patient preferences.",
"     </li>",
"     <li>",
"      An optimal target HGB cannot be definitively determined from the available literature. HGB levels should be increased to the lowest concentration needed to avoid transfusion, which may vary by patient and condition. Modification to reduce the ESA dose is appropriate when HGB reaches a level sufficient to avoid transfusion, or if the increase exceeds 1",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      in any two-week period. FDA-approved dose modification guidelines for ESA use in adults are presented in the table (",
"      <a class=\"graphic graphic_table graphicRef59470 \" href=\"mobipreview.htm?42/42/43692\">",
"       table 5",
"      </a>",
"      ). &nbsp;",
"      <br/>",
"      <br/>",
"      The FDA-approved labeling also indicates that ESAs should be withheld if hemoglobin exceeds a level needed to avoid transfusion, but the label does not specify a specific hemoglobin value [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/71\">",
"       71",
"      </a>",
"      ]. However, Centers for Medicare and Medicaid Services (CMS) restricts coverage of ESAs to patients with hemoglobin &lt;10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      and recommends further that therapy be discontinued once the hemoglobin is &ge;10",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Regulatory and fiscal policies'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Treatment with an ESA should be discontinued if there is no response to treatment within six to eight weeks, as evidenced by a rise in hemoglobin of less than 1 to 2",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      or no decrease in transfusion requirement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     NCCN guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2012 update of indications for ESAs in the management of cancer and chemotherapy-related anemia from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    can be summarized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ESAs are not indicated for anemia unrelated to chemotherapy.",
"     </li>",
"     <li>",
"      For anemia related to myelosuppressive chemotherapy, ESAs are not indicated if the cancer treatment goal is cure.",
"     </li>",
"     <li>",
"      ESAs may be appropriate for anemic patients receiving palliative myelosuppressive chemotherapy who do not need immediate correction of anemia.",
"     </li>",
"     <li>",
"      If considering the use of ESAs, evaluate for risk factors for thrombosis (eg, history of thromboembolism, heritable mutation, hypercoagulability, elevated prechemotherapy platelet count, hypertension, steroids, prolonged immobilization, recent surgery, certain therapies for multiple myeloma, hormonal agents).",
"     </li>",
"     <li>",
"      FDA indications, dosing and dosing adjustments should be used as a guideline for use of ESAs. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'United States FDA'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Regulatory and fiscal policies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     United States FDA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2007 and 2008, the results of various trials led the US Food and Drug Administration (FDA) to clarify several aspects of the usage of ESAs in patients with cancer.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients not receiving chemotherapy &mdash; A black box safety alert from the FDA indicates that treating the anemia of cancer with an ESA in patients who are not receiving chemotherapy offers no benefit and may cause serious harm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/72,73\">",
"       72,73",
"      </a>",
"      ]. As noted above, ESAs increase mortality in cancer patients not receiving chemotherapy or radiation therapy when administered to a target hemoglobin of &gt;12",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      The updated 2010 guidelines from ASH and ASCO are consistent with FDA-approved labeling [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Use in patients not receiving chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients receiving chemotherapy &mdash; As a result of safety information obtained from studies described above, black box warnings and labeling revisions for ESAs were issued by the FDA:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The lowest possible dose of ESAs should be used that will gradually increase the hemoglobin concentration to the lowest level sufficient to avoid blood transfusions.",
"     </li>",
"     <li>",
"      ESAs increase the risk for death and for serious cardiovascular events when administered to a target hemoglobin &gt;12",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"     </li>",
"     <li>",
"      ESAs are not indicated in patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Treatment with ESAs should not begin until the hemoglobin level drops to &le;10",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      ESAs should be withheld if hemoglobin exceeds a level needed to avoid transfusion but a specific hemoglobin value was not specified. The 2008 mandate removed previously approved language from the package insert that allowed earlier initiation of ESAs, or treatment to a higher hemoglobin target, if the patient was unable to tolerate anemia due to a comorbid condition.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The safety and efficacy of ESA use within these confines was shown in a small randomized trial in which 186 patients receiving chemotherapy for lung or gynecological cancer who had a hemoglobin",
"    <span class=\"nowrap\">",
"     &le;10g/dL",
"    </span>",
"    were randomly assigned to ESA use (epoetin beta 36,000 units or placebo weekly for 12 weeks) with weekly doses held for hemoglobin levels &gt;10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    and sustained levels &gt;12",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    avoided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/74\">",
"     74",
"    </a>",
"    ]. Transfusions were significantly less common in the ESA group (5 versus 20 percent of patients), and the incidence of thromboembolic events was similar, as was the one-year overall survival. While this trial provides some reassurance that the risk of thromboembolic events is not increased when ESAs are dosed according to established guidelines, it was not adequately powered to detect the magnitude of differences in survival or disease progression that have been noted with ESAs in much larger trials. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     European Medicines Agency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The same data that led the United States FDA to restrict approval for ESAs to palliative settings prompted the European Medicines Agency to recommend in June 2008 that blood transfusions are preferred over ESAs in cancer patients who have chemotherapy-related anemia and a \"reasonably long life expectancy\" (otherwise not defined) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348977446\">",
"    <span class=\"h3\">",
"     Medicare and Medicaid",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMS has restricted its coverage for ESAs in response to the controversies and safety concerns surrounding their use in patients with cancer. ESA use is currently limited to patients with chemotherapy-induced anemia whose hemoglobin level is &lt;10",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    Furthermore, treatment with ESAs is not reimbursed once the hemoglobin level has risen to &ge;10",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    CMS left coverage decisions about ESA use in MDS up to regional carriers, so there is geographic variability in reimbursement policies for ESA use in patients with MDS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     APPRISE: the US FDA Risk Evaluation and Mitigation Strategy program",
"    </span>",
"    &nbsp;&mdash;&nbsp;To ensure that patients receiving ESAs in the setting of cancer (regardless of the intent of therapy) are informed about the risks before they begin treatment, the US FDA approved a Risk Evaluation and Mitigation Strategy (REMS) risk management program, termed APPRISE (Assisting Provides and Cancer Patients with Risk Information for the Safe Use of ESAs) on February 16, 2010 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/53\">",
"     53",
"    </a>",
"    ]. The program requires hospitals and physicians prescribing ESAs for cancer patients to register and maintain enrollment in the REMS program, complete training on the use of ESAs in patients with cancer, and provide written documentation of the discussion with patients as to the risks of stroke, heart attack, blood clots, heart failure, tumor progression, and death, prior to instituting ESAs. Enrollment began March 24, 2010.",
"   </p>",
"   <p>",
"    In addition to providing the FDA-approved medication guide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/75,76\">",
"     75,76",
"    </a>",
"    ],",
"    <span class=\"nowrap\">",
"     ASCO/ASH",
"    </span>",
"    guidelines suggest that health care providers discuss specific issues with patients considering ESA therapy, as outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef55973 \" href=\"mobipreview.htm?5/5/5212\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Summary: patient selection for ESAs",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Minimum requirements",
"    </span>",
"    &nbsp;&mdash;&nbsp;ESAs are indicated for the treatment of anemia in patients with non-myeloid malignancies when the anemia is due to chemotherapy. In keeping with guidelines from",
"    <span class=\"nowrap\">",
"     ASH/ASCO,",
"    </span>",
"    cancer patients with anemia should meet all of the following criteria before being treated with an ESA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anemia should be symptomatic. Correctable causes of the anemia should be ruled out or treated, if present, prior to the use of an ESA.",
"     </li>",
"     <li>",
"      The patient's anemia should be due to chemotherapy for a non-hematologic malignancy. Current clinical trial evidence, professional society guidelines, and product approval indications do",
"      <strong>",
"       NOT",
"      </strong>",
"      support the use of ESAs for the treatment of anemia due to malignancy in the absence of chemotherapy. Use of ESAs in patients with lower-risk myelodysplastic syndrome (MDS) to avoid transfusions is an exception to this recommendation. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Use in patients not receiving chemotherapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/54/25450?source=see_link&amp;anchor=H7195992#H7195992\">",
"       \"Management of the complications of the myelodysplastic syndromes\", section on 'Erythropoiesis stimulating agents'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      ESAs should be instituted only if hemoglobin is &le;10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      prior to therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/52\">",
"       52",
"      </a>",
"      ]. However, in keeping with",
"      <span class=\"nowrap\">",
"       ASH/ASCO",
"      </span>",
"      guidelines, the decision to use an ESA for patients with highly symptomatic anemia and a hemoglobin level between 10 and 12",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      should be determined by clinical judgment, consideration of the risks and benefits of ESAs, and patient preferences [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Threshold and target hemoglobin levels'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinicians should carefully weigh the risks of thromboembolism in patients who are being considered for ESAs, particularly those with a heightened risk for thromboembolic events (eg, prior history of thromboses, surgery, prolonged periods of immobilization or limited activity, multiple myeloma treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      or a corticosteroid). The presence of uncontrolled hypertension is a contraindication to the use of ESAs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Intent of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;FDA-mandated labeling changes for ESAs in July 2008 state that these drugs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/52\">",
"     52",
"    </a>",
"    ]. This decision was based upon data from randomized trials suggesting worse outcomes in patients with early, potentially curable breast, head and neck, and cervical cancer who received ESAs compared to those who did not receive ESAs. In all of the trials, target hemoglobin levels were &ge;12",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    Furthermore, a meta-analysis found no association between darbepoetin use and risk of death or disease progression in patients with chemotherapy-induced anemia, the approved indication for ESAs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/77\">",
"     77",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Effect on disease control and survival'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p>",
"    In our view, whether ESAs should be avoided in patients receiving chemotherapy for a potentially curable cancer remains controversial. Updated guidelines for the use of ESAs from",
"    <span class=\"nowrap\">",
"     ASH/ASCO",
"    </span>",
"    do not differentiate between patients receiving potentially curative cancer therapy and those undergoing palliative cancer treatment, stating that no study has evaluated outcomes of ESA therapy by subgroups defined by chemotherapy intent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Given the general uncertainty about outcomes in patients being treated for cancer, whether individuals are receiving curative or palliative-intent therapy is not always a clear distinction.",
"   </p>",
"   <p>",
"    The FDA mandate neither prohibits nor prevents health care providers from prescribing ESAs in this situation. We suggest that the benefits and risks of ESAs be discussed with patients who meet the minimum requirements as outlined above regardless of the intent of therapy. If after discussion with a well-informed patient, the risks are felt to be counterbalanced by the benefits of avoiding transfusion or reducing the chemotherapy dose(s), then use of ESAs is appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     ESA FORMULATIONS AND DOSING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Epoetin alfa",
"    </span>",
"    &nbsp;&mdash;&nbsp;When",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/48/2825?source=see_link\">",
"     epoetin alfa",
"    </a>",
"    was initially approved for patients with chemotherapy-associated anemia, a starting dose of 100 to 150",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    administered subcutaneously (SC) was recommended three times weekly along with supplemental oral iron. Responders were expected to show an increase in the reticulocyte count within one week and a rise in the hemoglobin concentration of at least 0.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    by two to four weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/78,79\">",
"     78,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a subsequent meta-analysis of data from four randomized trials in 604 patients with non-myeloid malignancies concluded that up to 46 percent of those without a rise in hemoglobin by two to four weeks ultimately respond to ESA therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/68\">",
"     68",
"    </a>",
"    ]. Accordingly, most patients are treated for 8 to 12 weeks before treatment is considered a failure.",
"   </p>",
"   <p>",
"    The FDA-approved starting dose for epoetin is 150",
"    <span class=\"nowrap\">",
"     U/kg",
"    </span>",
"    three times weekly or 40,000 U weekly (",
"    <a class=\"graphic graphic_table graphicRef59470 \" href=\"mobipreview.htm?42/42/43692\">",
"     table 5",
"    </a>",
"    ). When a weekly single dose schedule was employed in anemic patients, results were similar to three times weekly administration, with an increase in mean hemoglobin concentration, a reduction in transfusion requirement, and an improvement in quality of life measures for patients receiving chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/80\">",
"     80",
"    </a>",
"    ] or chemoradiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/81\">",
"     81",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p>",
"    Less frequent administration of higher doses of epoetin is similarly effective but more convenient. Alternative schedules include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Every two weeks &mdash; In a trial of 298 anemic patients with non-myeloid malignancies undergoing chemotherapy, 80,000 units of epoetin given SC once every two weeks demonstrated similar hemoglobin increases, transfusion rates, and safety outcomes compared to patients treated with 40,000 units once every week [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Every three weeks &mdash; Another study randomly assigned 365 patients to receive three weekly doses of 40,000 units of epoetin, and then either 120,000 units of epoetin every three weeks or to continue 40,000 units of epoetin weekly [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/64\">",
"       64",
"      </a>",
"      ]. This study found no difference in transfusion endpoints or adverse events including thromboembolism, but observed a lower end-of-study hemoglobin in the treatment arm receiving 120,000 units every three weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If hemoglobin levels have not increased by six to eight weeks in the setting of adequate iron stores, the schedule can be intensified or the dose raised (",
"    <a class=\"graphic graphic_table graphicRef59470 \" href=\"mobipreview.htm?42/42/43692\">",
"     table 5",
"    </a>",
"    ). FDA-approved labeling guidelines suggest not continuing ESAs beyond eight weeks in the absence of a response (a &lt;1 to 2",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    increase in HGB or no diminution in transfusion requirements). (See",
"    <a class=\"local\" href=\"#H34\">",
"     'Iron monitoring and supplementation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Darbepoetin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Darbepoetin is indicated for the treatment of chemotherapy-induced anemia in non-myeloid malignancies. Darbepoetin is effective when given as infrequently as once every three to four weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/83-86\">",
"     83-86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Darbepoetin is a biochemically distinct form of erythropoietin that is produced in Chinese hamster ovary cells using recombinant DNA technology. Darbepoetin has a longer in vivo half-life than erythropoietin and a modestly lower EPO-R binding activity (",
"    <a class=\"graphic graphic_figure graphicRef51292 \" href=\"mobipreview.htm?29/23/30078\">",
"     figure 1",
"    </a>",
"    ). These properties are due to an altered glycosylation pattern compared to native erythropoietin, while the protein sequence of darbepoetin is the same as that of epoetin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/21/23896?source=see_link\">",
"     \"Darbepoetin alfa for the management of anemia in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The activity of darbepoetin in patients with chemotherapy-induced anemia was illustrated by a double-blind trial in 314 anemic patients (hemoglobin &le;11.0",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    receiving chemotherapy for lung cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/87\">",
"     87",
"    </a>",
"    ]. Patients were randomly assigned to weekly darbepoetin (initial dose 2.25",
"    <span class=\"nowrap\">",
"     microg/kg",
"    </span>",
"    SC) or placebo. Key findings included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fewer patients treated with darbepoetin required transfusion during the first 28 days of treatment (27 versus 52 percent with placebo, mean difference 25 percent, 95 % CI: 14 to 36 percent).",
"     </li>",
"     <li>",
"      The rate of hematopoietic response (defined by an increase in hemoglobin level &ge;2.0",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      or a hemoglobin &ge;12.0",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      was higher in patients treated with darbepoetin (66 versus 24 percent with placebo, mean difference 42 percent, 95% CI: 31 to 53 percent).",
"     </li>",
"     <li>",
"      More patients showed a &ge;25 percent improvement in a quality of life measurement, the FACT-fatigue score (32 versus 19 percent, mean difference 13 percent, 95% CI: 2 to 23 percent) (",
"      <a class=\"graphic graphic_table graphicRef76886 \" href=\"mobipreview.htm?7/4/7244\">",
"       table 8",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The FDA-approved starting dose for darbepoetin is 2.25",
"    <span class=\"nowrap\">",
"     microgram/kg",
"    </span>",
"    weekly or 500 micrograms every three weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/85\">",
"     85",
"    </a>",
"    ], subcutaneously (",
"    <a class=\"graphic graphic_table graphicRef59470 \" href=\"mobipreview.htm?42/42/43692\">",
"     table 5",
"    </a>",
"    ). Other guidelines for the use of darbepoetin in patients with chemotherapy-induced anemia recommend an initial dose of 200 micrograms every two weeks, a dose and schedule that is included in",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    guidelines. Three randomized trials for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic malignancy found this dose and schedule for darbepoetin achieved comparable clinical and hematologic outcomes compared to epoetin given at a dose of 40,000 units once per week [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/63,88,89\">",
"     63,88,89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with epoetin, if there is no increase in the hemoglobin concentration after four weeks in the setting of adequate iron stores, the dose can be increased (",
"    <a class=\"graphic graphic_table graphicRef59470 \" href=\"mobipreview.htm?42/42/43692\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Guidelines from",
"    <span class=\"nowrap\">",
"     ASCO/ASH",
"    </span>",
"    recommend not continuing ESAs beyond eight weeks in the absence of a response (a &lt;1 to 2",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    increase in HGB or no diminution in transfusion requirements) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Iron monitoring and supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the availability of iron can limit the hemoglobin response following treatment with ESAs in patients with cancer-related anemia as well as in those with renal failure. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Variability in and predictors of response to ESAs'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Iron deficiency may develop quickly in treated patients who have borderline iron levels at the onset of therapy. Furthermore, even normal subjects and cancer patients with adequate iron stores may have difficulty adequately mobilizing iron to respond to erythropoietin therapy, a phenomenon which has been termed \"functional iron deficiency\" or iron-restricted erythropoiesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/90-95\">",
"     90-95",
"    </a>",
"    ]. Anemic cancer patients treated with ESAs may have additional difficulties with iron mobilization, due to cytokine-mediated inhibition of the transfer of iron from macrophages to the developing erythron. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/13/9434?source=see_link&amp;anchor=H2#H2\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most widely available markers reflecting functional iron status of the body are transferrin saturation (serum iron divided by the total iron binding capacity [TIBC, transferrin]) and serum ferritin, although transferrin saturation is strongly influenced by daily variations in serum iron, and ferritin is an acute phase reactant protein that may be increased during acute inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, these are the best markers of iron stores that are currently available, and serum iron, TIBC, and serum ferritin should be assayed at baseline in all anemic patients who are being considered for an ESA and in patients who fail to respond to ESA therapy within six to eight weeks. Iron should be given during ESA therapy, if necessary, in order to maintain a transferrin saturation of &ge;20 percent and a serum ferritin level of &ge;100",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Oral versus parenteral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although some cancer patients will respond to the use of oral iron, such replacement has not been demonstrated to be consistently effective in patients receiving ESAs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. Parenteral iron, although less convenient for both the patient and staff, may augment erythropoiesis by providing iron in a more rapidly bioavailable form. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/55/37752?source=see_link\">",
"     \"Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38521?source=see_link\">",
"     \"Use of iron preparations in hemodialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple randomized trials in patients with chemotherapy-induced anemia have shown that parenteral iron supplementation (compared to either oral iron or no iron) increases the proportion of patients achieving an adequate hemoglobin response to ESA therapy and decreases the percentage of patients requiring transfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/65,66,92,96,97\">",
"     65,66,92,96,97",
"    </a>",
"    ]. This benefit has been seen both in iron-deficient and iron-replete patients. However, the benefit of parenteral as compared to oral iron has been called into question by the following results:",
"   </p>",
"   <p>",
"    Two trials, including the largest randomized trial to date of ESA with or without parenteral iron conducted in 502 patients receiving chemotherapy who had a hemoglobin &lt;11",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    failed to show any benefit with the intravenous iron preparation compared to oral iron [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/98,99\">",
"     98,99",
"    </a>",
"    ] or oral placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of eight trials comparing parenteral iron versus no iron or oral iron in anemic chemotherapy patients receiving ESAs (including the two negative trials cited above) concluded that the use of parenteral iron significantly reduced the risk of transfusion compared to no iron (relative risk 0.77, 95% CI 0.62-0.97), but the difference was not statistically significant when parenteral iron was compared to oral iron (RR 0.68, 95% CI 0.44-1.05) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Widespread adoption of parenteral iron in patients receiving ESAs has been slow. In the past, anaphylactic reactions have been a major problem for IV iron administration, particularly with high-molecular weight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/46/21222?source=see_link\">",
"     iron dextran",
"    </a>",
"    preparations (eg, ImFeron, which is no longer available, and DexFerrum, which is available). This problem has been reduced but not eliminated with the introduction of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/53/31573?source=see_link\">",
"     ferric gluconate",
"    </a>",
"    (Ferrlecit), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/31/41461?source=see_link\">",
"     iron sucrose",
"    </a>",
"    (Venofer), and low molecular weight iron",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    (InFed). With the exception of high molecular weight iron dextran, there appears to be little difference among the available parenteral agents in terms of efficacy and safety, although low molecular weight iron dextran is less costly.",
"   </p>",
"   <p>",
"    Another issue is that in the United States, Medicare rules do not allow the administration of an ESA and parenteral iron on the same day. &nbsp;",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    guidelines recommend use of low molecular weight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/46/21222?source=see_link\">",
"     iron dextran",
"    </a>",
"    (INfed),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/53/31573?source=see_link\">",
"     ferric gluconate",
"    </a>",
"    (Ferrlecit), or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/31/41461?source=see_link\">",
"     iron sucrose",
"    </a>",
"    (Venofer) for the treatment of iron deficiency in patients intolerant or unresponsive to oral iron therapy and for cancer patients who are receiving ESAs as long as their transferrin saturation is &lt;50 percent and serum ferritin &lt;800",
"    <span class=\"nowrap\">",
"     mg/mL.",
"    </span>",
"   </p>",
"   <p>",
"    Of interest, the newest preparation,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/46/27364?source=see_link\">",
"     ferumoxytol",
"    </a>",
"    , allows for the infusion of 510 mg of IV iron as a single push infusion, in contrast to the limit of 125 mg for Ferrlecit and Venofer. The use of these agents is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/62/25578?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of anemia due to iron deficiency\", section on 'Parenteral iron therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Even with the availability of safer parenteral agents, whether all patients receiving ESAs require IV iron remains controversial, and clinical practice varies. Randomized trials suggest that 50 to 70 percent of patients will respond to ESAs alone or with the addition of oral iron. Given this fact, some clinicians reserve IV iron for patients who fail to respond to an ESA within five to six weeks. On the other hand, particularly in patients with marginal or low iron stores, use of IV iron could be considered a faster way to ensure adequate iron stores than oral iron, and this might lead to the lowest possible dose of an ESA.",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    guidelines suggest IV iron in this setting, as long as active infection is excluded.",
"   </p>",
"   <p>",
"    Updated guidelines from the",
"    <span class=\"nowrap\">",
"     ASH/ASCO",
"    </span>",
"    expert panel state that the evidence is inadequate to consider IV iron as the standard of care in patients with chemotherapy-associated anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. They cite the heterogeneity across the trials in patient population, use of concomitant chemotherapy, ESA and iron formulations and schedules, control groups, and reported primary outcomes, the lack of standardization of transfusion use, the lack of blinding, and imbalances between the experimental and control groups (eg, more women with breast and gynecologic cancers), which could have led to greater degrees of iron deficiency in the groups receiving IV iron.",
"   </p>",
"   <p>",
"    In our view, the observed increase in erythropoiesis seen when using ESAs in combination with parenteral iron needs to be balanced against the increased cost, need for a several hour visit to an infusion center, small risk of an adverse reaction to the parenteral iron preparation and the very small potential risk of aggravating total body iron overload. Other potential long-term biologic effects of iron overload remain largely undefined, but concerns for promotion of tumor growth, enhanced oxidative stress, and exacerbation of infection have been voiced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/94,101\">",
"     94,101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/4/29762?source=see_link\">",
"       \"Patient information: When your cancer treatment makes you tired (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia in cancer patients may be due to the malignancy itself, myelosuppressive chemotherapy or radiation therapy, or any of the other causes of anemia that affect patients without cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/22/23914?source=see_link\">",
"     \"Hematologic consequences of malignancy: Anemia and bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the patient with cancer and chemotherapy-related anemia, erythropoiesis-stimulating agents (ESAs) may be used to reduce the need for red blood cell (RBC) transfusions. Transfusion is a reasonable alternative, particularly if a rapid increase in hemoglobin (HGB) is needed. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'ESAs: efficacy, side effects, and clinical use'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H5\">",
"     'ESAs versus transfusion'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The use of ESAs has been associated with an increased incidence of thromboembolic events and shortened survival, particularly when used in patients whose anemia is not due to myelosuppressive chemotherapy. Furthermore, randomized trials conducted in patients with potentially curable breast, head and neck, and cervical cancer raise the possibility that the use of ESAs might compromise tumor control and survival. In all of these trials, the target HGB level was &gt;12",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H264001313\">",
"     'Thromboembolic risk'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H13\">",
"     'Effect on disease control and survival'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following recommendations are for the use of ESAs in adult patients with non-hematologic malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cancer patients who are being considered for treatment with ESAs should meet all of the following criteria (see",
"      <a class=\"local\" href=\"#H29\">",
"       'Minimum requirements'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Symptomatic anemia due to chemotherapy for a non-hematologic malignancy. Use of ESAs for patients with lower-risk myelodysplastic syndrome to avoid transfusions is an exception to this recommendation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/54/25450?source=see_link&amp;anchor=H7195992#H7195992\">",
"       \"Management of the complications of the myelodysplastic syndromes\", section on 'Erythropoiesis stimulating agents'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other treatable causes of anemia (eg, blood loss, hemolysis, nutritional deficiency (eg, iron, B12, folate)) should be excluded or treated if present. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29418?source=see_link\">",
"       \"Approach to the adult patient with anemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An initial hemoglobin level of &lt;10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      should be present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with chemotherapy-induced anemia who meet all of these criteria, clinicians should discuss potential harms (thromboembolism, shorter survival) and benefits (decreased transfusions) of ESAs and compare them with potential harms (serious infection, immune-mediated adverse reactions) and benefits (rapid Hgb improvement) of RBC transfusions (",
"      <a class=\"graphic graphic_table graphicRef78476 \" href=\"mobipreview.htm?31/32/32267\">",
"       table 2",
"      </a>",
"      ). In addition to providing patients with the FDA-approved medication guide [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/75,76\">",
"       75,76",
"      </a>",
"      ],",
"      <span class=\"nowrap\">",
"       ASCO/ASH",
"      </span>",
"      guidelines suggest that the clinician discuss a number of specific issues before prescribing ESAs (",
"      <a class=\"graphic graphic_table graphicRef55973 \" href=\"mobipreview.htm?5/5/5212\">",
"       table 7",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      In general, we suggest the use of ESAs rather than transfusion for patients who meet all of the above criteria, and who do not have a heightened risk for thromboembolic events (eg, prior history of thromboses, surgery, prolonged periods of immobilization or limited activity, multiple myeloma treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      or a corticosteroid) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      RBC transfusion is an appropriate alternative for patients whose clinical condition indicates the need for immediate correction of the hemoglobin level, for those in whom reducing the frequency of transfusion is not an important consideration, and in patients who have established general risk factors for thromboembolic events. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Summary: patient selection for ESAs'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/37/21081?source=see_link\">",
"       \"Use of red blood cells for transfusion\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/52/5961?source=see_link\">",
"       \"Indications for red cell transfusion in the adult\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The decision to use an ESA for patients with highly symptomatic anemia and a hemoglobin level between 10 and 12",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      should be determined by clinical judgment, consideration of the risks and benefits of ESAs, and patient preferences [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Summary: patient selection for ESAs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Whether the use of ESAs should be restricted to patients receiving palliative rather than potentially curative chemotherapy is controversial. FDA-approved labeling states that ESAs are not indicated in patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/52\">",
"       52",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      However, updated guidelines for the use of ESAs from",
"      <span class=\"nowrap\">",
"       ASH/ASCO",
"      </span>",
"      do not differentiate between patients receiving potentially curative cancer therapy and those undergoing palliative cancer treatment, stating that no study has evaluated outcomes of ESA therapy by subgroups defined by chemotherapy intent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. Furthermore, determination of the goal of treatment requires clinical judgment in many cases.",
"      <br/>",
"      <br/>",
"      We follow the",
"      <span class=\"nowrap\">",
"       ASCO/ASH",
"      </span>",
"      guidelines and suggest that patients undergoing myelosuppressive chemotherapy for a potentially curative cancer be counseled as to the risks and benefits of ESA use versus RBC transfusion or chemotherapy dose reduction (",
"      <a class=\"graphic graphic_table graphicRef78476 \" href=\"mobipreview.htm?31/32/32267\">",
"       table 2",
"      </a>",
"      ). The wording of the FDA-mandated labeling neither prohibits nor prevents health care providers from prescribing an ESA to patients being treated with curative intent if, after discussion with a well-informed patient, the risks of therapy with an ESA are felt to be outweighed by the benefits of avoiding red cell transfusion. Patients must be informed that such use of an ESA may not be reimbursed.",
"     </li>",
"     <li>",
"      For patients with anemia due to a solid tumor or non-myeloid hematologic malignancy who are",
"      <strong>",
"       NOT",
"      </strong>",
"      receiving chemotherapy, we recommend",
"      <strong>",
"       NOT",
"      </strong>",
"      using an ESA to treat anemia (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The use of ESAs for patients with lower-risk myelodysplastic syndrome to avoid transfusions is one exception to this recommendation. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Use in patients not receiving chemotherapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Regulatory and fiscal policies'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/54/25450?source=see_link&amp;anchor=H7195992#H7195992\">",
"       \"Management of the complications of the myelodysplastic syndromes\", section on 'Erythropoiesis stimulating agents'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      ESAs should be used cautiously in patients with a high risk for thromboembolism, especially in the setting of malignancies that are associated with an elevated risk for thromboembolic complications (eg, multiple myeloma, treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      with either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      or corticosteroids). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'ESAs: efficacy, side effects, and clinical use'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/43/35514?source=see_link\">",
"       \"Hypercoagulable disorders associated with malignancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Choice of agent, dose titration, and supplemental iron",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ESAs epoetin and darbepoetin appear to be similarly effective. Darbepoetin may be more convenient, based upon a lower frequency of administration. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'ESA formulations and dosing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Starting doses and dose modifications after response or nonresponse should follow US FDA-approved labeling guidelines (",
"      <a class=\"graphic graphic_table graphicRef59470 \" href=\"mobipreview.htm?42/42/43692\">",
"       table 5",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The approved starting dose of epoetin is 150",
"      <span class=\"nowrap\">",
"       U/kg",
"      </span>",
"      three times weekly or 40,000 U weekly, subcutaneously; the approved starting dose for darbepoetin is 2.25",
"      <span class=\"nowrap\">",
"       microgram/kg",
"      </span>",
"      weekly or 500 micrograms every three weeks, subcutaneously.",
"     </li>",
"     <li>",
"      The dose should be adjusted in each patient to maintain the lowest hemoglobin level sufficient to avoid red cell transfusions; dose modification guidelines are presented in the table (",
"      <a class=\"graphic graphic_table graphicRef59470 \" href=\"mobipreview.htm?42/42/43692\">",
"       table 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Updated guidelines from",
"      <span class=\"nowrap\">",
"       ASCO/ASH",
"      </span>",
"      state that an optimal target HGB concentration cannot be definitively determined based on the available data. Modification to reduce the ESA dose is appropriate when the HGB reaches a level sufficient to avoid transfusion, or the increase exceeds 1",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      in any two week period. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Threshold and target hemoglobin levels'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Regulatory and fiscal policies'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      In keeping with",
"      <span class=\"nowrap\">",
"       ASCO/ASH",
"      </span>",
"      guidelines, we suggest discontinuing the ESA after eight weeks if the HGB has not increased by more than 1 to 2",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      or there is no diminution in the need for RBC transfusion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/15/38138/abstract/6,7\">",
"       6,7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For all patients treated with ESAs, we recommend that supplemental iron be given to maintain a transferrin saturation &ge;20 percent and a serum ferritin &ge;100",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Parenteral rather than oral iron might be considered for this purpose, but data are conflicting and inconclusive. IV iron might be preferred during ESA therapy in three settings: patients who have not had an adequate response to oral iron within five to six weeks, those who have demonstrated low or marginal iron levels, and those who cannot tolerate or refuse to take oral iron. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Iron monitoring and supplementation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/13/9434?source=see_link&amp;anchor=H2#H2\">",
"       \"Anemia of chronic disease (anemia of chronic inflammation)\", section on 'Pathogenesis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/1\">",
"      Cash JM, Sears DA. The anemia of chronic disease: spectrum of associated diseases in a series of unselected hospitalized patients. Am J Med 1989; 87:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/2\">",
"      Schilling RF. Anemia of chronic disease: a misnomer. Ann Intern Med 1991; 115:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/3\">",
"      Lind M, Vernon C, Cruickshank D, et al. The level of haemoglobin in anaemic cancer patients correlates positively with quality of life. Br J Cancer 2002; 86:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/4\">",
"      Samol J, Littlewood TJ. The efficacy of rHuEPO in cancer-related anaemia. Br J Haematol 2003; 121:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/5\">",
"      Straus DJ, Testa MA, Sarokhan BJ, et al. Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies. Cancer 2006; 107:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/6\">",
"      Rizzo JD, Brouwers M, Hurley P, et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 2010; 116:4045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/7\">",
"      Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010; 28:4996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/8\">",
"      Klarenbach S, Manns B, Reiman T, et al. Economic evaluation of erythropoiesis-stimulating agents for anemia related to cancer. Cancer 2010; 116:3224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/9\">",
"      Vekeman F, Bookhart BK, White J, et al. Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin. Transfusion 2009; 49:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/10\">",
"      Tonia T, Mettler A, Robert N, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2012; 12:CD003407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/11\">",
"      Pronzato P, Cortesi E, van der Rijt CC, et al. Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial. Oncologist 2010; 15:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/12\">",
"      Chang J, Couture F, Young S, et al. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 2005; 23:2597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/13\">",
"      Glaspy J. Update on safety of ESAs in cancer-induced anemia. J Natl Compr Canc Netw 2012; 10:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/14\">",
"      Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008; 299:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/15\">",
"      Tonelli M, Hemmelgarn B, Reiman T, et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ 2009; 180:E62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/16\">",
"      Glaspy J, Crawford J, Vansteenkiste J, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010; 102:301.",
"     </a>",
"    </li>",
"    <li>",
"     Seidenfeld, J, Piper, M, Borhuis, J, et al. Comparative effectiveness Review No. 3.  file://effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&amp;productid=461 (Accessed on November 01, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/18\">",
"      Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002; 100:2303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/19\">",
"      Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002; 20:4083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/20\">",
"      Bohlius J, Langensiepen S, Schwarzer G, et al. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 2005; 97:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/21\">",
"      Robnett TJ, Machtay M, Hahn SM, et al. Pathological response to preoperative chemoradiation worsens with anemia in non-small cell lung cancer patients. Cancer J 2002; 8:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/22\">",
"      Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001; 91:2214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/23\">",
"      Waters JS, O'Brien ME, Ashley S. Management of anemia in patients receiving chemotherapy. J Clin Oncol 2002; 20:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/24\">",
"      Glaser CM, Millesi W, Kornek GV, et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001; 50:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/25\">",
"      Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2008; 26:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/26\">",
"      Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood 2008; 111:25.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/28\">",
"      Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007; 43:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/29\">",
"      Henke M, Laszig R, R&uuml;be C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362:1255.",
"     </a>",
"    </li>",
"    <li>",
"     Overgaard J, Hoff CM, Hansen HS, et al. Randomized study of darbepoetin alfa as modifier of radiotherapy in pateints with primary squamous cell carcinoma of the head and neck: Final outcome of the DAHANCA 10 trial (abstract). J Clin Oncol 2009; 27(suppl): abstract 6007. Abstract available online at file://www.asco.org/ascov2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=65&amp;abstractID=35348 (Accessed on March 26, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/31\">",
"      Acs G, Acs P, Beckwith SM, et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001; 61:3561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/32\">",
"      Yasuda Y, Fujita Y, Matsuo T, et al. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 2003; 24:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/33\">",
"      Liang K, Esteva FJ, Albarracin C, et al. Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell 2010; 18:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/34\">",
"      Hedley BD, Allan AL, Xenocostas A. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression. Clin Cancer Res 2011; 17:6373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/35\">",
"      Belenkov AI, Shenouda G, Rizhevskaya E, et al. Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin. Mol Cancer Ther 2004; 3:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/36\">",
"      Sinclair AM, Todd MD, Forsythe K, et al. Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer 2007; 110:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/37\">",
"      Aapro M, Jelkmann W, Constantinescu SN, Leyland-Jones B. Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer. Br J Cancer 2012; 106:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/38\">",
"      Laugsch M, Metzen E, Svensson T, et al. Lack of functional erythropoietin receptors of cancer cell lines. Int J Cancer 2008; 122:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/39\">",
"      Hardee ME, Kirkpatrick JP, Shan S, et al. Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis. Br J Cancer 2005; 93:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/40\">",
"      Swift S, Ellison AR, Kassner P, et al. Absence of functional EpoR expression in human tumor cell lines. Blood 2010; 115:4254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/41\">",
"      Brown WM, Maxwell P, Graham AN, et al. Erythropoietin receptor expression in non-small cell lung carcinoma: a question of antibody specificity. Stem Cells 2007; 25:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/42\">",
"      Elliott S, Busse L, Bass MB, et al. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 2006; 107:1892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/43\">",
"      Elliott S, Busse L, McCaffery I, et al. Identification of a sensitive anti-erythropoietin receptor monoclonal antibody allows detection of low levels of EpoR in cells. J Immunol Methods 2010; 352:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/44\">",
"      Hardee ME, Cao Y, Fu P, et al. Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS One 2007; 2:e549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/45\">",
"      Okazaki T, Ebihara S, Asada M, et al. Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis. Neoplasia 2008; 10:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/46\">",
"      Carlini RG, Reyes AA, Rothstein M. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int 1995; 47:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/47\">",
"      Ribatti D, Presta M, Vacca A, et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999; 93:2627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/48\">",
"      Kirkeby A, Torup L, Bochsen L, et al. High-dose erythropoietin alters platelet reactivity and bleeding time in rodents in contrast to the neuroprotective variant carbamyl-erythropoietin (CEPO). Thromb Haemost 2008; 99:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/49\">",
"      Borsig L. The role of platelet activation in tumor metastasis. Expert Rev Anticancer Ther 2008; 8:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/50\">",
"      Hadland BK, Longmore GD. Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms. J Clin Oncol 2009; 27:4217.",
"     </a>",
"    </li>",
"    <li>",
"     Press release available at www.emea.europa.eu/pdfs/human/press/pr/33396308en.pdf.",
"    </li>",
"    <li>",
"     www.fda.gov/medwatch/safety/2008/ESA_DHCP_Aug2008.pdf (Accessed on November 02, 2010).",
"    </li>",
"    <li>",
"     www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm200391.htm (Accessed on November 02, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/54\">",
"      Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005; 23:5960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/55\">",
"      Brower V. Erythropoietin may impair, not improve, cancer survival. Nat Med 2003; 9:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/56\">",
"      Rosenzweig MQ, Bender CM, Lucke JP, et al. The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events. J Pain Symptom Manage 2004; 27:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/57\">",
"      Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007; 25:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/58\">",
"      Hudis CA, Vogel CL, Gralow JR, et al. Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life. Clin Breast Cancer 2005; 6:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/59\">",
"      Aapro M, Osterwalder B, Scherhag A, Burger HU. Epoetin-beta treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events. Br J Cancer 2009; 101:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/60\">",
"      Aapro M, Scherhag A, Burger HU. Effect of treatment with epoetin-beta on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients. Br J Cancer 2008; 99:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/61\">",
"      Goldberg P. Study finds more deaths on aranesp arm in cancer anemia study, no benefit seen. Cancer Lett 2007; 33:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/62\">",
"      Smith RE Jr, Aapro MS, Ludwig H, et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008; 26:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/63\">",
"      20030125 Study Group Trial, Glaspy J, Vadhan-Raj S, et al. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. J Clin Oncol 2006; 24:2290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/64\">",
"      Steensma DP, Molina R, Sloan JA, et al. Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer. J Clin Oncol 2006; 24:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/65\">",
"      Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004; 22:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/66\">",
"      Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007; 12:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/67\">",
"      Miller CB, Jones RJ, Piantadosi S, et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990; 322:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/68\">",
"      Littlewood TJ, Zagari M, Pallister C, Perkins A. Baseline and early treatment factors are not clinically useful for predicting individual response to erythropoietin in anemic cancer patients. Oncologist 2003; 8:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/69\">",
"      Hellstr&ouml;m-Lindberg E, Gulbrandsen N, Lindberg G, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003; 120:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/70\">",
"      Pavese I, Satta F, Todi F, et al. High serum levels of TNF-&alpha; and IL-6 predict the clinical outcome of treatment with human recombinant erythropoietin in anaemic cancer patients. Ann Oncol 2010; 21:1523.",
"     </a>",
"    </li>",
"    <li>",
"     FDA letter available online at www.fda.gov/medwatch/safety/2008/ESA_DHCP_Aug2008.pdf (Accessed on November 02, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/72\">",
"      Steensma DP. Is anemia of cancer different from chemotherapy-induced anemia? J Clin Oncol 2008; 26:1022.",
"     </a>",
"    </li>",
"    <li>",
"     United States Food and Drug Administration Med Watch file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm150441.htm (Accessed on June 02, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/74\">",
"      Fujisaka Y, Sugiyama T, Saito H, et al. Randomised, phase III trial of epoetin-&beta; to treat chemotherapy-induced anaemia according to the EU regulation. Br J Cancer 2011; 105:1267.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration medication guide for darbepoetin alfa (Aranesp), Available online at  file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085918.pdf (Accessed on November 01, 2010).",
"    </li>",
"    <li>",
"     US Food and Drug Administration medication guide for epoetin alfa (Procrit) available online at file://www.fda.gov/downloads/Drugs/Drugsafety/ucm088988.pdf (Accessed on November 01, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/77\">",
"      Ludwig H, Crawford J, Osterborg A, et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol 2009; 27:2838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/78\">",
"      Ludwig H, Fritz E, Leitgeb C, et al. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 1994; 84:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/79\">",
"      Gonz&aacute;lez-Bar&oacute;n M, Ord&oacute;&ntilde;ez A, Franquesa R, et al. Response predicting factors to recombinant human erythropoietin in cancer patients undergoing platinum-based chemotherapy. Cancer 2002; 95:2408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/80\">",
"      Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19:2875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/81\">",
"      Shasha D, George MJ, Harrison LB. Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 2003; 98:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/82\">",
"      Henry DH, Gordan LN, Charu V, et al. Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia. Curr Med Res Opin 2006; 22:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/83\">",
"      Kotasek D, Steger G, Faught W, et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 2003; 39:2026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/84\">",
"      Hedenus M, Adriansson M, San Miguel J, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003; 122:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/85\">",
"      Canon JL, Vansteenkiste J, Bodoky G, et al. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 2006; 98:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/86\">",
"      Gordon D, Nichols G, Ben-Jacob A, et al. Treating anemia of cancer with every-4-week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study. Oncologist 2008; 13:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/87\">",
"      Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002; 94:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/88\">",
"      Schwartzberg LS, Yee LK, Senecal FM, et al. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist 2004; 9:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/89\">",
"      Senecal FM, Yee L, Gabrail N, et al. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly. Clin Breast Cancer 2005; 6:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/90\">",
"      Brugnara C, Chambers LA, Malynn E, et al. Red blood cell regeneration induced by subcutaneous recombinant erythropoietin: iron-deficient erythropoiesis in iron-replete subjects. Blood 1993; 81:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/91\">",
"      Goodnough LT, Price TH, Friedman KD, et al. A phase III trial of recombinant human erythropoietin therapy in nonanemic orthopedic patients subjected to aggressive removal of blood for autologous use: dose, response, toxicity, and efficacy. Transfusion 1994; 34:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/92\">",
"      Hedenus M, Birgeg&aring;rd G, N&auml;sman P, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007; 21:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/93\">",
"      Goodnough LT. Erythropoietin and iron-restricted erythropoiesis. Exp Hematol 2007; 35:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/94\">",
"      Katodritou E, Zervas K, Terpos E, Brugnara C. Use of erythropoiesis stimulating agents and intravenous iron for cancer and treatment-related anaemia: the need for predictors and indicators of effectiveness has not abated. Br J Haematol 2008; 142:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/95\">",
"      Goodnough LT, Nemeth E, Ganz T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 2010; 116:4754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/96\">",
"      Bastit L, Vandebroek A, Altintas S, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008; 26:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/97\">",
"      Pedrazzoli P, Farris A, Del Prete S, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 2008; 26:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/98\">",
"      Steensma DP, Sloan JA, Dakhil SR, et al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol 2011; 29:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/99\">",
"      Macci&ograve; A, Madeddu C, Gramignano G, et al. Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study. Oncologist 2010; 15:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/100\">",
"      Petrelli F, Borgonovo K, Cabiddu M, et al. Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. J Cancer Res Clin Oncol 2012; 138:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/15/38138/abstract/101\">",
"      Gilreath JA, Stenehjem DD, Rodgers GM. Total dose iron dextran infusion in cancer patients: is it SaFe2+? J Natl Compr Canc Netw 2012; 10:669.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2799 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-D795AC79FE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_15_38138=[""].join("\n");
var outline_f37_15_38138=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF TREATMENT OPTIONS FOR ANEMIA IN CANCER PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H348976573\">",
"      Transfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ESAs: epoetin and darbepoetin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ESAs versus transfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Androgens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ESAS: EFFICACY, SIDE EFFECTS, AND CLINICAL USE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Meta-analyses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H264001313\">",
"      Thromboembolic risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Effect on disease control and survival",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H691539292\">",
"      - Potential mechanisms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Use in patients treated with curative intent: recommendations of EMA, FDA, ASCO/ASH, and NCCN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Threshold and target hemoglobin levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Use in patients not receiving chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Variability in and predictors of response to ESAs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      INDICATIONS FOR ESA THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H348975780\">",
"      Recommendations from expert groups",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - ASH/ASCO guidelines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - NCCN guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Regulatory and fiscal policies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - United States FDA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - European Medicines Agency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H348977446\">",
"      - Medicare and Medicaid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - APPRISE: the US FDA Risk Evaluation and Mitigation Strategy program",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Summary: patient selection for ESAs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Minimum requirements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Intent of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      ESA FORMULATIONS AND DOSING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Epoetin alfa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Darbepoetin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Iron monitoring and supplementation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Oral versus parenteral",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Choice of agent, dose titration, and supplemental iron",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2799\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2799|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/23/30078\" title=\"figure 1\">",
"      Pharmacokinetics of epoetin alfa and darbepoetin alfa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2799|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/59/31676\" title=\"table 1\">",
"      Infection risk of blood products",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/32/32267\" title=\"table 2\">",
"      Risk ben ESA RBC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/62/26606\" title=\"table 3\">",
"      Trials ESA in patients treated with RT or chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/31/7677\" title=\"table 4\">",
"      Meta-analyses trials of ESA use addressing cancer outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/42/43692\" title=\"table 5\">",
"      ESA Adult dosing guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/17/17691\" title=\"table 6\">",
"      Evaluation of anemia when ESA use is considered",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/5/5212\" title=\"table 7\">",
"      Patient counseling for ESA use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/4/7244\" title=\"table 8\">",
"      FACT fatigue anemia subscales",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/13/9434?source=related_link\">",
"      Anemia of chronic disease (anemia of chronic inflammation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/18/41257?source=related_link\">",
"      Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11242?source=related_link\">",
"      Cancer-related fatigue: Prevalence, screening and clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27098?source=related_link\">",
"      Cancer-related fatigue: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/21/23896?source=related_link\">",
"      Darbepoetin alfa for the management of anemia in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/36/6730?source=related_link\">",
"      Drug-induced thrombosis and vascular disease in patients with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/45/33496?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/31/5626?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/22/23914?source=related_link\">",
"      Hematologic consequences of malignancy: Anemia and bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/43/35514?source=related_link\">",
"      Hypercoagulable disorders associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/52/5961?source=related_link\">",
"      Indications for red cell transfusion in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/55/37752?source=related_link\">",
"      Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38856?source=related_link\">",
"      Iron overload syndromes other than hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/41/40601?source=related_link\">",
"      Laboratory testing of donated blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/54/25450?source=related_link\">",
"      Management of the complications of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/62/28649?source=related_link\">",
"      Methods to overcome radiation resistance in head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/8/9353?source=related_link\">",
"      Non-iron pharmacologic adjuvants to erythropoiesis stimulating agent therapy in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/12/35017?source=related_link\">",
"      Overview of the complications of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/4/29762?source=related_link\">",
"      Patient information: When your cancer treatment makes you tired (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/3/36922?source=related_link\">",
"      Prognosis and treatment of primary myelofibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/4/8265?source=related_link\">",
"      Pure red cell aplasia due to anti-erythropoietin antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/46/10986?source=related_link\">",
"      The approach to the patient who refuses blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/62/25578?source=related_link\">",
"      Treatment of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/13/23769?source=related_link\">",
"      Treatment of the complications of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38521?source=related_link\">",
"      Use of iron preparations in hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/37/21081?source=related_link\">",
"      Use of red blood cells for transfusion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_15_38139="Causes of pediatric hypertensive emergencies";
var content_f37_15_38139=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of pediatric hypertensive emergencies by age",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Infancy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Childhood",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adolescence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Renal vascular disease*",
"        </p>",
"        <p>",
"         Congenital renal anomaly*",
"        </p>",
"        <p>",
"         Bronchopulmonary dysplasia*",
"        </p>",
"        <p>",
"         Coarctation of the aorta*",
"        </p>",
"        <p>",
"         Volume overload",
"        </p>",
"        <p>",
"         Renal parenchymal disease",
"        </p>",
"        <p>",
"         Renal vein thrombosis",
"        </p>",
"        <p>",
"         Congenital adrenal hyperplasia",
"        </p>",
"        <p>",
"         Tumor (eg, neuroblastoma)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Renal parenchymal disease*",
"        </p>",
"        <p>",
"         Renovascular disease*",
"        </p>",
"        <p>",
"         Coarctation of the aorta",
"        </p>",
"        <p>",
"         Pheochromocytoma",
"        </p>",
"        <p>",
"         Increased intracranial pressure",
"        </p>",
"        <p>",
"         Drug induced/toxicologic",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Primary hypertension*",
"        </p>",
"        <p>",
"         Non-adherence to medication*",
"        </p>",
"        <p>",
"         Renal parenchymal disease*",
"        </p>",
"        <p>",
"         Renovascular disease",
"        </p>",
"        <p>",
"         Toxemia of pregnancy",
"        </p>",
"        <p>",
"         Drug induced/toxicologic",
"        </p>",
"        <p>",
"         Pheochromocytoma",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Common causes of hypertensive emergency.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Constantine, E. Hypertension. In: Textbook of Pediatric Emergency Medicine, 6th ed, Fleisher GR, Ludwig S, Henretig, FM (Ed), Lippincott, Williams &amp; Wilkins, Philadelphia, 2010, p.315.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_15_38139=[""].join("\n");
var outline_f37_15_38139=null;
var title_f37_15_38140="Definitions and classification of stent restenosis";
var content_f37_15_38140=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56696&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56696&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Definitions and classification of stent restenosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Angiographic restenosis and classification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diameter stenosis &ge;50 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Type I focal: &le;10 mm in length",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        IA articulation or gap",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        IB margin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        IC focal body",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        ID multifocal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Type 2 diffuse: &gt;10 mm intrastent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Type 3 proliferative: &gt;10 mm extending beyond the stent margins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Type 4 total occlusion: Restenotic lesions with TIMI flow grade of 0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical restenosis: Assessed objectively as requirement for ischemia-driven repeat revascularization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Diameter stenosis &ge;50 percent",
"        <strong>",
"         and",
"        </strong>",
"        one of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        - Positive history of recurrent angina pectoris, presumably related to target vessel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        - Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to target vessel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        - Abnormal results of any invasive functional diagnostic test (eg, coronary flow velocity reserve, FFR &lt;0.80); IVUS minimum cross-sectional area &lt;4 mm",
"        <sup>",
"         2",
"        </sup>",
"        (and &lt;6.0 mm",
"        <sup>",
"         2",
"        </sup>",
"        for left main stem) has been found to correlate with abnormal FFR and need for subsequent TLR",
"        <sup>",
"         [1-3]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        - TLR with diameter stenosis &ge;70 percent even in absence of the above ischemic signs or symptoms",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ECG; electrocardiography; FFR: fractional flow reserve; IVUS: intravascular ultrasound; TLR: target lesion revascularization.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Abizaid AS, Mintz GS, Mehran R, et al. Long-term follow-up after percutaneous transluminal coronary angioplasty was not performed based on intravascular ultrasound findings: importance of lumen dimensions. Circulation 1999; 100:256.",
"       </li>",
"       <li>",
"        Jasti V, Ivan E, Yalamanchili V, et al. Correlations between fractional flow reserve and intravascular ultrasound in patients with an ambiguous left main coronary artery stenosis. Circulation 2004; 110:2831.",
"       </li>",
"       <li>",
"        Doi H, Maehara A, Mintz GS, et al. Impact of in-stent minimal lumen area at 9 months poststent implantation on 3-year target lesion revascularization-free survival: a serial intravascular ultrasound analysis from the TAXUS IV, V, and VI trials. Circ Cardiovasc Interv 2008; 1:111.",
"       </li>",
"      </ol>",
"      <br>",
"       Original table modified for this publication. From: Dangas G, Claessen B, Caixeta A, et al. In-Stent Restenosis in the Drug-Eluting Stent Era. J Am Coll Card 2010; 56:1897. Table used with the permission of Elsevier Inc. All rights reserved.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_15_38140=[""].join("\n");
var outline_f37_15_38140=null;
var title_f37_15_38141="Melioidosis clinical features";
var content_f37_15_38141=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical presentations and outcomes of 540 melioidosis cases over 20 years in the Northern Territory of Australia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Total",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Bacteremic",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Non-bacteremic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Number",
"       </td>",
"       <td class=\"subtitle2\">",
"        Deaths (mortality percent)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Number",
"       </td>",
"       <td class=\"subtitle2\">",
"        Deaths (mortality percent)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Number",
"       </td>",
"       <td class=\"subtitle2\">",
"        Deaths (mortality percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Septic shock",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        116 (21)",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        58 (50)",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        103",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        48 (47)",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        13",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        10 (77)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pneumonia",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        43 (49)",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        35 (45)",
"       </td>",
"       <td>",
"        10*",
"       </td>",
"       <td>",
"        8 (80)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        No evident focus",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        8 (62)",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        7 (58)",
"       </td>",
"       <td>",
"        1",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1 (100)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Genitourinary",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        5 (50)",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        4 (44)",
"       </td>",
"       <td>",
"        1",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        1 (100)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Osteomyelitis/septic arthritis",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        2 (50)",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        2 (50)",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0 (0)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Soft tissue abscess",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0 (0)",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0 (0)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Non-septic shock",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        424 (79)",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        19 (4)",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        195",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        13 (7)",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        229",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        6 (3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pneumonia",
"       </td>",
"       <td>",
"        190",
"       </td>",
"       <td>",
"        12 (6)",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        9 (10)",
"       </td>",
"       <td>",
"        101",
"       </td>",
"       <td>",
"        3 (3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Skin infection",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        0 (0)",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0 (0)",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        0 (0)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Genitourinary",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        2 (3)",
"       </td>",
"       <td>",
"        41",
"       </td>",
"       <td>",
"        2 (5)",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        0 (0)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        No evident focus",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        2 (4)",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        2 (4)",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        0 (0)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Soft tissue abscess(es)",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        0 (0)",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        0 (0)",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        0 (0)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Osteomyelitis/septic arthritis",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        0 (0)",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        0 (0)",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        0 (0)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neurological",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        3 (21)",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        0 (0)",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        3 (27)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Total",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         540",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         77 (14)",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         298 (55)",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         61 (20)",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         242 (45)",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         16 (7)",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Seven blood cultures not done, three blood cultures negative.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Culture positive for B. pseudomallei only from rectal swab, although fatal septic shock.",
"      <br>",
"       &Delta; Blood culture not done.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Currie BJ, Ward L, Cheng AC. The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study. PLoS Negl Trop Dis 2010; 4:e900. Copyright &copy; 2010 Public Library of Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_15_38141=[""].join("\n");
var outline_f37_15_38141=null;
var title_f37_15_38142="Common allergens in North America";
var content_f37_15_38142=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F57728&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F57728&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 589px\">",
"   <div class=\"ttl\">",
"    Common allergens in North America",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 569px; height: 511px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Arndt, K, Robinson, J, LeBoit, P, Wintroub, B (Eds). Cutaneous Medicine and Surgery: An Integrated Program in Dermatology. WB Saunders; p. 175.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_15_38142=[""].join("\n");
var outline_f37_15_38142=null;
var title_f37_15_38143="IVUS tranplanted heart";
var content_f37_15_38143=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72154&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72154&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Early atherosclerosis in a transplanted heart assessed with intracoronary ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 168px; height: 305px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Athough atherosclerotic changes are not seen on coronary angiography (bottom), extensive atherosclerosis is evident with intracoronary ultrasound (top).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Yock P, Fitzgerald P, Popp R. Science and Medicine 1995; 2:68.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_15_38143=[""].join("\n");
var outline_f37_15_38143=null;
